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ABSTRACT 
Objectives: This project aimed to investigate effects of purvalanol A on 
imatinib-sensitive and -insensitive chronic myeloid leukaemia (CML) cell lines, 
and normal white blood cells. 
Methods: Imatinib-sensitive (LAMA-84) and –insensitive (KCL-22) 
CML cell lines and human neutrophils and PBMCs were incubated with imatinib, 
and purvalanol A. Cell apoptosis was measured using flow cytometry and the 
expression of proteins was measured by Western blotting. Mcl-1 mRNA 
expression was quantified using real-time PCR.  
Results: The CDK2 inhibitor, purvalanol A, induced cell death in both 
CML cell lines. In the KCL-22 cell line, purvalanol A treatment resulted in a rapid 
(≤1 h) decrease in levels of the anti-apoptotic protein, Mcl-1. This decrease in 
Mcl-1 was mediated by a decrease in mRNA and a marked acceleration in the rate 
of turnover of the protein (half-life decreased from ~3 h in control cells to ~1.5 h 
in drug-treated cells). Purvalanol A also induced cell death in LAMA-84 cell line, 
although it was not as potent and cell death occurred in the absence of a decrease 
in Mcl-1, suggesting different signalling pathways in these two lines and hence 
different capacity to alter Mcl-1 stability.  Furthermore, purvalanol A also 
increased Mcl-1 turnover rate and phosphorylated p38-MAPK activity in 
neutrophils and in KCL-22 cells. In addition, the p38 MAPK inhibitor, BIRB796, 
decreased apoptosis and prevented the decrease in Mcl-1 expression induced by 
purvalanol A in both CML cell lines and neutrophils. 
Conclusions: The development of drug resistance in patients with CML 
results in a continuing need to develop new ways to treat patients that become 
refractory to tyrosine kinase inhibitors. The results of this study indicate that 
purvalanol A might provide an adjunct to TKIs in the therapy of CML. This study 
shows that the effects of purvalanol A on induction of cell death in KCL-22 cell 
line are independent of the effects of this drug on cell cycle kinetics, but instead 
point to a direct or indirect effect on post-translational modifications of Mcl-1 that 
enhance its turnover rate.  
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CHAPTER 1: INTRODUCTION 
1.1 Chronic Myeloid Leukaemia 
Chronic Myeloid Leukaemia (CML), also known as chronic 
granulocytic leukaemia (CGL), is a cancer of white blood cells. It is 
characterised by the unregulated growth of predominantly myeloid cells in 
the bone marrow and accumulation of these cells in the blood. This results 
from the BCR-ABL gene products in haematopoietic stem cells (HSCs), 
which differentiate into common myeloid progenitors (CMPs) and common 
lymphoid progenitors (CLPs). CMPs may then differentiate into 
granulocyte/macrophage progenitors (GMPs) and progenitors of red blood 
cells and megakaryocytes (MEPs), before differentiating into many types of 
circulating cells, such as granulocytes (G), macrophages (M), 
megakaryocytes (MEG) and red blood cells (RBC) (Ren, 2005), (Figure 
1.1). Proliferation of mature granulocytes such as neutrophils, eosinophils, 
and basophils, along with their precursors, results in many of the clinical 
signs found in CML patients. 
1.1.1 Incidence 
CML accounts for approximately 15-20 % of all newly diagnosed 
adult leukaemia cases and 14 % of leukaemia overall (including the 
paediatric population) (Jemal et al., 2010). The incidence rate is higher in 
men compared to woman (Rohrbacher and Hasford, 2009). The incidence 
and the age of onset of this disease in Western countries appears to be 
higher compared to Asian countries, as described in Table 1.1.  
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Figure 1.1 The development of chronic myelogenous leukaemia In CML 
chronic phase (CML-CP), there are high numbers of granulocytes 
circulating in the blood. CML can progress from the chronic phase into 
blast phase (CML-BP). (HSCs = hematopoietic stem cells; CMPs = 
common myeloid progenitors; CLPs = common lymphoid progenitors; 
GMPs = granulocytes (G) and macrophage (M) progenitors (GMPs); MEPs 
= megakaryocytes and erythrocytes progenitors; RBC = red blood cells; 
MEGs = and megakaryocyte) (Redrawn from (Ren, 2005)). 
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Table 1.1 Characteristics of the CML populations of Western and Asian 
countries.  
Country/region Source Annual 
incidence 
(100,000-1) 
Median 
Age of 
diagnosis 
United Kingdom Haematological 
Malignancy Research 
Network 
(Smith et al., 2014) 
0.9 59 y 
USA North American 
Association of Central 
Cancer Registries 
(Siegel et al., 2014) 
1.48 65 y 
China Local Surveys 
(Au et al., 2009) 
0.39-0.55 45-50 y 
Thailand Nine leading 
University hospitals 
(Au et al., 2009) 
0.5 36-38 y 
 
 
 
 
1.1.2 Diagnosis and Laboratory Findings 
This disease is diagnosed on routine physical examination and blood 
tests. 20-40 % of asymptomatic patients are diagnosed to have CML by a 
persistence of leucocytosis (median white blood cell (WBC) count 
~100,000/µL) with a population of neutrophils in different developmental 
stages, and high levels of segmented neutrophils and myelocytes (Savage et 
al., 1997, Cotta and Bueso-Ramos, 2007, Spiers et al., 1977).  
The presence of the Ph chromosome is one of the characteristics of 
CML. It can be detected by cytogenetic, fluorescence in situ hybridisation 
(FISH), and polymerase chain reaction (PCR) (Jabbour et al., 2008, 
Kantarjian et al., 2008, Schoch et al., 2002). FISH analysis, based on the 
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hybridisation of fluorescent genomic probes specific to BCR and ABL 
genes is useful to detect the Ph chromosome, while PCR assays, based on 
amplification of the region around the splice junctions between BCR and 
ABL gene are also used. Both reverse transcriptase-polymerase chain 
reaction (RT-PCR) and qualitative polymerase chain reaction (qPCR) are 
suitable for CML diagnosis, while qPCR is ideal for monitoring residual 
disease (Vardiman, 2009, Stentoft et al., 2001, Lowenberg, 2003).   
1.1.3 Clinical Manifestations and Staging 
CML disease has 3 phases: (1) chronic phase (CP); (2) accelerated 
phase (AP); (3) blast phase (BP). In the first 3-5 years period after disease 
onset, CML patients are in the CP, which is characterised by high white 
blood cell counts, splenomegaly and extra medullary haematopoiesis. CP 
has common clinical signs of leucocytosis, fatigue, gout, weight loss, 
malaise, and left upper quadrant-pain, which results from anaemia and 
splenomegaly. Rare manifestations, which may include bleeding, 
thrombosis, and retinal haemorrhage are also found in some cases. 
Untreated patients will progress into the AP, but approximately 20 % of the 
patients will enter into BP without AP (Jabbour and Kantarjian, 2014).  
AP is known as a progressive phase. According to the World Health 
Organisation (WHO), AP is characterized by persistence of elevated WBC 
counts (>100,000/µL), splenomegaly, persistent thrombosis (platelet count 
over than 1,000,000/µL), persistent thrombocytopenia (platelet count less 
than 100,000 / µL), and increased basophils (>20 % in peripheral blood) 
and myeloblasts (>10-19 % in peripheral blood) (Vardiman, 2010).  
BP is a fatal acute phase. The immature myeloid cells (blast cells) 
are expanded rapidly due to rapid disease progress (Jaiswal et al., 2003). BP 
is characterized by persistence of blast cells (>20 % of the peripheral blood 
leukocytes) and a medullary infiltration by blast cells (Vardiman, 2010). In 
this phase, most of the patients suffer from the accumulation of blast cells, 
resulting in an increased susceptibility to infections and a shortage of red 
blood cells and platelets, two cell types that are derived from the same 
myeloid progenitor. 
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1.1.4 Pathophysiology 
CML is associated with expression of the BCR/ABL fusion gene 
which encodes a constitutively-active protein tyrosine kinase, leading to a 
deregulation of tyrosine kinase activity in cells (Deininger et al., 2000). The 
downstream signalling events activated by this kinase activity result in the 
CML phenotype (Quintas-Cardama and Cortes, 2009). A variety of 
signalling pathways are affected by the uncontrolled kinase activity of 
BCR-ABL and these are usually involved in pathways associated with cell 
proliferation, control of apoptosis, differentiation and adhesion, all of which 
are implicated in CML pathology. 
The role of BCR-ABL in CML was confirmed by studies in murine 
models (Daley et al., 1990, Kelliher et al., 1990, Elefanty et al., 1990). Mice 
that were induced to be express endogenous BCR-ABL via retrovirus-
transduced bone marrow transplantation, developed CML-like 
myeloproliferative disorder (Daley et al., 1990, Lowenberg, 2003). This 
experiment confirmed that BCR-ABL is required to induce 
leukaemogenesis in vivo. 
1.1.4.1 Philadelphia Chromosome  
CML results from a single genetic abnormality leading to 
haematological malignancy. The chromosomal abnormality is known as the 
Philadelphia (Ph) chromosome, which is found in over 90 % of all cases 
diagnosed as CML (Shepherd et al., 1995). The Ph chromosome is the 
result of a fusion caused by the reciprocal translocation of the Abelson 
(ABL) tyrosine kinase gene on the 3ꞌ end of chromosome 9 and the break-
point cluster region (BCR) gene on the 5ꞌ end of chromosome 22 (Figure 
1.2) (Rowley, 1973). This translocation results in the formation of the BCR-
ABL gene, which encodes an abnormal chimeric fusion protein, which is a 
constitutively active protein tyrosine kinase (Quintas-Cardama and Cortes, 
2006).  Three different types of fusion protein are formed depending on the 
breakpoint of BCR gene. The most common is the 210-kDa fusion protein, 
but 230-kDa and 190-kDa fusion proteins are also found (Clark et al., 1987, 
Fainstein et al., 1987, Deininger et al., 2000). 
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Figure 1.2 Philadelphia Chromosomes In normal chromosomes, 
the ABL and BCR genes are located on chromosomes 9 and 22, 
respectively. The BCR-ABL fusion gene is formed on the derivative 
chromosome 22 due to the (9;22) translocation. (Redrawn from (Lydon, 
2009)). 
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1.1.4.2 Anatomy and auto-regulation of BCR-ABL protein 
ABL is the human homologue of the viral abl (v-abl) oncogene 
carried by the Abelson murine leukaemia virus (A-MuLV) (Abelson and 
Rabstein, 1970). This gene encodes a non-receptor tyrosine kinase that is 
expressed in many tissues (Laneuville, 1995). ABL protein (145 kDa) is 
distributed in both the cytoplasmic and nuclear compartments of cells and 
normally moves between these two compartments in order to transduce 
signals from cell surface growth factor receptors for regulating cytoskeleton 
structure (Woodring et al., 2003). In addition, the ABL gene is involved in 
cell cycle regulation in the cellular response to genotoxic stress (Kipreos 
and Wang, 1990, Sawyers et al., 1994, Yuan et al., 1999). 
 The ABL central core consists of a tyrosine kinase, Src-Homology-
2 (SH2) and a SH3 domain. Its last exonic region contains 4 proline-rich PP 
motifs which serve as binding sites of the SH3 domains of other proteins 
(Hantschel and Superti-Furga, 2004, Smith et al., 1999, Cohen et al., 1995). 
Toward the 3’ end of the gene, DNA-binding, nuclear localisation signals 
and actin-binding motifs are also found (Kipreos and Wang, 1990). 
The BCR gene encodes a 160-kDa protein, which, like the ABL 
protein, is ubiquitously expressed. The only substrate of this kinase that has 
been discovered so far is Bap-1, a member of 14-3-3 family of proteins 
(Reuther et al., 1994). It is also a signalling protein that contains multiple 
modular domains, such as a coiled/coil oligomerisation (CC) domain, 
serine/threonine kinase (ST-K) domain, pleckstrin homology (PH) domain, 
and Dbl/CDC24 guanine nucleotide exchange factor homology (DH) 
domain. The CC domain plays a role in dimer formation (McWhirter et al., 
1993), while PH and DH domains stimulate the exchange of guanosine 
triphosphate (GTP) to guanosine diphosphate (GDP) on Rho guanine 
exchange factors (Denhardt, 1996, Diekmann et al., 1991). Tyr177 of BCR 
acts as a docking site for Growth factor Receptor-Bound protein 2 (GRB2) 
and the ABL1 protein (Wu et al., 1998, Ma et al., 1997). 
Therefore, fusion with BCR brings new regulatory domains to the 
ABL protein and an increased tyrosine kinase activity of ABL (Figure 1.3). 
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Figure 1.3 Schematic representation of the BCR-ABL kinase  This 
Figure illustrates the structural modularity of BCR-ABL. ABL is composed 
of a tyrosine kinase (Y-K), a SRC-homology-2 (SH2) domain, a SH3 
domain, proline-rich SH3 binding sites (PP), nuclear localization signals 
(NLS), a DNA-binding domain (DBD) and an actin-binding domain 
(ABD). BCR is composed of coiled-coil oligomerisation domain (CC), 
serine/threonine (S/T) kinase, Dbl/CDC24 guanine nucleotide exchange 
factor homology (DH), and pleckstrin homology (PH) domain, and also has 
an exposed binding site for other signalling proteins at tyrosine 177 (Y177). 
The fusion point occurs after the PH domain of BCR (Redrawn from Ren, 
2005)). 
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1.1.4.3 Mechanism of ABL kinase activation 
ABL kinases contain two flexible loops which are the ATP-binding 
loop (p-loop) and the activation loop. These loops are arranged to stabilise 
the inactive conformation of the protein.  
ABL kinases consist of a number of domains:  N-terminal 
myristoylation, SH3, and SH2 kinase. In the inactive conformation of ABL, 
the N-terminal myristoyl group is positioned on a hydrophobic pocket in 
the ABL tyrosine kinase domain. This results in a clamped structure that 
has SH2 and SH3 domains on the back of the protein. This clamping 
structure hinders the activation loop and obstructs ATP binding.  In order to 
activate ABL kinase, the N-terminus must be unlatched from the 
hydrophobic pocket to expose the SH2 and SH3 domains. Then, SH2 and 
SH3 bind to the tyrosine and proline rich regions, respectively, to expose 
the activation loop. This leads to tyrosine 412 phosphorylation and full 
activation of the kinase (Figure1.4) (Hantschel et al., 2003, Nagar et al., 
2003).  
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Figure 1.4 Mechanism of ABL kinase activation.  The activation loop is 
exposed in the active conformation of ABL leading to tyrosine 
phosphorylation and activation of ABL kinase. (Redrawn from (Wong and 
Witte, 2004)). 
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1.1.4.4 Signalling pathways downstream of BCR-ABL1 kinase 
BCR-ABL activates various downstream signalling pathways. The 
N-terminal CC domain of BCR-ABL induces dimerization and auto-
transphosphorylation (McWhirter et al., 1993). BCR-ABL-mediated 
leukaemogenesis depends on the autophosphorylation at tyrosine 177 
(Tyr177) (Zhang et al., 2001) which normally serves as a docking site for 
growth factor receptor-bound protein 2 (GRB2) by acting as a high-affinity 
binding site for the SH2 domain of GRB2 (Pendergast et al., 1993). Then, 
GRB2 recruits Son of Sevenless (SOS) protein, which is a guanine-
nucleotide exchanger of RAS, to trigger RAS activation (Puil et al., 1994, 
Sattler et al., 2002).  
Signalling from RAS activates the mitogen-activated protein kinases 
(MAPK) to enhance cell proliferation. RAS protein can be activated by a 
complex of GRB2 and SOS. RAS then activates RAF kinase, which is a 
serine/threonine kinase that phosphorylates and activates MEK 
(tyrosine/threonine kinase). Subsequently, MEK phosphorylates and 
activates MAPK, also known as extracellular signal-regulated kinase (Erk). 
This RAS-RAF-MEK-ERK pathway is involved in regulation of several 
transcription factors, such as MYC (Cahill et al., 1996, Marais et al., 1995).  
In addition, GRB-2 can form a complex with a scaffold adapter 
GRB-2 associating binding protein 2 (GAB2) (Sattler et al., 2002). GAB2 
then recruits phosphatidylinositol 3-Kinase (PI3K), which activates the 
phosphoinositide-dependent kinase (PDK-1) and serine/threonine kinase 
Akt (Skorski et al., 1995, Hemmings and Restuccia, 2012). Akt promotes 
cell survival, enhances cell proliferation and activates protein translation. 
These events result in an anti-apoptotic activity within the cells (Franke et 
al., 1997). In addition, Akt was found to decrease an expression of p27KIP1, 
the CDK2 inhibitor, and thus leads to cell cycle deregulation (Gesbert et al., 
2000). 
BCR-ABL constitutively activates signal transducer and activation 
of transcription protein family (STATs) (Ilaria and Van Etten, 1996). 
STAT5 induces the transcriptional activation of the anti-apoptotic proteins 
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of the B cell lymphoma 2 (Bcl-2) family, such as Bcl-XL. As a 
consequence, this increases the survival of the myeloid progenitors (Figure 
1.5) (Quintas-Cardama and Cortes, 2009).  
 
 
Figure 1.5 Molecular signalling in BCR-ABL–positive myeloid cells. 
BCR-ABL proteins form a dimer through their CC domains, which results 
in trans-autophosphorylation to activate many signalling pathways 
(Redrawn from (Ren, 2005)).  
1.1.5 Treatment 
Allogenic stem cell transplantation (AlloSCT) is the only way to 
cure CML. However, this treatment carries a high risk of morbidity and 
mortality, and also has limitations. It is restricted to patients with good 
health status and having an appropriate stem cell donor (Druker et al., 
2001). As a consequence, drug treatments have been developed as the main 
therapy for this disease. 
 
Previously, drug therapy for CML disease was limited to non-
specific agents such as hydroxylurea, hydroxylcarbamide, busulfan, and 
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interferon-α (IFN-α) (Wong and Witte, 2004). Of these drugs, IFN-α 
induced cytogenetic responses in CML patients (Talpaz et al., 1986), 
improved survival rate of CML patients and induced disease regression, 
compared to conventional chemotherapy. However, it has relatively high 
toxicity, and 20 % of CML patients cannot tolerate IFN-α therapy (Salesse 
and Verfaillie, 2002).  
However, the emergence of tyrosine kinase inhibitors (TKIs) totally 
changed the landscape for the treatment of CML. Imatinib mesylate 
(Gleevec, STI-571) was developed as a small molecule inhibitor of ABL 
kinase (Detailed in 1.2.1) and is now used as a frontline therapy for this 
disease (Vigano et al., 2014)). Despite its clinical success, imatinib-resistant 
CML has emerged as a result of mutations in the BCR-ABL kinase. 
Therefore, second generation TKIs were introduced to overcome this 
resistance, such as nilotinib and dasatinib. These drugs have been approved 
as first line therapy for newly-diagnosed CML patients by the Food and 
Drug Administration (FDA). However, these drugs fail to overcome one of 
the most common mutations, T315I. As a result, third generation TKIs, 
such as ponatinib have been developed and approved by the FDA. 
Ponatinib exhibited activity against CML with the T315I (gatekeeper) 
mutation and therefore is considered as a treatment for imatinib-resistant 
CML (reviewed in (Deininger et al., 2005, Weisberg et al., 2007, Shamroe 
and Comeau, 2013)). 
Other than ponatinib, non BCR-ABL targeted agents, such as 
omecetaxine, have been introduced to use in patients who have developed 
resistance to imatinib. Omacetaxine is a natural alkaloid that inhibits protein 
synthesis and also induces apoptosis. Omacetaxine induces cytogenetic 
responses in CML and has recently been approved by the FDA as a 
treatment option for patients who fail several TKIs (Nazha et al., 2013). 
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1.1.6 Prognosis 
Before the advent of TKIs, CML was considered to be a fatal 
disease, as the survival time for CML patients was about 3-5 years from 
diagnosis. Since the use of TKIs, the survival times have improved to over 
5 years in most of cases (>89%) (Druker et al., 2006). 
1.2 Tyrosine Kinase Inhibitors 
In 1845, CML was first described by the pathologists Bennet, 
Craigie, and Virchow (reviewed in (Wong and Witte, 2004)) but it was only 
in 1960 that the Ph chromosome was discovered by Nowell and Hangerford 
(Nowell, 1962) and the molecular basis for the disease was understood. In 
1986, Shtivelman and colleagues showed that the Ph chromosome was a 
BCR-ABL fusion gene via the mapping of both ABL and BCR probes to 
the mRNA product of the Ph chromosome (Shtivelman et al., 1985, Ben-
Neriah et al., 1986, Stam et al., 1987). Therefore, BCR-ABL targeted 
therapy was investigated for CML treatment.  
A decade later, Anafi and colleagues reported that a tyrphostin could 
inhibit the tyrosine kinase activity of BCR-ABL. Therefore, they suggested 
that designing specific compounds for the treatment of BCR-ABL 
associated leukaemia may be possible.  However, this compound and its 
derivatives have not been developed for clinical use because of toxicity 
issues (Anafi et al., 1993). At around the same time, Lydon and Matterat at 
Ciba Geigy (now Novartis), initiated a project to identify compounds that 
inhibit kinase activity. They found that 2-phenylaminopyridine-type 
tyrosine kinase inhibitor gave a promising result. 
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Figure 1.6 Timeline of major discoveries in CML (Redrawn from (Wong 
and Witte, 2004)) 
1.2.1 Imatinib 
In 1996, imatinib mesylate (Gleevec, STI-571), the specific BCR-
ABL inhibitor, was developed and this was a major breakthrough in the 
treatment of CML (Buchdunger et al., 1996, Druker et al., 1996).  Imatinib 
is a 2-phenylaminopyridine-type tyrosine kinase inhibitor with the addition 
of a 3’-pyridyl group at the 3’ position of the pyrimidine (Fig. 1.7). This 
pyridyl group enhanced the intracellular inhibitory activity of the drug. In 
addition, a benzamide group and a flag-methyl group were introduced at the 
phenyl ring and the diaminophenyl ring, respectively, to improve activity 
against tyrosine kinases. A N-methylpiperazine group was added to 
increase oral bioavailability and water solubility  (reviewed in (Deininger et 
al., 2005)) (Figure 1.7). 
Imatinib acts by competitive binding to the adenosine triphosphate 
(ATP) binding site of BCR-ABL protein and stabilising the inactive non-
ATP-binding form of BCR-ABL, thus blocking auto-phosphorylation and 
subsequent signal transduction. This inhibition of BCR-ABL activity results 
in the anti-proliferative effect of the drug (Schindler et al., 2000). 
Crystallographic studies showed that imatinib binds to ABL kinase domain 
through six hydrogen bond interactions and thus prevents ATP from 
accessing the ATP-binding pocket. The hydrogen bonds involve the 
following interactions between imatinib and BCR-ABL: the pyridine-N and 
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M318 backbone-NH; the amide-NH and E286 side chain; the 
aminopyrimidine and T315 side chain; the carbonyl group and D381 
backbone-NH, and the methypiperazine with I360 and H361 (Figure 1.7) 
(Manley et al., 2002).  In addition, there are a number of van der Waals 
interactions that contribute to this binding. Also, there are interactions 
between hydrophobic pockets of the protein, and the phenyl ring and the 
piperazine methyl group of imatinib (Asaki et al., 2006, Eck and Manley, 
2009).  
Imatinib not only inhibits ABL kinase, but also stem-cell growth 
factor receptor (c-KIT) and platelet-derived growth factor (PDGFR) 
(Buchdunger et al., 2000). Imatinib was approved for CML treatment by the 
FDA in 2001 and it dramatically improves CML patient survival time 
(Kalaycio, 2001). Imatinib induces complete cytogenetic response in almost 
80% of patients diagnosed with CML chronic phase with mild toxicity 
(Kantarjian et al., 2002).  
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Figure 1.7 Chemical structure and binding site of imatinib melysate to 
BCR-ABL. The structural features of imatinib are designated as (A) 2-
phenylaminopyridine backbone (B) Pyridyl group (C) flag-methyl group 
(D) benzamide group (E) N-methylpiperazine group. The key hydrogen 
bonds and hydrophobic pocket that interact with BCR-ABL are shown in 
dashed lines, and key residues of BCR-ABL that interact with these 
imatinib domains are indicated (Redrawn from (Manley et al., 2010)). 
 
Following its initial clinical success, resistance to this drug 
especially via mutations to BCR-ABL, were observed. Hence, second 
generation tyrosine kinase inhibitors (TKIs) have been developed such as 
nilotinib and dasatinib (Deininger et al., 2005).  
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1.2.2 Nilotinib 
A decade after the introduction of imatinib, the second generation 
TKI, nilotinib (Tasigna, AMN107), was developed by the same company 
for use as a treatment in BCR-ABL positive CML (Golemovic et al., 2005). 
Nilotinib is a rationally designed imatinib derivative. A 3-methylimidazole 
and a trifluoro-methyl group were introduced to enhance its interactions 
with the Abl kinase domain, compared to imatinib. 
Nilotinib also binds to the inactive conformation of ABL kinase. 
Nilotinib binding with the ABL kinase domain involves four hydrogen 
bond interactions. These include interactions between: pyridine-N and 
M318 backbone; the aminopyrimidine and T315 side chain; the amide-NH 
and E286 side chain; and the carbonyl group and D381 backbone-NH.  The 
3-methylimidazole and trifluoro-methyl groups stabilise the shape of 
nilotinib and also bind to the ABL kinase domain with a greater number of 
van der Waals interactions compared to imatinib  (Figure 1.8) (Manley et 
al., 2010). 
Nilotinib is approximately 43-60 fold more potent than imatinib in 
imatinib-sensitive cell lines, and has a 20-fold greater potency than imatinib 
in imatinib-resistant cell lines (Golemovic et al., 2005). It displays a similar 
specificity profile to imatinib as it has a specific activity toward BCR-ABL, 
c-ABL, and c-KIT targets (Kantarjian et al., 2006, Melo and Chuah, 2008). 
It has been approved to use as a treatment for both CP and AP and for 
imatinib-resistant CML patients (Bumbea et al., 2010, Ramirez and 
DiPersio, 2008).  
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Figure 1.8 Chemical structure and binding site of nilotinib. Nilotinib is 
a close analogue of imatinib with the addition of (A) methylimidazole 
group (B) trifluoro-methyl groups. The key hydrogen bonds and 
hydrophobic pocket are shown in dashed lines (Redrawn from (Manley et 
al., 2010)). 
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1.2.3 Dasatinib 
Dasatinib (Sprycel, BMS-354825) is a structurally-distinct TKI that 
has approximately 350-fold higher potency than imatinib. Dasatinib can 
bind to both active and inactive forms of BCR-ABL (Tokarski et al., 2006, 
Das et al., 2006).  
Dasatinib is a thiazolylaminopyrimidine analogue. The 2-chloro-6-
methyl phenyl ring binds to the hydrophobic pocket of the ABL kinase, and 
blocks ATP reaching its binding site. Dasatinib requires fewer binding 
interactions compared to imatinib and nilotinib, leading to a higher potency. 
Dasatinib binds to ABL kinase via three hydrogen bonds. These hydrogen 
bonds result from interactions between: the aminothiazole ring and the 
amide nitrogen of M318; the 2-amino hydrogen and the carbonyl oxygen of 
M318; the amide nitrogen and the T315 side chain. The other interactions 
are mainly via van der Waals interactions (Figure 1.9) (Tokarski et al., 
2006).  
Dasatinib is a multi-kinase inhibitor as it has activity against BCR-
ABL, c-Kit, PDGFR, and SRC family kinases, such as mitogen-activated 
protein kinase and receptor tyrosine kinase (Shah et al., 2004). It is active 
against many BCR-ABL kinase domain mutations due to it having fewer 
binding requirements.  
It has been approved for use in all phases of CML especially 
patients who failed previous imatinib treatment (Muller et al., 2009, 
Hochhaus et al., 2009). This improved potency inhibits most, but not all of 
the imatinib resistant mutants, especially the T315I mutant (Rix et al., 
2007).  
Although second generation TKIs exhibit clinical success in most 
CML cases, emerging mutations, such as T315I still present an obstacle to 
overcome imatinib resistance. The third generation TKIs, ponatinib and 
rebastinib, have been developed for this purpose. 
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Figure 1.9 Chemical structure and binding site of dasatinib The 
structure of dasatinib is defined as (A) 2-chloro-6-methyl phenyl group, (B) 
amide group, (C) aminothiazole group, (D) pyrimidine ring, and (E) 
hydroxyethyl-piperazine group. The key hydrogen bonds and hydrophobic 
pocket are shown in dash lines (Redrawn from (Tokarski et al., 2006)).  
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1.2.4 Ponatinib 
Ponatinib (Iclusig, AP24534) was developed by rational design 
based on the crystal structure of ABL kinase domains in complex with 
imatinib. To avoid the interaction with side chain of 315I (i.e. to target the 
T315I mutation) (detailed in 1.3.1), ponatinib was designed with a linear 
ethynyl linker in order to bind tightly with ABL kinase and avoid the bulky 
isoleucine side chain.  In addition, ponatinib forms five hydrogen bonds 
with ABL kinase domain, which are interactions between: the nitrogen 
atom of the purine group and the backbone of M318; the amide group and 
backbone of D381 and the E286 side chain; the protonated 
methylpiperazine and the backbone-carbonyl atoms of I360 and H361. The 
methyphenyl group binds to the hydrophobic pocket of ABL kinase while 
the trifluoromethyl group binds to the DFG-out pocket, which is a novel 
pocket induced by the inactive conformation of ABL kinase domain (Figure 
1.10) (Zhou et al., 2011).  
Ponatinib also inhibits other kinases such as PDGFR, and c-Kit 
(Lierman et al., 2012). It is active against a range of TKI resistant CML 
cells (Cassuto et al., 2012) and has exhibited clinical efficacy in patients 
with multi-TKIs resistance (Jain et al., 2013). However, some reports have 
shown that ponatinib resistance has been developed in some cases 
(Zabriskie et al., 2014). 
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Figure 1.10 Chemical structure and binding site of ponatinib. The 
structure of ponatinib is defined as (A) purine group, (B) ethynyl linker, (C) 
methylphenyl group, (D) amide group, (E) trifluoromethyl group, and (F) 
N-methylpiperazine group. The key hydrogen bonds, hydrophobic pocket, 
and DFG-out pocket are shown in dashed lines (Redrawn form (Zhou et al., 
2011)).  
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1.3 Tyrosine Kinase Inhibitor Resistance in CML 
During the advanced stages of CML, rates of mutations are high, 
thus resistance to imatinib has emerged by various mechanisms. 
Therapeutic resistance to imatinib occurs in approximately 10-15 % of 
patients (Zhang et al., 2009b). This resistance is classified as primary 
(intrinsic) and secondary (extrinsic) resistance, depending on the time of 
onset.  The primary resistance is defined by a lack of response to imatinib 
from the onset of the disease, while secondary resistance is defined as a loss 
of efficacy of imatinib after an initial response (Mauro, 2006). In this 
section, some mechanisms leading to imatinib resistance are reviewed.  
1.3.1 BCR-ABL Oncogene Amplification 
BCR-ABL oncogene amplification was the first mechanism of 
imatinib resistance to be identified.  In 2000, Mahon and colleagues found 
an amplification of Abl sequences in BCR-ABL-positive cells, leading to 
imatinib resistance. This amplification resulted in an elevated level of BCR-
ABL protein and thus decreased the effectiveness of imatinib at clinically-
used doses (Mahon et al., 2000, le Coutre et al., 2000). 
1.3.2 BCR-ABL1 kinase domain mutations  
40-90 % of imatinib-resistance patients develop BCR-ABL1 kinase 
domain mutations (Corbin et al., 2003). These mutations cause imatinib 
resistance by either impairing imatinib binding with BCR-ABL kinase or 
indirect modulation of kinase function. These mechanisms are usually 
associated with secondary imatinib resistance (Zhang et al., 2009b).   
35-70 % of patients displaying imatinib resistance have developed 
point mutations (Jabbour et al., 2006). More than 100 different point 
mutations of BCR-ABL kinase domain have been reported so far (Rix et al., 
2007). The regions that are important for imatinib binding are often the 
regions in which acquired mutations are reported. These regions are the P-
loop, tyrosine 315 (T315), methionine 351 (M351), glutamate 355 (E355), 
and the activation loop. These mutations all contribute to the activated 
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conformation of imatinib-insensitive ABL kinase. Soverini and colleagues 
reported that most of the mutations associated with imatinib resistance are 
related with amino acid substitution at one of seven residues (Soverini et 
al., 2011). These residues are M244V, G250E, Y253F/H, and E255K (in 
the P-loop); T315I (at the TKI contact site); M351T and F359V at the 
catalytic domain However, the most important of these mutations, are the 
T315I and P-loop mutations. 
1.3.2.1 T315I mutation 
T315 is a non-conserved residue that is located in the binding pocket 
of ABL kinase and imatinib. The T315I mutant is a frequently observed 
mutation in imatinib-resistant CML patients (Apperley, 2007). It results 
from a single amino acid substitution at position 944 of the ABL kinase 
leading to a threonine to isoleucine substitution.  
In general, TKIs form a key hydrogen bond interaction with 
Tyrosine 315 in the BCR-ABL protein. Therefore, this mutation will impair 
this H-bond interaction and hence TKIs binding (Gorre et al., 2001). This 
mutation is associated with poor prognosis and various studies have 
reported that it promotes disease progression (Azam et al., 2008, Nicolini et 
al., 2013). In addition to imatinib, all second generation TKIs, such as 
dasatinib and nilotinib cannot inhibit this T315I mutant, as they require the 
same critical hydrogen bond with T315 of ABL kinase for binding. 
1.3.2.2 P-loop mutations 
The P-loop is a highly conserved region that is responsible for 
phosphate binding. P-loop mutations induce inactive ABL to transform into 
active ABL with intrinsic kinase activity. These P-loop mutations are 
frequently associated with the progression from CP, and from AP to BP 
(reviewed in (O'Hare et al., 2007, Comert et al., 2013)).  
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1.3.2.3 Other mutations 
The BCR-ABL is composed of many domains, such as SH2, SH3, 
and DNA-binding domains and several in vitro studies have shown that 
mutations of these sites can also confer imatinib resistance. These domains 
exhibit auto-inhibitory effects on ABL kinase; therefore their mutation can 
result in the auto-activation of ABL kinase. In addition, some mutations are 
located at substrate binding sites, such as the activation loop (Roche-
Lestienne et al., 2002, Soverini et al., 2006).  
These mutations cause imatinib-resistance, but they are not as 
common as the T315I and the P-loop mutations. 
1.3.3 BCR-ABL independent mechanisms 
BCR-ABL independent mechanisms can also result in TKIs 
resistance and development of multidrug resistance. These mechanisms 
include decreased TKIs influx, increased TKIs efflux, and other events that 
result in loss of effectiveness of drugs. 
1.3.3.1 Modulation influx transport 
Impairment of imatinib uptake can result in failure to inhibit CML 
cell proliferation because an effective inhibitory concentration of imatinib 
cannot be achieved within the cell. The organic cation transporter-1 (Oct-1) 
has been reported to be responsible for imatinib transport into BCR-ABL 
positive cells (White et al., 2006). There is evidence that alteration in the 
expression and function of Oct-1 leads to imatinib-resistance in CML 
(White et al., 2012, Engler et al., 2010). 
1.3.3.2 Modulation efflux transport 
Impairment of imatinib efflux is another way to prevent imatinib 
from attaining its inhibitory cellular concentration. ATP binding cassette 
(ABC) transporter family members include Polyglycoprotein multidrug 
resistance 1 (ABCB1), multidrug resistance-associated proteins 1 
(ABCC1), and breast cancer resistance protein (ABCG2) and are all drug 
efflux transmembrane proteins that regulate drug transport. There is a report 
44 
 
showing that the overexpression of ABCB1 and ABCG2 contributes to 
imatinib-resistance in CML (Dohse et al., 2010).   
1.3.3.3 Modulation of survival mechanisms 
The increased resistance to apoptosis of CML cells is regulated by 
several survival mechanisms, such as a deregulation of Bcl-2 family 
proteins and an increased expression of inhibitors of apoptosis proteins 
(IAPs) (reviewed in (Rumjanek et al., 2013)). 
1.4 Apoptosis   
The term of apoptosis is used to describe the ordered sequence of 
events that a cell undergoes in response to certain death-inducing stimuli 
(Kerr, 1999). Apoptosis is associated with physical and biochemical 
changes in the cytoplasm, plasma membrane and nucleus of cells. The 
apoptotic cell morphology is defined by cell rounding, nuclear 
fragmentation, blebbing of the plasma membrane, loss of mitochondrial 
membrane potential and chromatin fragmentation (Ziegler and Groscurth, 
2004).  The biochemical changes that occur in apoptosis are divided into 
three main categories: (1) membrane changes and recognition of apoptotic 
cells by phagocytic cells; (2) breakdown of DNA and cellular proteins and 
(3) caspase activation.  
In early apoptotic cells, phosphatidylserine, which is normally 
located on the inner plasma membrane of the cell, becomes externally 
exposed. This external expression is recognised by phagocytic cells and 
results in the phagocytosis of the apoptotic cell, normally without activating 
an inflammatory response. Other features of apoptosis include DNA 
breakdown via endonuclease activation and caspase activation. This latter 
event results from the activation of the group of cysteine proteases, which 
can cleave a number of cellular proteins (reviewed in (Wong, 2011)). 
Apoptosis is classified into two major pathways; death-receptor-
mediated (extrinsic) and mitochondrial-mediated (intrinsic) pathways. 
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1.4.1 Receptor-Mediated Apoptosis (Extrinsic pathway) 
The extrinsic pathway of apoptosis is one of the major mechanisms 
that results in cell death. It is activated when extracellular ligands bind to 
plasma membrane receptors to ultimately trigger apoptosis. The typical 
death receptors are Fas (Apo-1 or CD95) and Tumour Necrosis Factor 
Receptor (TNF-R), and their ligands are Fas ligand (FasL) and TNF, 
respectively. These receptors recruit adapter proteins such as Fas-associated 
death domain (FADD) and TNF receptor associated death domain 
(TRADD), as well as cysteine protease (caspase 8) via their intracellular 
death domains.  
These receptor-ligand-adaptor protein complexes are termed death-
inducing signalling complexes (DISC), which then activate pro-caspase 8 to 
become an initiator caspase. This initiator caspase then activates the 
executioner caspases to degrade cellular targets (Schneider and Tschopp, 
2000). 
1.4.2 Mitochondrial-Mediated Apoptosis (Intrinsic pathway) 
The intrinsic pathway is activated within cells by various internal 
stimuli or growth factor/cytokine depletion. These internal stimuli include 
genetic damage, high concentrations of cytosolic calcium, hypoxia, and 
oxidative stress. This pathway is often activated when the cell no longer 
receives growth factors/cytokines or when there is disruption in the 
expression/localisation/activity of members of the B cell lymphoma 2 (Bcl-
2) family of proteins (see below). It results in disruption of the potential of 
the inner mitochondrial membrane and the release of anti-apoptotic 
molecules, such as cytochrome c into the cytosol to bind with apoptotic 
protease activation factor-1 (Apaf-1). This binding, together with ATP, 
triggers apoptosome formation, which contains seven molecules of Apaf-1, 
seven cytochrome c molecules, and seven Procaspase-9 molecules. This 
results in activation of the initiator apoptosome-bound, procaspase-9. This 
then activates downstream effector caspases, particularly caspase-3, to 
cleave cellular targets (Lawen, 2003, Danial and Korsmeyer, 2004). Other 
apoptotic factors that are released from the space between the outer and 
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inner mitochondrial membranes into the cytoplasm include mitochondria-
derived activator of caspases (Smac) and direct IAP binding protein with 
low pI (DIABLO). These proteins can also promote caspase activation via 
binding to inhibitor of apoptosis proteins (IAP). This contributes to 
inhibition of the interactions between IAPs and caspase-3 and/or caspase-9 
(Kroemer et al., 2007, LaCasse et al., 2008). 
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Figure 1.11 The extrinsic and intrinsic pathways of apoptosis The 
extrinsic pathway is activated by death receptor ligands binding to death 
receptors leading to activated caspase 8 by the receptor-associated death 
domains. Then, effector caspases are activated by caspase 8. The intrinsic 
pathway is regulated by Bcl- 2 family proteins.  BH-3 family members 
(initiators) are activated and then inhibit pro-survival Bcl-2 family 
(guardians), thus enabling activation of BAX and BAK (pro-apoptotic 
effectors), which form pores in the mitochondrial membrane to release 
cytochrome C. Cytochrome C then promotes caspase 9 activation through 
APAF-1 to activate effector caspases (Redrawn from (Czabotar et al., 
2014)). 
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1.5 Apoptosis and carcinogenesis 
Delayed or resistance to apoptosis can lead to cancer development. 
In general, the mechanisms that alter apoptosis in cancer cells can be 
divided into three main categories: (1) disruption of pro-apoptotic and anti-
apoptotic proteins; (2) decreased caspase activity and (3) impairment of 
death receptor signalling.  
1.5.1 Disruption of pro-apoptotic and anti-apoptotic proteins 
Anti-apoptotic members of the Bcl-2 family are often located at the 
outer membrane of mitochondria, where they function to preserve to 
mitochondrial membrane permeability (Martinou and Youle, 2011). 
The Bcl-2 protein family is divided into three subgroups based on 
their pro- or anti-apoptotic function and the number of Bcl-2 Homology 
(BH) domains that they possess. Bcl-2 family proteins have motifs of 
sequence homology known as BH domains. Some pro-survival family 
members have four BH domains (except Mcl-1 that has only three BH 
domains) and adopt similar globular structures. However, BH3-only family 
members express only the BH3 domain (Kvansakul et al., 2008, Hinds et 
al., 2007) (Figure 1.12). 
Changes in the function or localization of these proteins results in a 
deregulation of apoptosis by an imbalance in the interactions of pro-
apoptotic and anti-apoptotic proteins. This can result from over-expression 
of an anti-apoptotic protein or under-expression of a pro-apoptotic protein, 
or a combination of both. There are various reports that show that 
deregulation of expression of Bcl-2 family proteins is involved in many 
types of cancer, such as neuroblastoma, glioblastoma, breast cancer, and 
CML (reviewed in (Frenzel et al., 2009). 
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Figure 1.12 Sequence homology and structure of Bcl-2 family proteins 
Some anti-apoptotic proteins possess four BH domains (BH1-BH4) while 
the BH3-only proteins possess only the BH3 amphipathic helix, which 
allows them to interact with other Bcl-2 family member proteins (Redrawn 
from (Czabotar et al., 2014)).  
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1.5.1.1 Pro-survival or Anti-apoptotic Bcl-2 Family Members 
This subgroup includes Bcl-2, Bcl-XL, Bcl-w, Bfl-1/A1, and 
myeloid cell leukaemia sequence 1 (Mcl-1) (Figure 1.12). They all possess 
anti-apoptotic functions by preventing mitochondrial outer membrane 
permeabilisation (MOMP).  Structural studies have revealed that BH 
domains (BH1, BH2, and BH3) of these anti-apoptotic proteins possesses a 
hydrophobic groove on their surface and thus act as a binding site for the α-
helical BH3 domain of pro-apoptotic proteins, in order to neutralize their 
pro-apoptotic action (Petros et al., 2004).  
They protect mitochondrial membrane integrity and inhibit 
apoptosis via inhibiting other pro-apoptotic proteins, such as Bak and Bax, 
which may otherwise form pores in the mitochondrial membrane via 
oligomerisation (Khemtemourian et al., 2006). Anti-apoptotic family 
members also therefore prevent activation of various initiator caspases and 
prevent Apaf-1 and caspase 9 activation (reviewed in (Youle and Strasser, 
2008)).   
Mcl-1 protein has unique characteristics among the anti-apoptotic 
subgroup of Bcl-2 family, due to its short half-life and ability to undergo 
post-translational modifications in its unique N-terminal domain. This 
domain contains many sites that are subject to reversible modifications, 
such as ubiquitination and phosphorylation (Figure 1.13) (Akgul, 2009). In 
addition, it has a relatively large size (350 amino acids and residues) 
compared to other members in Bcl-2 family, such as Bcl-2 (239 residues) 
and Bcl-XL (233 residues) (Day et al., 2005). Mcl-1 protein levels are 
dynamically regulated in cells (via changes in its rate of synthesis and 
turnover) and it is an important regulator of cell survival, particularly in 
cancer cells.  
Over-expression of Mcl-1 is associated with a number of 
malignancies that include several types of tumours, including CML 
(Aichberger et al., 2005).  
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Figure 1.13 A schematic representation of the functional domains and 
sites of post-translational modification of Mcl-1 protein. The 
transmembrane (TM), the Bcl-2 homology domains (BH1-3), two weak 
(lower case) and two strong (upper case) PEST sequences are highlighted 
along with post-translational sites, including ubiquitination (Ub), caspase 
cleavage (Casp), and phosphorylation (Phos). A schematic representation of 
Bcl-2 protein is also shown below to compare the relative size and domain 
organization (Redrawn from (Thomas et al., 2010)).  
  
52 
 
1.5.1.2 Pro-apoptotic Family Members 
This subfamily includes Bak, Bax, and Bok. Their protein oligomers 
can insert into the mitochondrial membrane which results in pore formation 
and the release of the apoptotic factor, cytochrome c, leading to activation 
of caspases. These activated caspases then cleave specific cellular proteins 
leading to cell death (Petros et al., 2004).  
1.5.1.3 BH-3-only Family Members 
The proteins in this subgroup share similarity only in the BH3 
domain, and comprise proteins, such as BH3-interacting domain death 
agonist (Bid), Bim, Bad, Bik, Bmf, Hrk, Noxa, Diva, and Puma. In 
response to intracellular signals, BH3-only proteins initiate apoptosis by 
either inhibiting anti-apoptotic proteins or activating pro-apoptotic proteins 
(Chen et al., 2005, Willis et al., 2005, Willis et al., 2007, Letai et al., 2002, 
Kuwana et al., 2005). BH3-only proteins bind to the hydrophobic groove of 
anti-apoptotic proteins and pro-apoptotic proteins in order to neutralise (Liu 
et al., 2003, Petros et al., 2004). 
Bid has a unique activation mechanism among this subgroup 
because it interconnects the death receptor mediated pathway and the 
mitochondrial mediated pathway (Kaufmann et al., 2007). The structure of 
Bid is different from other family members because it has a key BH3 
residue that is normally inactivated (Chou et al., 1999, McDonnell et al., 
1999).  After death receptor simulation, Bid is then cleaved by caspase 8 
into tBid, which then induces apoptosis by enhancing oligomerisation of 
pro-apoptotic proteins (Wei et al., 2001, Eskes et al., 2000).  
1.5.1.4 Bcl-2 family in Chronic Myeloid Leukaemia 
Many studies have shown that BCR-ABL positive cells are 
relatively resistant to apoptosis. In part, this may be explained by the fact 
that BCR-ABL activates many signalling pathways, some of which regulate 
the expression of Bcl-2 protein members.  
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There many reports that show that altered expression of anti-
apoptotic proteins is involved in CML pathology. For example, the level of 
expression of the anti-apoptotic protein, Bcl-2, was downregulated after 
treatment with imatinib (Jacquel et al., 2003), suggesting that this protein is 
involved in CML pathogenesis. Moreover, levels of expression of another 
anti-apoptotic protein, Bcl-XL were increased by activation of the PIK-
3/Akt pathway through BCR-ABL (Tzifi et al., 2012). Another study 
showed that Mcl-1 expression was higher in BCR-ABL expressing cells, 
when compared to normal cells and imatinib decreased the level of Mcl-1 
expression in CML cell lines (Aichberger et al., 2005).   
In addition to the effects of BCR-ABL on expression of anti-
apoptotic protein, pro-apoptotic proteins are also affected. BCR-ABL 
expression prevents translocation of the pro-apoptotic proteins, Bad and 
Bax, and binding with the mitochondrial membrane. This loss of apoptosis 
control can lead to more unregulated cell growth and development of TKI 
resistance (Keeshan et al., 2002).   
1.5.2 Decreased caspase activity   
The caspases that play a role in apoptosis can be classified into 
initiator caspases and effector caspases. The initiator caspases (caspase-2, -
8,-9, and -10) are primarily responsible for initiation of apoptosis pathway, 
while the effector caspases (caspase-3, -6, and -7) are responsible for the 
cleavage of cellular targets (Fink and Cookson, 2005).  
Down-regulation of caspase activity has been reported in many 
types of cancer. For example, the down-regulation of caspase-9 has been 
frequently found in colorectal cancer patients (Shen et al., 2010). In 
addition, there is a report showing that deficiency of caspase-3 leads to 
breast cancer cell survival and resistance to chemotherapeutic agents 
(Devarajan et al., 2002).  
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1.5.3 Impairment of death receptor signalling 
Death receptors and their ligands play a central role in the extrinsic 
pathway of apoptosis.  These receptors possess a death domain that can 
bind to various effector molecules after the cell receives a death signal. This 
results in the activation of a signalling cascade leading to caspase 
activation. A number of abnormalities of death receptors have been reported 
in leukaemia, including the down-regulation of death receptor expression 
and the impairment of death receptor function. For example, the down-
regulation of the Fas receptor was found in treatment-resistant leukaemia 
(Friesen et al., 1997).  
1.6 Novel Agents in CML Therapy  
A number of new approaches and agents have been developed as 
alternative treatments for imatinib-resistant CML. These include 
modifications/derivatives of conventional therapeutic agents (new 
generations of TKIs) and other protein kinase inhibitors which target 
activated signal transduction pathways in CML. 
Inhibiting the downstream signalling pathways of BCR-ABL 
activity is an important strategy to improve imatinib-resistant CML therapy. 
There are several studies showing that the combination of the conventional 
TKIs and inhibitors that down-regulate BCR-ABL signalling pathways 
leads to an additive or even synergistic effect in imatinib-resistant CML 
models. For example, the combination of imatinib and OSU03012, a PDK-
1 inhibitor, has been shown to induce synergistic effects in imatinib-
resistant cell lines (Tseng et al., 2005). As a result of some of these additive 
and synergistic drugs effect in CML cell models, some of these inhibitors 
have now entered clinical trials for CML patients (reviewed in (Deininger et 
al., 2005)). In addition, other inhibitors that target different pathways are 
also reported for use in CML, including aurora kinase inhibitors and 
proteasome inhibitors, as described in the following sections.  
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1.6.1 PI3K inhibitors 
Phosphatidylinositol 3-kinases (PI3K) are a family of lipid kinases 
that mediate intracellular signalling from cell surface receptors. One such 
inhibitor, CAL-101 (GS11-01), is a PI3K inhibitor that has shown 
preclinical activity in CML cell lines. CAL-101 enhanced apoptosis in 
CML cell lines when used in combination with nilotinib (Airiau et al., 
2013). Moreover, another study showed that the PI3K inhibitor, 
wortmannin (KY12420), enhanced the effect of imatinib in induction of 
apoptosis in imatinib-resistant CML cell lines (Klejman et al., 2002). 
1.6.2 Cyclin Dependent Kinase inhibitors 
A recent report supported the idea that CML is associated with 
altered CDK activity, particularly CDK2. CDKs are a family of 
serine/threonine kinases that are involved in cell cycle progression (Diallo 
and Prigent, 2011).  A number of oncogenes in CML, such as ras, target 
CDKs leading to their inappropriate activation. Thus, targeting CDKs is a 
promising future avenue for CML treatment (Cortez et al., 1997) (more 
details are described in section 1.7). 
1.6.3 Aurora kinase inhibitor 
Aurora kinases comprise a family serine/threonine kinases that are 
essential for cell proliferation. They play a role in cell division by 
controlling chromatid segregation while their over-expression has been 
found in various types of cancers, such as leukaemia and colon cancer (Fu 
et al., 2007).  There are three major types of aurora kinase: aurora kinases 
A, B, and C. Aurora kinase A is involved in mitotic spindle formation and 
centrosome maturation, while aurora kinase B is involved in binding of the 
mitotic spindle to the centromere (Giet and Prigent, 1999). However, the 
function of aurora C is still unclear (Katayama et al., 2003). 
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The pan inhibitor of aurora kinases, danusertib, has entered phase II 
clinical trials in imatinib-resistant CML patients, as it has been found to 
inhibit the T315I mutant of BCR-ABL (Gontarewicz et al., 2008a, 
Gontarewicz et al., 2008b). 
1.6.4 Proteasome inhibitors 
The ubiquitin-proteasome pathway provides a major intracellular 
mechanism to degrade cellular components and is thus critical for cell 
survival and function. Proteasome inhibitors suppress proteasomal 
degradation of several cell cycle regulator proteins, as well as Bcl-2 family 
proteins (reviewed in (Crawford et al., 2011)).   
The proteasome inhibitor, bortezomib, inhibits cell proliferation and 
induces apoptosis in imatinib-resistant CML cells (Gatto et al., 2003, Soligo 
et al., 2001). Moreover, the combination of proteasome inhibitor with 
imatinib and other agents such as CDK inhibitors, showed synergistic 
effects on growth inhibition in imatinib-resistant CML cell lines in vitro 
(Yu et al., 2003, Dai et al., 2004). 
1.7 Cyclin-Dependent Kinases and Cell Cycle Regulation 
Cyclin-dependent kinases (CDKs) play important roles in the 
sequence of events that control progression through the cell cycle. 
Deregulation of CDK activity results in various proliferative disorders, 
especially cancer.  
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1.7.1 Control of the Cell Cycle 
Cell division is defined by DNA replication and segregation of 
replicated chromosomes into two separated cells. Cell division consists of 2 
stages: (1) mitosis (M phase) and (2) the interphase between mitosis. The M 
phase consists of prophase, metaphase, anaphase, and telophase, while 
interphase can be divided into G1, S, and G2 phases (Norbury and Nurse, 
1992). DNA replication occurs in the S phase which is preceded by G1 gap 
(a gap for cell preparation) and is followed by G2 Gap (a gap for cell 
preparation for mitosis). In addition, there is a G0 Gap which is a cell 
resting stage. Therefore, a cell in G1 phase can enter G0 phase and stop 
growing and proliferating (Figure 1.14). 
Transition between phases of cell cycle is regulated by different 
cellular proteins. CDKs are the key regulatory proteins which are activated 
by cyclins at specific points of the cell cycle. Activated CDKs then 
phosphorylate various proteins (Morgan, 1995). 
1.7.2 CDK Diversity and Function 
Several CDKs have been identified in mammalian cells. Each CDK 
contains a catalytic core, which remains inactivated until it forms a complex 
with its cyclin partner. This generates a conformational change in the CDK 
to expose its ATP-binding site (Fisher and Morgan, 1994). In addition to 
cyclin binding, CDKs are required to be phosphorylated at conserved 
tyrosine and threonine residues by cdk-activating kinase (CAK; cyclin H 
and CDK7) which results in conformation changes for enhanced cyclin 
binding (Jeffrey et al., 1995). CDKs functions in cell cycle regulation are 
described in Table 1.2. 
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Table 1.2 Mammalian CDKs and Cyclins (reviewed in (Vermeulen et al., 
2003, Fischer and Lane, 2000)) 
CDK Associated cyclins Function 
CDK1 and CDK2 A G2-M transition and S phase 
progression 
CDK1 B1 and B2 G2 phase exit and mitosis 
CDK2 E G1-S phase transition 
CDK4 and CDK6 D1, D2, and D3 G0-S phase transition 
CDK5 G1 and G2 DNA damage response 
CDK7 H CDK activation (CAK), 
transcriptional regulation, and 
DNA repair 
CDK9 T1 and T2 Transcriptional regulation 
 
CDKs can be divided into two groups based on their roles in cell 
cycle progression and transcriptional regulation (Meyerson et al., 1992). 
The first group that is involved in cell cycle progression includes CDK1, 2, 
4, and 6. CDK4 and 6 are associated with cyclin D to facilitate G1 entry 
(Sherr, 1994), while the CDK2/cyclin E complex facilitates G1 to S phase 
transition (Ohtsubo et al., 1995). The CDK2 and cyclin A complex is 
required for S phase progression (Girard et al., 1991). CDK1 can form a 
complex with either cyclin A or cyclin B in order to facilitate G2 to M 
phase transition and M phase progression, respectively (King et al., 1994) 
(Figure 1.16). This activation is regulated by phosphorylation via CAK 
(Harper and Elledge, 1998). 
The other group of CDKs that is involved in transcriptional 
regulation consists of CDK7/cyclin H and CDK9/cyclin T. They promote 
initiation and elongation of RNA transcripts through phosphorylating RNA 
polymerase II (Palancade and Bensaude, 2003). 
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Figure 1.14 The stages of cell cycle. The sites of cell cycle progression 
regulated by CDK and their associated cyclins are indicated (Redrawn from 
(Vermeulen et al., 2003)).  
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1.7.3 CDK Inhibitors in Anti-cancer Drug Development 
In view of the fact that CDKs and their regulators are altered in 
many types of cancer, the development of chemical CDK inhibitors as 
potential anti-cancer agents has been a major focus for drug discovery. Two 
different strategies have been utilised; inhibiting CDK activity (direct 
strategy) and targeting CDK regulators (indirect strategy). However, the 
direct strategy has had far more success to date than the indirect strategies. 
More than 50 inhibitors that can inhibit CDK activity have been discovered 
so far (reviewed in (Fischer and Lane, 2000)), and some of these are in 
clinical trials. These CDK inhibitors exhibit ATP antagonist activity by 
binding to the ATP- binding site of the CDKs. CDK inhibitors that have 
been developed so far are summarized below. 
1.7.3.1 Purine Analogues  
The natural phytohormone, dimethylaminopurine, was first 
identified as a CDK inhibitor that inhibits CDK1/cyclin B complex activity 
(Neant and Guerrier, 1988).  This finding led to the development of the 
synthetic purine analogue, olomoucine, which is a highly specific CDK 
inhibitor (Vesely et al., 1994). Olomoucine has been found to inhibit cell 
proliferation and induce apoptosis in various types of cancer by inhibiting 
both CDK1/cyclin B and CDK2/cyclin E/A complexes (Abraham et al., 
1995).  
From the success of olomoucine in CDK inhibition, another 
synthetic purine, roscovitine, has been developed. Roscovitine generates 
more potent inhibitory effects with CDK1/cyclin B complex and 
CDK2/cyclin E/A complex compared to olomoucine. It has a strong anti-
proliferative effect, and now has entered clinical trials for solid tumour 
treatment (Meijer et al., 1997, Clough, 2002, Cicenas et al., 2014). Another 
purine-based molecule that exhibits CDK inhibitory effects is purvalanol A 
which is a trisubstituted purine that has been found to inhibit CDK2 activity 
(Gray et al., 1998) (for more detail see section 1.8). 
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1.7.3.2 Butyrolactone 
Butyrolactone was isolated from the fungus, Aspergillus strain F-
25799. It is a CDK inhibitor which exhibits inhibitory effects on CDK1, 
CDK2 and CDK4 (Kitagawa et al., 1993). Butyrolactone I inhibits cell 
cycle proliferation in lung-, colon-, and pancreatic-cancer cell lines 
(Kitagawa et al., 1994, Yamamoto et al., 1998).  
1.7.3.3 Flavonoids 
Flavonoids have been found to inhibit various protein kinases, 
especially protein kinase C. The most important flavonoid that inhibits 
CDK activity is flavopiridol, which is a synthetic analogue of a natural 
plant alkaloid. It has been found to inhibit CDK1, CDK2 and CDK4 
activities (Carlson et al., 1996). Before entering clinical trials, flavopiridal 
showed an inhibitory effect on many cell lines, such as breast and lung 
cancer cell lines (Kaur et al., 1992). It has entered phase I and phase II 
clinical trials and has been found to decrease cancer cell proliferation in 
solid tumours, pancreatic cancer, and leukaemias (Carvajal et al., 2009, 
Blum et al., 2010, Lin et al., 2009).  
1.7.3.4 Paullones 
Paullones were discovered during an in vitro anti-proliferative drug 
screening programme by National Cancer Institute (NCI). It has been found 
to inhibit CDK1 and CDK2. Among this group of compounds, kenpaullone 
was identified as an inhibitor of CDK1/cyclin B, CDK2/cyclin A and 
CDK2/cyclin E complexes by arresting cell cycle progression at the G1/S 
boundaries in breast cancers (Zaharevitz et al., 1999).  
1.7.3.5 Indolinones 
Indirubin was originally isolated from a Chinese herbal mixture and 
has been used to treat CML. Recently, indirubin and its analogues have 
been found to exhibit inhibitory effects to CDK1, CDK2, CDK4, and 
CDK5, and to induce cell cycle arrest at the G2/M phase boundaries 
(Hoessel et al., 1999). 5’-OH-5-nitro-idirubin oxime (AGM130) is a 
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synthetic idirubin derivative that efficiently decreases the viability of 
imatinib-resistant CML cell lines (Kim et al., 2013).  
1.7.3.6 Non-specific CDK inhibitors 
This group of compounds is characterized by non-specific effects 
that inhibit protein kinase activities. Thus, not only CDK activities are 
inhibited, but also other protein kinases such as protein kinase C. This 
group includes suramin, quinazolines, aminothiazole, and staurosporine. 
Staurosporine is a microbial alkaloid that was isolated from Streptococcus 
sp. It inhibits both CDK1 and PKC to induce cell cycle arrest. 
Staurosporine analogues also exhibit an anti-proliferative effects on various 
cancer cell lines and this has now entered clinical trials for treating non-
small-cell-lung cancer (Tamaoki, 1991, Gani and Engh, 2010). 
1.8 CDK inhibitors and CML  
Among the above-mentioned CDK inhibitors, flavopiridol (HMR 
1275, L86-8275) has entered clinical trials for treatment of CML. 
Flavopiridal demonstrated potent and specific in vitro inhibition of various 
CDKs (CDK 1, 2, 4 and 7) and inhibits cell cycle progression at the G1/S 
and G2/M boundaries. In addition, it also inhibits angiogenesis (Rapella et 
al., 2002) and transcriptional processes through inhibition of the 
CDK9/cyclin T complex (Chao and Price, 2001).  
Flavopiridal induces apoptosis in human leukaemic cells in both in 
vitro and in vivo experiments (Decker et al., 2001) and it enhances the 
activity of imatinib in imatinib-resistant CML cell lines (Yu et al., 2002). 
Thus, the combination use of flavopiridal and imatinib has entered phase I 
clinical trials in CML patients and responses are favourable, particularly in 
imatnib-resistant CML patients (Bose et al., 2012). Moreover, the 
combination of flavopiridol and other agents, such as the proteasome 
inhibitor, bortezomib, and microtubule-targeting agent, pyrrolo-1, 5-
benzodiazepine, have also been found to induce synergistic effects in 
inducing apoptosis in imatinib-resistant CML cell lines (Dai et al., 2004, 
Bright et al., 2010).  
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1.9 Purvalanol A 
Purvalanol A binds between the 2,6,9-trisubstituted purines and the 
ATP-binding site of the human cyclin dependent kinase 2 (CDK2) (Gray et 
al., 1998, Gray et al., 1999). This competitive inhibition of ATP binding 
induces a reversible arrest in the G1 and G2 phases of the cell.  
Purvalanol A inhibits the phosphorylation of cyclin dependent 
kinase substrates, such as Retinoblastoma protein (Rb) and cyclin E. 
Moreover, it increases the level of the cdk inhibitory protein, p21 WAF1/CIP1. 
These effects lead to inhibition of cell proliferation in a range of human 
cancer cell lines and mouse fibroblasts (Villerbu et al., 2002). Purvalanol A 
also suppresses Src-mediated transformation of cells.  It has been shown 
that it suppresses c-SRC transformation by inhibiting both cell cycle 
progression and c-SRC signalling. Therefore, the multi-target, purvalanol A 
could be a potential inhibitor of cancers that are characterised by c-SRC up-
regulation (Hikita et al., 2010).  
  Recent studies in human cancer cell lines showed that purvalanol 
A treatment inhibits both CDK2 and the expression of several anti-
apoptotic proteins of the Bcl-2 family. Studies in the human gastric 
adenocarcinoma and aggressive breast cancer cell lines showed that 
purvalanol A affected both Bcl-2 and Bcl-XL (Iizuka et al., 2007, OBakan 
et al., 2014). Furthermore, it can inhibit the phosphorylation at Tyr707 of 
STAT3 by Janus kinase 2 (JAK2). Therefore, these data suggest that 
purvalanol A can induce apoptotic cell death by both the down-regulation 
of anti-apoptotic proteins, and the inhibition of JAK2/STAT3 and 
polymerase II (Iizuka et al., 2008).   
Purvalanol A has now been used in preclinical trials for treating 
several cancers (Cicenas and Valius, 2011) and so its mechanism of action 
and effects on drug transporter processes have been investigated. A recent 
study showed that Purvalanol A is not transported by Breast Cancer 
Resistance Protein (ABCG2) and P-glycoprotein (ABCB1) (Hofman et al., 
2013). In addition, Purvalanol A can inhibit ABCG2 and ABCB1 
transporter in ABCG2- and ABCB1- expressing cells, respectively 
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(Hofman et al., 2013). Thus, this drug is now an interesting candidate for 
treating efflux transporter-based multidrug resistant tumours.  
 
 
 
Figure 1.15 Chemical structure of Purvalanol A (Monaco et al., 2004) 
Purvalanol A is a 2,6,9-trisubstituted purine that inhibits CDK2. 
1.10 Summary 
CML is a biphasic, myeloproliferative disorder that is associated 
with expression of the BCR/ABL fusion gene, which encodes a 
constitutively-active protein tyrosine kinase, leading to a deregulation of 
tyrosine kinase activity.  Although the BCR/ABL tyrosine kinase inhibitor, 
imatinib, is the frontline therapy for CML, imatinib acquired resistance 
from mutations in the BCR/ABL gene is a major problem for therapy. Thus, 
there is a need to find a novel ways to overcome TKI resistance in this 
disease.  
This research project investigates the roles of the protein kinase 
inhibitor, purvalanol A, in regulating growth and survival in the imatinib-
sensitive and imatinib-insensitive CML cell lines, LAMA-84 and KCL-22, 
respectively.  
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1.11 Research Aims 
The aims of the research are to investigate the effects of purvalanol 
A on apoptosis of TKI-insensitive CML cells and to elucidate its 
mechanism of action. The main objectives of this study are: 
i) To determine the effects of purvalanol A on apoptosis of TKI-
sensitive and -insensitive CML cells. 
ii) To investigate the mechanism of action of purvalanol A on CML 
cells. 
iii) To identify the signalling pathways regulated by purvalanol A 
iv) To determine the effect of purvalanol A on primary immune 
cells. 
v)  To investigate the mechanism of action of JAK3 inhibitor, 
ZM39923 in CML cells. 
1.12 Hypothesis 
The main hypothesis to be tested in this project is that “Purvalanol 
A will provide an adjunct to TKIs in the treatment of CML by inducing 
apoptosis in TKI-insensitive CML cells”. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
 
Table 2.1 Materials for neutrophil isolation 
Materials Supplier 
Lithium heparin vacutainers Grenier Bio-one (Gloucestershire, 
UK) 
HetaSepTM Stem cell technologies 
(Cambridge, UK) 
Ficoll-PaqueTM GE Healthcare (Buckinghamshire, 
UK) 
RPMI 1640 (+25 mM Hepes with L-
glutamine) 
Gibco (Paisley, UK) 
 
Fetal Bovine Serum 
Human pooled AB serum Sigma (Poole, UK) 
 Ammonium chloride lysis buffer 
 Ammonium chloride 
(NH4CL) 
 Potassium hydrogen 
carbonate (KHCO3) 
 Ethylenediaminetetracetic 
acid (EDTA) 
Isoton Beckman Coulter Inc. (Florida. 
USA) 
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Table 2.2 Materials for CML cell culture 
Materials Supplier 
RPMI 1640 Gibco (Paisley, UK) 
 Foetal Bovine Serum 
Penicillin-Streptomycin 
Isoton Beckman Coulter Inc. (Florida. 
USA) 
Rapid Romanowsky stain HD Supplies (Aylesbury , UK) 
 
Table 2.3 Materials for Guava ViaCount assay 
Materials Supplier 
Guava ViaCount reagent Millipore (Hertfordshire, UK) 
 
Table 2.4 Materials for cell cycle analysis 
Materials Supplier 
Phosphate buffered saline Gibco (Paisley, UK) 
Propidium iodine Sigma (Poole, UK) 
 Ribonuclease A 
Ethanol 
Triton X-100 
  
Table 2.5 Materials for Annexin V and PI assay 
Materials Supplier 
Hanks balanced salt solution Gibco (Paisley, UK) 
FITC-conjugated Annexin V Invitrogen (Paisley, UK) 
Propidium iodide Sigma (Poole, UK) 
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Table 2.6 Materials for preparation of protein lysates and Western blotting 
Materials Supplier 
Laemmli lysis buffer 
 Glycerol 
 Tris 
 Sodium dodecyl sulphate 
Fisher Scientific (Loughborough, 
UK)  
Dithiothreitol  Sigma (Poole, UK) 
 Bromophenol blue 
Pierce™ BCA protein assay kit Fisher Scientific (Loughborough, 
UK) 
SDS running buffer 
 Glycine 
 Sodium dodecyl sulphate 
 Tris 
Sigma (Poole, UK) 
 
 
 
Transfer buffer 
 Tris 
 Glycine 
 Methanol 
Washing buffer 
 Tris 
 Sodium Chloride 
 Tween-20     
Hydrochloric acid VWR International 
(Leicestershire, UK) 
Stripping buffer 
 Glycine 
 Sodium Chloride 
Sigma (Poole, UK) 
 
Phosphate buffer saline tablets Oxoid Ltd (Basingstoke, UK) 
Ammonium persulphate Sigma (Poole, UK) 
 Isopropanol 
Tetramethylethylenediamine 
Acrylamide solution Severn Biotech (Kidderminster, 
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UK) 
Biotinylated protein ladder detection 
pack 
Cell-Signalling Technology 
(USA) 
Polyvinylidene fluoride membrane Millipore (Hertfordshire, UK) 
Whatman filter paper Sigma (Poole, UK) 
 Ponceau S 
Marvel non-fat dry milk Home Bargain (Liverpool, UK) 
Bovine serum albumin Sigma (Poole, UK) 
Immobilon P membrane 
Chemiluminescence HRP substrate 
Millipore (Billerica, UK) 
Film developing (developer and fixer) Millipore (Hertfordshire, UK) 
Enhanced chemiluminescence 
Hyperfilm 
Amersham Life Science (Bucks, 
UK) 
 
Table 2.7 Western blotting antibodies 
Materials Supplier 
anti-human Mcl-1  
#HPA008455 
Sigma (Poole, UK) 
anti-human Mcl-1  
#4572 
Cell-Signalling Technology (USA) 
 
anti-human Bcl-2 
 #2870 
anti-human Bcl-XL  
#2764 
anti-human Bak  
#3814 
anti-human p-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (E10)  
#9106 
anti-human p44/42 MAPK (Erk1/2) 
#9102 
anti-human p-STAT3 (Tyr705) 
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(3E2)  
#9138 
anti-human STAT3 (124 h6)  
#9139 
anti-human p-Akt (Ser473)  
#9271 
anti-human Akt  
#9272 
anti-human p-NFKB p65 (Ser536) 
(93 h1)  
#3033 
anti-human Phospho-p38 MAPK 
(Thr180/Tyr182) (28B10)  
#9216 
anti-human p38 MAPK  
#9212 
anti-human p-Mcl-1 
(Ser159/Thr163) 
#4579 
anti-human β-actin  
#ab8226 
Abcam (Cambridge, UK) 
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Table 2.8 Material for isolation of mRNA, cDNA synthesis and quantitative 
PCR 
Materials Supplier 
RNeasy kit Qiagen (Crowley, UK) 
 DNA digestion solution 
Quantitect SYBR green PCR kit 
Superscript III first strand cDNA 
synthesis kit 
Invitrogen (Paisley, UK) 
 
RNase OUT RNase inhibitor 
Random primers Promega (Southampton, UK) 
Primers Eurofins (UK) 
 
Table 2.9 Other materials 
Materials Supplier 
Imatinib Cell Signalling (Herts, UK) 
Purvalanol A Tocris Bioscience (Bristol, UK) 
ZM39923 
MG-132 
Pan caspase inhibitor Calbiochem (Darmstadt, Germany) 
Cycloheximide Sigma (Poole, UK) 
Phosphatase inhibitor 
JC-1 dye ThermoFisher Scientific (Waltham, 
USA) FCCP 
BIRB796 Selleck Chemicals (Houston, USA) 
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2.2 Methods 
2.2.1 Cell culture 
Two BCR-ABL kinase-expressing CML cell lines were used in this 
study: LAMA-84 (imatinib-sensitive) (Seigneurin et al., 1987, le Coutre et 
al., 2000) and KCL-22 (imatinib-insensitive) (Kubonishi and Miyoshi, 
1983, Quentmeier et al., 2011). Both cell lines were generously provided by 
Prof. R. E. Clarke, University of Liverpool. Cells were grown at 37ºC in 
RPMI 1640 medium supplemented with 1 % L-glutamine, 1 % 
penicillin/streptomycin antibiotics and 10 % Foetal bovine serum (FBS) in 
a humidified atmosphere containing 5 % CO2 and maintained in 
exponential growth phase by routine passaging. Approximately 1 x 106 cells 
in 20 ml media were routinely transferred into 75 cm² flasks, as described 
below.  
For passaging, the cell suspension was centrifuged at 500 g for 4 
min at 37˚C. The supernatant was discarded and 5 ml of media was added 
before mixing well. An aliquot was removed and, after a suitable dilution in 
isoton (balanced electrolytic solution), the cell concentration was measured 
using a Multisizer 3 cell counter (Beckman coulter). Fresh medium was 
added so that the final cell density was 5 x 104 cells/mL.  
For cytospins, cells were diluted into a final concentration of 1 x 105 
cells/200 µL of phosphate buffered saline (PBS) before being centrifuged at 
30 g for 5 min in a Shandon Cytospin3. Cells were then stained with Rapid 
Romanowsky staining and checked under the light microscope.  
Cells were cultured (in the presence and absence of inhibitors) as 
described in the text, and to avoid mutations, cultures were replenished 
from frozen stocks every 3 months.  
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2.2.2 Isolation of primary immune cells from whole blood 
The study of adult heathy controls was approved by the University 
of Liverpool Committee for Research Ethics (CORE). Whole blood was 
collected into heparinised vacuette containers by venepuncture and 
processed within 2 h. Neutrophils and PBMCs were isolated by 
centrifuging over Ficoll-PaqueTM, as described in the manufacturer’s 
instructions. Briefly, whole blood was incubated in 5:1 ratio with 
HetaSepTM for 30 min at 37˚C. The supernatant was collected and diluted in 
RPMI 1640 media with 25 mM Hepes with L-glutamine (2 mM) before 
centrifuging at 400 g for 10 min at room temperature. The cell pellet was 
diluted in media and layered in a 1:1 ratio onto Ficoll-PaqueTM before 
centrifuging at 500 g for 30 min at room temperature. After that, the 
neutrophils and PBMCs were separated by isosmotic density barrier. The 
cell bands were then extracted and resuspended into media. The cell 
suspension was centrifuged at 500 g for 3 min before being resuspended in 
fresh media. Contaminating erythrocytes were removed by hypotonic lysis 
(ammonium chloride lysis buffer: 155 mM NH4Cl, 13.4 mM KHCO3, and 
96.7 mM EDTA). The cell media to lysis buffer ratio was 1:9. After 3 min 
incubation, the cell suspension was centrifuged at 500 g for 3 min. Cells 
were then resuspended in fresh media and counted before being adjusted a 
final concentration of 5 x 106 cells/mL. The purity of the samples was 
assessed by light microscopy and cytospins, as described for CML cell 
lines. Neutrophils and PBMCs were incubated in a 5 % CO2 incubator at 
37ºC with gentle agitation under experimental conditions as described in 
the text. 
2.2.3 Drugs 
All drugs used were listed in Table 2.9.  All solutions were kept in 
DMSO at -20˚C.  
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2.2.4 Flow cytometry for CML cell apoptosis 
2.2.4.1 Guava ViaCount assay 
Flow cytometry and the ViaCount Assay (Guava Technologies) 
were used to determine the viability of cells after culture under different 
conditions. Viability was measured by the permeability of the plasma 
membrane to DNA-staining dyes.  
25 μL of cell suspension was added to 225 μL of Guava Viacount 
reagent in each well of a 96-well plate. The contents of each well was then 
analysed on the flow cytometer using Guava software. 5,000 gated cells 
were measured and the percentages and numbers of viable cells were 
calculated for each sample.  
2.2.4.2 Cell cycle analysis 
The cell cycle kinetics assay measures the amount of the DNA per 
cell using flow cytometry by DNA staining of permeabilised cells with 
propidium iodide (PI). The DNA content per cell is related to the position 
of the cell in the cell cycle.  
200 μL of cell suspension were centrifuged at 1000 g for 4 min and 
washed in 200 μL of PBS.   Cells were then fixed in 200 μl of 70 % ethanol 
(which also increases plasma membrane permeability) for at least 2 h, 
before being washed twice and resuspended in 200 μL of PBS in a well of a 
96 well plate. 25 μl of PI solution was added (containing 1 mg/mL 
RibonucleaseA in 1 % Triton/PBS, final PI concentration of 100 µg/mL), 
and incubated for at least 1 h (in the dark) before analysing by flow 
cytometry. The data were then analysed using Guava Cell Cycle software to 
calculate the percentage of cells in different phases of the cell cycle 
(G0/Apoptotic, G1, G2 and S).  
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2.2.5 Flow cytometry to determine primary immune cell apoptosis 
Apoptosis of neutrophils and PBMCs was measured by flow 
cytometry. Phosphatidylserine expressed on the membrane of apoptotic 
cells was stained by Annexin V-FITC, while DNA was stained by PI in 
necrotic cells. Cells at a concentration of 2 x 105 in 200 µL HBSS were 
incubated with Annexin V-FITC (10 µL/mL) for 15 min at room 
temperature. Prior to the flow analysis, Propidium Iodide (final 
concentration of 100 µg/mL) was added to the cells. 5,000 gated cells were 
then analysed by the Guava Easycyte flow cytometer. 
In all experiments using the flow cytometer, the absolute number of 
cells was routinely counted in order to avoid misinterpretation due to lysed 
cells. The % and actual number of cells were routinely measured and 
compared.   
2.2.6 Flow cytometry to determine mitochondrial depolarisation 
Flow cytometry was used to measure changes in polarisation of the 
inner mitochondrial membrane by JC-1 fluorescence after incubation under 
different conditions. After incubation, suspensions containing 106 cells 
were pipetted into a 1.5 ml microfuge tube and centrifuged at 2000 g for 3 
min. The pellet was resuspended in 1 mL HBSS, 1 µl JC-1 dye (Molecular 
Probes) added (final concentration of 1 µg/mL) and incubated at 37˚C for 
15 min in the dark. 25 μl of cell suspension were removed and mixed with 
225 μl HBSS in a 96 well plate and analysed by flow cytometry. As a 
positive control to show mitochondrial membrane depolarisation, one well 
was treated with 1 µl FCCP (final concentration 1 µg/mL) and incubated at 
37˚C for further 15 min before analysis.  Membrane depolarization was 
measured as a red to green shift in fluorescence.  
2.2.7 Preparation of protein lysates 
106 CML cells per sample were centrifuged and washed with PBS to 
obtain cell pellets, which were resuspended in 100 μL hot Laemmli lysis 
buffer  (10 % (v/v) glycerol, 1 M Tris-HCl (pH 6.8), and 3 % (w/v) SDS), 
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to a final concentration of 1 x 104 cells/μL before boiling for 5 min. All 
protein extract samples were then analysed for total protein levels by the 
bicinchoninic acid (BCA) assay and adjusted to achieve the same protein 
concentration. The BCA assay is a detergent-compatible formulation for the 
colorimetric detection and quantitation of proteins. The principle of BCA is 
based on a chelation of copper with protein in an alkaline environment. 
Thus, BCA binds to the reduced cuprous cation (Cu1+) and exhibits a strong 
linear absorbance at 562 nm (Smith, et al. 1985).  
5 μL of cell lysate from each sample was incubated with 195 μL of 
BCA solution (sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tartrate in 0.1 M sodium hydroxide with 4 % cupric sulfate) in a 
96-well plate for 30 min in a 5 % CO2 incubator at 37ºC with gentle 
agitation. Then, the plates were analysed on a plate reader at 562 nm, before 
adjusting the samples to achieve equal concentrations by adding Laemmli 
lysis buffer, DTT, and bromophenol blue. Samples were then stored at -
20oC until analysis.  
2.2.8 Western blotting 
Thawed protein extract samples were re-heated and separated by 
SDS-PAGE on a 8-12% resolving gel, depending on the relative molecular 
mass of the proteins to be resolved. The resolving gels were composed of 8-
12 % (v/v) polyacrylamide, 1 % (w/v) SDS, 370 mM Tris-HCl (pH 8.8), 1 
% (w/v) APS and 0.1 % (v/v) TEMED. To induce polymerization, APS and 
TEMED were added last. The stacking gels were composed of 4.5 % (v/v) 
polyacrylamide, 1 % (v/v) SDS, 122 mM Tris-HCl (pH 6.8), 1 % (w/v) 
APS and 0.1 % (v/v) TEMED.  15 µl of protein extract was added to each 
well of the gel, with pre-stained marker proteins loaded in the first well. 
The gel was electrophoresed at 180 V for 55 min in SDS running buffer (25 
mM Tris, 0.1 % (w/v) SDS, and 192 mM glycine) using a Bio-Rad Mini 
Protean II Electrophoresis kit. Then, separated proteins were transferred 
onto a PVDF membrane by electrophoresis at 100 V for 80 min in transfer 
buffer (20 % (v/v) methanol, 12.5 mM Tris, and 95 mM glycine) using the 
same apparatus. The membrane was checked to determine if the proteins 
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had been successfully transferred onto the membrane, by immersing into 
Ponceau S stain (0.1 % (w/v) Ponceau S and 5 % (v/v) acetic acid). After 
washing off the Ponceau stain by washing buffer (150 mM NaCl, 10 mM 
Tris HCl (pH 8), and 0.1 % (v/v) Tween-20), the membrane was blocked by 
blocking solution (5 % non-fat dried skim milk (Marvel) in TBS-T (0.05 % 
Tween 20 in Tris-buffered saline, pH 8.0)) at room temperature for at least 
1 h on an orbital shaker in order to prevent non-specific antibody binding. 
After blocking, the membrane was rinsed with washing buffer for 30 sec 
and then incubated with the specific primary antibody (dilutions as 
specified by manufacturer’s datasheet, Table 2.10) at 4°C overnight on an 
orbital shaker.  
The following day, the membrane was washed with wash buffer for 
3 x 10 min and then incubated with secondary horseradish peroxidase 
(HRP)-linked antibody for 1 h on the same apparatus. After washing again 
by wash buffer for 3 x 10 min, the membrane was covered with Enhanced 
Chemiluminescence (ECL) reagents for 1 min and then exposed to 
photosensitive film for periods of 1-10 min depending on intensity of the 
signal, taking care to avoid saturation of the film. 
After developing the blot, the membrane was stripped by immersing 
in stripping buffer (50mM glycine, 150 mM NaCl, 0.1 % (v/v) Tween-20, 
and HCl to pH 2.5) for 15 min with gentle agitation and then washed. The 
membrane was re-blocked and re-probed with actin antibody to ensure 
equal loading of wells. The membrane was then developed as indicated 
above. The exposed film was then analysed by AQM advance 6 Kinetic 
Imaging System. Table 2.10 summarises antibodies used for western 
blotting.  
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Table 2.10 Western blot antibodies 
Protein of interest Primary antibody Secondary antibody 
Mcl-1 Rabbit anti-human 
Mcl-1 (1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Bcl-2 Rabbit anti-human 
Bcl-2 (1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Bcl-XL Rabbit anti-human 
Bcl-XL (1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Bak Rabbit anti-human 
Bak (1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Phospho-Erk Mouse anti-human 
phospho-Erk (1:2,000) 
HRP-conjugated sheep 
anti-mouse IgG 
(1:10,000) 
Erk Rabbit anti-human Erk 
(1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Phospho-STAT3 Mouse anti-human 
phospho-STAT 3 
(1:1,000) 
HRP-conjugated sheep 
anti-mouse IgG 
(1:10,000) 
STAT 3 Rabbit anti-human 
STAT 3 (1:2,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Phospho-Akt Rabbit anti-human 
phospho-Akt (1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Akt Rabbit anti-human Akt 
(1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Phospho-p38 Mouse anti-human HRP-conjugated sheep 
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phospho-p38 (1:2,000) anti-mouse IgG 
(1:10,000) 
p38 Rabbit anti-human p38 
(1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
Phospho-Mcl-1 Rabbit anti-human p38 
(1:1,000) 
HRP-conjugated 
donkey anti-rabbit IgG 
(1:10,000) 
β-actin Mouse anti-human β-
actin (1:10,000) 
HRP-conjugated sheep 
anti-mouse IgG 
(1:10,000) 
 
2.2.9 Isolation of CML cells mRNA 
Total mRNA of CML cells was isolated using the RNeasy kit 
(Qiagen), according to the manufacturer’s instructions. First, 106 CML cells 
were centrifuged at 1,000 g for 3 min to obtain a cell pellet.  The cell pellet 
was disrupted using 350 µL of a highly denaturing guanidine-thiocyanate-
containing buffer (Buffer RLT) with 3.5 µL β-mecaptoethanol (to inactivate 
RNases) before being homogenised by a syringe and needle. Cell lysates 
were passed through a 20-guage needle 5 times or until the lysate became 
homogeneous. Then, 350 µL ethanol (70 % (v/v) in DEPC-treated water) 
was added to create conditions that promote selective binding of RNA to a 
RNeasy silica-membrane.  After that, 700 µL of sample was transferred to 
RNase Mini spin column. Each column was then centrifuged at 8,000 g for 
15 sec and the flow-through discarded before the column was washed with 
350 µL RW1 buffer by centrifuging at 8,000 g for 15 sec. Residual DNA 
was removed from the column by DNA digestion using RNase-Free DNase. 
The column was treated by DNase I (10 µL DNase (2.7 units/µL) with 70 
µL RDD buffer) for 15 min at room temperature and washed with 350 µL 
RW1 buffer (centrifuging at 8,000 g for 15 sec). The column was then 
washed twice with 500 µL RPE buffer by centrifuging at 8,000 g for 15 sec 
and 2 min, respectively. 
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The column was then placed into a 2 ml collection tube and 
centrifuged at the full speed for 1 min to get rid of excess buffer. Then, the 
column was transferred to a new 2ml collection tube. 30 µL RNase-free 
water was directly added to the membrane before being centrifuged at 8,000 
g for 1 min in order to elute RNA in RNase-free water. 
The quantity and quality of RNA obtained was measured using a 
Nanodrop ND-100 spectophotometer. The RNA samples were then stored 
at -80˚C. 
2.2.10 cDNA synthesis 
Complementary DNA was converted from total mRNA using the 
Superscript III First Strand Synthesis Kit and RNAse OUT (Qiagen), 
according to the manufacturer’s instructions. The amount of RNA in each 
sample was adjusted between samples within each experiment with RNase–
free water to a concentration of 200-250 ng. Each RNA sample was added 
to 1 µL (250 ng or 20 µM) random primer, 1 µL (10 mM) dNTPs and 
RNase-free water to a total volume of 13 µL. The samples were then heated 
in a thermo PX2 thermal cycler at 65˚C for 5 min before cooling on ice for 
at least 1 min. A mixture of 4 µL First-Strand buffer, 1 µL (0.1 M) DTT, 1 
µL RNase OUT (RNase inhibitor), and 1 µL (200 units/µL) Superscript III 
reverse transcriptase were added to each sample. Each sample was then 
incubated 25˚C for 5 min for initiation, 50 ˚C for 60 min, and 70˚C for 15 
min. The synthesized cDNA was then stored at -20˚C. Table 2.11 
summarises the cDNA synthesis procedure. 
 
 
 
 
 
 
81 
 
Table 2.11 cDNA synthesis procedure 
Reagents Volume 
(µL) 
Concentration Temp 
(˚C) 
Time 
(min) 
RNA (with RNase-free 
water) 
Random primer 
dNTPs 
11 
 
1 
1 
200-250 ng/µL 
 
20 µM 
10 mM 
60 
 
On ice 
5 
 
>1 
First-Strand buffer 
DTT 
RNase OUT 
Superscript III reverse 
transcriptase 
4 
1 
1 
1 
5X 
0.1 M 
40 units/ µL 
200 units/ µL 
25 
 
50 
70 
5 
 
60 
15 
Total volume 20 
 
2.2.11 SYBR based Quantitative Polymerase Chain Reaction  
SYBR based Quantitative Polymerase Chain Reaction (qPCR), was 
used to amplify and simultaneously detect and quantify amplified 
cDNA molecules using appropriate forward and reverse primers by qPCR. 
After converting mRNA into cDNA, cDNA was quantified by a thermal 
cycler (Light cycler) using the QuantiTect SYBR green detection kit 
(Qiagen), according to manufacturer’s instructions. 1 µL cDNA was added 
to a mixture of 10 µL Quantitect and 0.8 µL (10 pM) of each forward and 
reverse primer, and RNase free-water to a 20 µL of total reaction volume. 
Each sample was prepared in duplicate and qPCR was performed using a 
Roche LightCycler 480 qPCR machine. The level of gene expression of 
target gene (e.g. Mcl-1) was normalised to β-Actin by comparing the Ct 
value, according to the Pfaffl method (Pfaffl, 2001).  Table 2.12 and 2.13 
summarise the primer sequences and quantitative PCR cycle setting 
protocols, respectively.  
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Table 2.12 Gene and Primers for qPCR 
Gene Base pair 
length 
Forward primer 5ꞌ-
3ꞌ 
Reverse primer 3ꞌ-5ꞌ 
Mcl-1L 170 TTATCTCTCGGTA
CCTCCGG 
GATGTCCAGTTTC
CGAAGCA 
β-Actin 211 CATCGAGCACGGC
ATCGTCA 
TAGCACAGCCTGG
ATAGCAAC 
 
Table 2.13 qPCR cycling parameters 
Step Temp 
(˚C) 
Time Number of 
cycles 
Analysis 
Mode 
1. Taq 
activation 
95 15 min 1 None 
2. Denaturation 
Annealing 
Elongation 
94 
55 
72 
1 min 
30 sec 
30 sec 
45 Quantification 
3. Generating 
melt curves and 
checking 
product 
specificity 
60 
 
30 sec 
 
1 Melting 
Curves 
4. Cooling 40 10 sec 1 None 
 
 
 
 
 
83 
 
2.2.12 Statistics 
All data sets are expressed as mean ± SEM, and differences are 
considered significant for p values of ≤ 0.05. Comparisons are made using a 
parametric statistical analyses, as specified and as appropriate to the data 
sets. Paired two-tailed Student’s t-test or One-way ANOVA followed by 
post hoc comparisons tests were used for normally distributed data. Error 
bars, representing SEM, are shown in most of figures, but due to the low 
error in some datasets some error bars may appear extremely small or 
undetectable.  
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CHAPTER 3:  EFFECTS OF IMATINIB ON 
IMATINIB-SENSITIVE AND -INSENSITIVE CML CELL 
LINES 
3.1 Introduction 
CML results in the increased and unregulated growth of 
predominantly myeloid cells in the bone marrow and the accumulation of 
these cells in the blood. It is associated with a single genetic abnormality 
known as the Philadelphia (Ph) chromosome which results from a t(9;22) 
reciprocal translocation to generate the BCR/ABL fusion gene.  This gene 
encodes a constitutively-active protein tyrosine kinase, leading to a 
deregulation of tyrosine kinase activity within CML cells. This results in 
the activation of pathways associated with cell proliferation, control of 
apoptosis, differentiation, and adhesion, which are all implicated in CML 
pathology (Ren, 2005, Deininger et al., 2000, Kurzrock et al., 1988, 
Quintas-Cardama and Cortes, 2009).  
The BCR/ABL tyrosine kinase inhibitor (TKI), imatinib, which 
binds directly to the adenosine triphosphate-binding site of BCR-ABL 
kinase, was developed as a frontline therapy for CML (Nagar et al., 2002). 
Imatinib increases the average life expectancy of CML patients from the 4-
6 years obtained with interferon-based treatment (Sacchi et al., 1997) to a 
survival rate of decades (Smith et al., 2010). It has been reported that 
imatinib can induce complete cytogenetic response in almost 80% of 
patients diagnosed with CML chronic phase with mild toxicity (Kantarjian 
et al., 2002) and more than 70 % of patients may achieve a major molecular 
response by 5 years of therapy (Kantarjian et al., 2008). 
 However, imatinib-acquired resistance occurs and this remains an 
obstacle to eradicate this disease. The most common mechanism that results 
in acquired resistance is mutation of the BCR/ABL kinase domain that 
affects its binding with imatinib (Soverini et al., 2014, Branford et al., 
2003), while other mechanisms, such as BCR-ABL amplification and 
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alterations in drug influx and efflux mechanisms are also found (Mahon et 
al., 2000, Ni et al., 2011, Gorre et al., 2001). While the introduction of 
second- and third-generation TKIs such as nilotinib, dasatinib, and 
ponatinib can overcome much of this imatinib-resistance, the high rate of 
mutations that occur in CML cells also result in the development of 
resistance to these new drugs. (An et al., 2010, Kantarjian et al., 2006, 
Talpaz et al., 2006, Zabriskie et al., 2014). As a result of this development 
of resistance to TKIs, there is a need to find alternative ways to kill CML 
cells by other kinase inhibitors that may induce apoptosis in TKI-resistant 
CML cells.  
Immortalised cell lines derived from patients who develop 
malignancies are an important tool to understand cancer biology (Drexler et 
al., 2000). Thus, the use of such cell lines in leukaemia research can help 
understand disease mechanisms and test new therapeutic approaches 
(Drexler and MacLeod, 2002, Drexler and Matsuo, 2000). 
There are several BCR-ABL-positive cell lines that have been used 
in CML studies. These cell lines include LAMA-84, EM3, K562, KYO1, 
KU812, KCL-22, BV173, AR230, TOM1 and SD1. Most of them were 
derived from CML patients in blast crisis (Mahon et al., 2000), while two of 
them, TOM1 and SD1 were derived from BCR-ABL-positive acute 
lymphocytic leukaemia patients (Okabe et al., 1987, Dhut et al., 1991). 
Previous research has shown that imatinib suppressed the growth of most of 
BCR-ABL-positive cell lines. However, there are two cell lines, KCL-22 
and SD1, which demonstrate natural resistance to imatinib (Deininger et al., 
1997).  
LAMA-84 cell line was derived from the peripheral blood of a 29-
year old CML patient who had been treated with busulfan for 5 consecutive 
years. The cells were collected one month after the onset of blast crisis. 
These cells are reported to express BCR-ABL and respond to several agents 
including imatinib (Blom et al., 1996, Seigneurin et al., 1987). 
KCL-22 cell line was established from the plural effusion of a 32-
year old CML patient in blast crisis. These cells are described to contain 
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BCR-ABL (Kubonishi and Miyoshi, 1983). The KCL-22 cell line was 
found to be insensitive to imatinib despite its expression of wild type BCR-
ABL (Deininger et al., 1997).  
Thus, these cell lines could be potential in vitro models to determine 
the mechanisms of imatinib resistance. In addition, they have been 
previously shown in this laboratory to have different sensitivity to imatinib 
(Guest, 2012) LAMA-84 cells, are imatinib-sensitive and KCL-22 cells 
have greater resistance to imatinib. Therefore, LAMA-84 and KCL-22 cell 
lines were selected in this study to represent as imatinib-sensitive and –
insensitive CML cell lines, respectively. 
The aims of the work described in this Chapter were: 
i) To determine the effects of imatinib on the growth and 
apoptosis of these two cell lines. 
ii)  To measure the expression of Bcl-2 family members in these 
two cell lines and to determine how the levels of these 
proteins are affected by imatinib. 
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3.2 Methods 
All methods described in this Chapter are more fully detailed in 
Chapter 2. Imatinib was used at 10 µM (unless otherwise stated) which was 
shown in previous studies in this laboratory (Guest, 2012, Goodman, 2012) 
to induce maximal effects on the growth of these cells and is the serum 
concentration that is obtained therapeutically during the treatment of CML 
patients (Rezende et al., 2013). As imatinib was dissolved in DMSO, all 
control experiments contained equivalent amounts of this solvent (typically 
0.1 %, v/v unless stated otherwise). In experiments using imatinib plus 
other compounds dissolved in DMSO, the maximal DMSO used in 
experiments was 0.3 % (v/v) and this concentration did not have any 
measured effect of any of the cell parameters analysed. 
3.3 Results 
Initial experiments measured the effects of imatinib on apoptosis of 
these cell lines,  which was measured in the following ways: (a) using the 
Viacount assay, which measures changes in the plasma membrane 
permeability to DNA-binding dyes; (b) measuring cell cycle kinetics, by 
measuring the proportion of cells in each of the cell cycle phases, including 
G0 (measuring the decreased DNA content of apoptotic cells); (c) using JC-
1 dye, which measures changes in mitochondrial inner membrane potential, 
which becomes depolarised during the initiation of apoptosis and detected 
as a shift in JC-1 fluorescence from red to green; (d) using western blotting 
to detect changes in Bcl-2 family protein expression of pro- and anti-
apoptotic proteins, such as Mcl-1, Bcl-2, Bcl-XL, and Bak; (e) using the 
pan-caspase inhibitor, Z-VAD which blocks the function of activated 
caspases and hence prevents the development of apoptotic cell features that 
occur via caspase-dependent processes. 
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3.3.1 Effects of imatinib on the viability of LAMA-84 and KCL-22 
cell lines 
LAMA-84 and KCL-22 cells were initially tested for their 
sensitivity to different concentrations of imatinib, in terms of the ability of 
this drug to induce changes in viability. LAMA-84 cells and KCL-22 cells 
were incubated for 24 h in the presence and absence of gradient 
concentrations of imatinib (2.5, 5, 10, and 15 µM) and viability was 
assessed using the ViaCount assay.  
These two cell lines showed significantly different sensitivities to 
these concentrations of imatinib (P≤0.001, two-way ANOVA with 
replication), as shown in Figure 3.1. At a concentration of 15 µM imatinib, 
KCL-22 cells showed only less than 10 % decrease in viability, while 
LAMA-84 cells showed more than 30 % loss of viability.  The results show 
that imatinib at 10 µM induced apoptosis significantly in LAMA-84 cells 
within 24 h of incubation, from 92.7 ± 0.5 % viability of control samples to 
61.7 ± 1 % viability of imatinib treated samples (p≤0.01, n=3). However, 
under these experimental conditions, this drug had no significant effect on 
the viability of KCL-22 cells (control 92.4 ± 0.6 % viability of control 
samples and 89.4 ± 0.4 % viability of imatinib treated samples) (p>0.05, 
n=3). 
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Figure 3.1 Differential sensitivity of LAMA-84 and KCL-22 cell lines to 
imatinib. Viability was determined using the Viacount assay, in control 
cells or cells incubated with gradient concentrations of imatinib, as follows: 
LAMA-84 cell line ●; KCL-22 cell line ○. Data are shown as mean (±SEM, 
n=3) *= p≤0.05, **=p≤0.01 (paired two-tailed student’s t-test).  
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3.3.2 Effects of imatinib on cell number and morphology of LAMA-
84 and KCL-22 cell lines  
The numbers of LAMA-84 and KCL-22 cells after 24 h incubation 
in the absence (control) and presence of imatinib, were counted by flow 
cytometry, while cell morphology was evaluated by light microscopy. 
These combined parameters were used to confirm apoptosis of CML cells 
by appearance of apoptotic morphology.  
Imatinib significantly decreased the number of LAMA-84 cells 
(from 2.2 x 106 ± 1.7 x105 cells/ml in control samples to 1.8 x 106 ± 1.1 x 
105 cells/ml in imatinib treated suspensions), (p≤0.05, n=3), but it had no 
significant effect on the number of KCL-22 cells counted (average 2.2 x 106 
± 1.3 x 105 cells/ml of control samples to 2 x 106 ± 3.3 x104 cells/ml in 
imatinib treated samples), (p>0.05, n=3) (Figure 3.2). These results 
correlate with the viability change measured (using the Viacount assay) 
after treating cells with imatinib. 
 After counting cell numbers, cell samples were stained and 
visualised by light microscopy (see Materials and Methods). These results 
confirmed that imatinib induced apoptosis in LAMA-84 cell, but had little 
effect on KCL-22 cells. After treatment of LAMA-84 cells with imatinib, 
the cells were smaller and showed condensed chromatin (cells in Figure 3.3, 
particularly inset at high magnification) In contrast, cells with this 
morphology were not frequently found in KCL-22 cells treated with 
imatinib, compared to LAMA-84 cells (Figure 3.3). 
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Figure 3.2 Effect of imatinib on the number of LAMA-84 and KCL-22 
cells. Both LAMA-84 and KCL-22 cells were incubated for 24 h in the 
absence (U) and presence (I) of imatinib (10 μM). Total cell counts were 
assessed by flow cytometry using Viacount reagent (see Materials and 
Methods). Data are shown as mean (±SEM, n=3) *=p≤0.05 (paired two-
tailed student’s t-test). 
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Figure 3.3 Effect of imatinib on LAMA-84 and KCL-22 cell 
morphology. Both LAMA-84 and KCL-22 cells were incubated for 24 h in 
the absence (U) and presence (I) of imatinib (10 μM). Cell morphology was 
observed by light microscopy after staining of cytospins (see Materials and 
Methods).  
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3.3.3 Effects of imatinib on cell cycle kinetics of LAMA-84 and KCL-
22 cell lines 
The effects of imatinib on the growth parameters of LAMA-84 and 
KCL-22 cells were also measured by cell cycle analysis. LAMA-84 cells 
and KCL-22 cells were incubated for 24 h in the presence and absence of 
gradient concentrations of imatinib (2.5, 5, 10, and 15 µM) prior to 
measuring cell cycle kinetics by analysis of DNA content. 
As shown in Figure 3.4, imatinib treatment caused a significant 
increase in the number of cells in the G0 phase (low DNA content per cell, 
or apoptotic cells) of LAMA-84 cells, but not in KCL-22 cells. 24 h 
incubation of 10 µM imatinib in LAMA-84 cells induced 46.4 ± 1.9 % of 
the total cell population to accumulate in G0. This was significantly 
increased compared to untreated cells (14.4 ± 1.5 % of total cell population, 
p≤0.01, n=3) (Figure 3.4A) and confirmed the results obtained with the 
Viacount assay that this agent induced apoptosis in these cells (Section 
3.3.1).  
In contrast, 10 µM imatinib did not cause a significant increase in 
the G0 population of KCL-22 cells, but instead, this drug induced a partial 
cell cycle arrest in G1 (59.2 ± 3.4 % of total cell population in G1 of 
imatinib treated samples compared to 46.1 ± 1.1 % of untreated samples, 
p≤0.05, n=3), with fewer cells accumulating in G2 (results not shown) after 
drug treatment (Figure 3.4B). 
In summary, cell cycle analysis confirmed an induction of apoptosis 
in LAMA-84 cells by imatinib but additionally revealed a G1 arrest of 
KCL-22 cells.  
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Figure 3.4 Effect of imatinib on LAMA-84 and KCL-22 cell cycle 
kinetics. Cell cycle parameters (expressed as a percentage of the total cell 
population) of cells arrested in G0 (A) and G1 (B) were determined by 
measuring DNA content and flow cytometry. Data are shown as mean 
(±SEM, n=3) *=p≤0.05, **=p≤0.01 (paired two-tailed student’s t-test). 
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3.3.4 Effects of imatinib on mitochondrial polarisation of LAMA-84 
and KCL-22 cell lines 
LAMA-84 and KCL-22 cells were incubated in the presence and 
absence of 10 µM imatinib and then samples were collected at time points 
of 0 h, 30 min, and 1, 2, 4, 6, 18 and 24 h. They were then incubated with 
JC-1 dye before measuring the fluorescence shift by flow cytometry (see 
Materials and Methods). JC-1 binds to mitochondrial membranes and 
exhibits red fluorescence when the membrane is highly polarised, but green 
fluorescence when the inner mitochondrial membrane becomes depolarised 
during the early stages of induction of apoptosis.  
In untreated cells, no membrane depolarization was detected in 
either cell line at any time point. However, imatinib induced mitochondrial 
membrane depolarisation in LAMA-84 cells, but not in KCL-22 cells, as 
shown in Figure 3.5. Imatinib caused significant mitochondrial 
depolarisation in LAMA-84 cells within 4 h from 4.2 ± 0.3 % of 0 h to 13.9  
± 0.2 % by 4 h of imatinib incubation, (p≤0.01, n=3). This indicates that 
imatinib caused rapid changes in mitochondrial function that may be 
attributed to the induction of apoptosis. 
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Figure 3.5 Effects of Imatinib on mitochondrial polarisation in LAMA-
84 and KCL-22 cells. Both LAMA-84 and KCL-22 cell lines were 
incubated in the absence (U ○) and presence of imatinib (10 μM) (I ●). The 
samples were collected at various time points after addition of drugs. 
Mitochondrial polarisation (expressed as a percentage of the total cell 
population) was determined by flow cytometry as a shift from red 
fluorescence to green fluorescence (see Materials and Methods). Data are 
shown as mean (±SEM, n=3) **=p≤0.01, ***=p≤0.001, compared to 0 h 
time point (One-way ANOVA followed by Bonferroni post hoc 
comparisons tests). 
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3.3.5 Effects of imatinib on expression of anti-apoptotic Bcl-2 family 
proteins in LAMA-84 and KCL-22 cell lines 
Western blotting was used to determine the effects of imatinib on 
the expression levels of Bcl-2 family proteins in both LAMA-84 and KCL-
22 cell lines. Both cell lines were treated with and without imatinib (10 µM) 
for 24 h and then protein lysates collected for western blotting.  
3.3.5.1 Anti-apoptotic protein, Bcl-2 
Imatinib resulted in a small decrease in Bcl-2 expression in LAMA-
84 cells, but these small changes were not significantly different to control 
cell values. In contrast, KCL-22 cells did not express Bcl-2 protein (Figure 
3.6). This latter experiments were repeated a number of times with different 
anti-Bcl-2 antibodies and similar results were obtained. Thus, it can be 
concluded that KCL-22 cells do not express Bcl-2 protein. 
3.3.5.2 Anti-apoptotic protein, Bcl-XL 
Imatinib resulted in a small decrease in expression levels of Bcl-XL 
levels in both LAMA-84 and KCL-22 cells, but these decreases did not 
reach statistical significance compared to untreated values (Figure 3.6).  
3.3.5.3 Pro-apoptotic protein, Bak 
Imatinib resulted in a small increase in Bak expression in both cell 
lines, but these small changes in expression values did not reach statistical 
significance (Figure 3.6). 
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Figure 3.6 Effects of imatinib on expression of Bcl-2, Bcl-XL and Bak in 
LAMA-84 cells and KCL-22 cells. Cells were incubated in the absence 
(U) or presence (I) of 10 µM imatinib for 24 h and protein extracts were 
analysed by western blotting. (A) shows examples of western blots for Bcl-
2 (22 kDa), Bcl-XL (25 kDa), Bak (30 kDa) and actin (42 kDa). (B) shows 
densitometric analysis of the effects of imatinib on Bcl-2, Bcl-XL and Bak 
expression, normalised for actin levels and expressed as a % of untreated 
values (±SEM, n=3). Western blot shown is representative from n=3 
experiments. 
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3.3.5.4 Anti-apoptotic protein, Mcl-1 
In LAMA-84 cells, imatinib resulted in a significant decrease of 
Mcl-1 protein expression. Densitometric analysis indicated that Mcl-1 
expression was decreased significantly from 100% of untreated samples to 
51.5 ± 6.7 % of imatinib treated samples (p≤0.05, n=3) (Figure 3.7B). In 
contrast, imatinib had no significant effect on Mcl-1 expression in KCL-22 
cells. After 24 h of imatinib incubation, the relative expression of Mcl-1 in 
KCL-22 cells was 98.8 ± 9 % in the presence of imatinib, compared 100 % 
in control cells (Figure 3.7B).  
In conclusion, imatinib caused no significant changes in expression 
of Bcl-2, Bcl-XL, and Bak in both cell lines, but caused a significant 
decrease in expression of the anti-apoptotic protein, Mcl-1 in LAMA-84 
cells, which is sensitive to imatinib. In addition, the KCL-22 cell line does 
not express Bcl-2 protein.  
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Figure 3.7 Effects of imatinib on expression of Mcl-1 of LAMA-84 cells 
and KCL-22 cells. Cells were incubated for 24 h in the absence (U) and 
presence (I) of imatinib (10 μM) and samples were prepared for western 
blotting for Mcl-1 (40 kDa) and  actin (42 kDa). (A) shows representative 
western blots, while (B) shows densitometric analysis of the effect of 
imatinib on Mcl-1 expression. Data expressed as a % of untreated samples 
which was taken as 100 % (±SEM, n=3) *=p≤0.05 (paired two-tailed 
student’s t-test). Western blot shown is representative from n=3 
experiments. 
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3.3.6 Effects of imatinib and the pan-caspase inhibitor on LAMA-84 
and KCL-22 cell apoptosis 
The effects of the pan-caspase inhibitor, Z-VAD which blocks 
activated caspases and hence cell apoptosis, were investigated to confirm 
that imatinib induces cell death of LAMA-84 cells via induction of 
apoptosis. The effects of Z-VAD and imatinib on cell viability, cell cycle 
kinetics and Bcl-2 family protein expressions were therefore determined.  
3.3.6.1 Effects of imatinib and the pan-caspase inhibitor, Z-VAD, on cell 
viability. 
After 24 h incubation, imatinib decreased the cell viability of 
LAMA-84 cells in the absence of Z-VAD. Incubation of cells in the 
presence of imatinib together with Z-VAD resulted in significantly 
increased viability (from 61.7 ± 1 % in absence of Z-VAD to 83.1 ± 1.5 % 
in presence of Z-VAD), (p≤0.05, n=3) (Figure 3.8). This confirms that 
imatinib induces caspase-dependent apoptosis in LAMA-84 cells. 
While KCL-22 cells only underwent a slight, but statistically 
insignificant  decrease in cell viability after 24 h incubation with imatinib, 
the presence of Z-VAD did not affect this (from 89.4 ± 0.4 % in the absence 
of Z-VAD to 88.7 ± 2.9 % in presence of Z-VAD), (p>0.05, n=3) (Figure 
3.8). This result is not surprising as imatinib does not induce apoptosis in 
this cell line. 
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Figure 3.8 Effect of imatinib and the pan-caspase inhibitor, Z-VAD, on 
LAMA-84 and KCL-22 cell viability. Both LAMA-84 and KCL-22 cells 
were incubated for 24 h in the absence (U) and presence (I) of imatinib (10 
μM), with and without the broad spectrum caspase inhibitor Z-VAD-fmk 
(Z) (20 μM). Viability was assessed by flow cytometry using the Viacount 
reagent and protocol (see Materials and Methods). Data are shown as a 
percentage of viable cells (±SEM, n=3) *=p≤0.05, **= p≤0.01, (paired two-
tailed student’s t-test). 
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3.3.6.2 Effects of imatinib and the pan-caspase inhibitor, Z-VAD, on cell 
cycle kinetics. 
After 24 h incubation of LAMA-84 cells in the presence of imatinib 
there was a large increase in the percentage of cells in the G0 phase of the 
cell cycle and a corresponding decrease in the number of cells in S-phase 
and G2-phase (Figure 3.9). The pan-caspase inhibitor, Z-VAD, prevented 
these changes in cell cycle parameters, confirming induction of apoptosis in 
LAMA-84 cells by imatinib (from 46.4 ± 1.9 % of cell cycle arrest in G0 in 
the absence of Z-VAD to 30.5 ± 8.1 % of cell cycle arrest in G0 in the 
presence of Z-VAD, (p≤0.05, n=3) (Figure 3.9).  
In KCL-22 cells, imatinib induced a partial cell cycle arrest in G1, 
with fewer cells accumulating in G2. This G1 arrest was particularly 
evident after 24 h incubation with imatinib, but was not prevented by Z-
VAD (from 59.8 ± 4.4 % of cell cycle arrest in G1 in absence of Z-VAD to 
56.6 ± 2.9 % of cell cycle arrest in G1 in presence of Z-VAD), (p>0.05, 
n=3)  (Figure 3.9).  
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Figure 3.9 Effect of imatinib and the pan-caspase inhibitor, Z-VAD, on 
LAMA-84 and KCL-22 cell cycle kinetics.  Both LAMA-84 and KCL-22 
were incubated for 24 h in the absence (U) and presence (I) of imatinib (10 
μM), with and without Z-VAD (Z) (20 μM). Cell cycle parameters 
(expressed as a percentage of the total cell population) were determined by 
measuring DNA content and flow cytometry (see Materials and Methods). 
Data are shown as mean (±SEM, n=3) *=p≤0.05 (paired two-tailed 
student’s t-test). 
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3.3.6.3 The effects of imatinib and the pan-caspase inhibitor, Z-VAD, on 
anti-apoptotic protein, Mcl-1 expression. 
From previous experiments described earlier in this Chapter, Mcl-1 
protein expression was decreased by imatinib in LAMA-84 cells unlike 
other Bcl-2 family proteins such as Bcl-2, Bcl-XL, and Bak protein. As a 
consequence, Mcl-1 expression was investigated further with the pan-
caspase inhibitor, Z-VAD. Western blotting was performed to determine the 
effects of imatinib and Z-VAD on the expression level of this protein in 
both cell lines. 
After 24 h incubation of LAMA-84 cells with imatinib, Mcl-1 levels 
were significantly decreased in an absence of Z-VAD. In the presence of Z-
VAD, the loss of Mcl-1 expression by imatinib was significantly protected 
(relative expression 58.2 ± 2.8 % from 100 % of control in absence of Z-
VAD and 84.3 ± 9.1 % in presence of Z-VAD), (p≤0.05, n=3) (Figure 
3.10A). This confirms that imatinib induced a caspase-mediated decrease in 
Mcl-1 levels. 
In contrast to LAMA-84 cells, imatinib induced only a small and 
insignificant decrease in Mcl-1 levels in KCL-22 cells in the absence of Z-
VAD. In the presence of Z-VAD, this decrease in Mcl-1 was slightly 
protected (relative expression 98.8 ± 9 % from 100 % of control in absence 
of Z-VAD to 95.6 ± 9.1 % in presence of Z-VAD), (p>0.05, n=3) (Figure 
3.10B). This confirms the caspase-independency of this small decrease in 
protein level. 
To conclude, the decrease in Mcl-1 expression induced by imatinib 
can be protected by Z-VAD in LAMA-84 cells, but not KCL-22 cells. 
These results confirm previous experiments in this Chapter that imatinib 
induces apoptosis in LAMA-84 cells (but not in KCL-22 cells).  
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Figure 3.10 Effect of imatinib and the pan caspase inhibitor, Z-VAD, 
on expression of Mcl-1 in (A) LAMA-84 cells and (B) KCL-22 cells. Cells 
were incubated for 24 h in the absence (U) and presence (I) of imatinib (10 
μM) ± ZVAD (20 μM), and samples were prepared for Western blotting for 
Mcl-1 (40 kDa) and actin (42 kDa), quantified by densitometry. Data 
expressed as a % of untreated samples (±SEM, n=3) * = p≤0.05, **= 
p≤0.01 (paired two-tailed student’s t-test). Western blot shown is 
representative from n=3 experiments. 
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3.4 Discussion and Conclusions 
The aims of this Chapter were to determine the effects of imatinib 
on the viability of two CML cell lines, LAMA-84 and KCL-22, in order to 
establish their usefulness as in vitro models to test for the effects of new 
kinase inhibitors on the growth parameters of TKI-sensitive and -insensitive 
cell lines. The results in this Chapter confirm previously published results 
(see section 3.1) and background work in this laboratory, which has shown 
that LAMA-84 cells are imatinib-sensitive and that KCL-22 cells are 
relatively imatinib-insensitive. However, new data presented in this Chapter 
show that imatinib induces cell death in LAMA-84 cells by a caspase-
sensitive mechanism, which is likely to be apoptosis, as this drug also 
induces a rapid (within a few hours) depolarisation of the mitochondrial 
inner membrane. Unexpectedly, the results also show that whilst imatinib 
did not induce cell death in KCL-22 cells, it did induce a cell cycle arrest in 
G1, which was not affected by the presence of the pan-caspase inhibitor. 
LAMA-84 cell line was established from the blood of a patient with 
chronic myeloid leukaemia, in accelerated phase. It is reported to retain the 
patient's Philadelphia chromosome. However, recent study shows that 
LAMA-84 cell line has lower BCR-ABL mRNA level compared to another 
imatinib-resistant cell line, IRK562.  Also, it has been reported that LAMA-
84 showed greater sensitivity to imatinib compared to IRK562 (Mendonca 
et al., 2010).  
Imatinib significantly decreased LAMA-84 viability at 
concentrations of 5 μM and above. This finding is in line with several other 
studies that have used this LAMA-84 cell line as a model imatinib-sensitive 
CML cell line (Greene et al., 2007, Dasmahapatra et al., 2007, Mendonca et 
al., 2010). My results show that imatinib induced apoptosis (that was partly 
reversed by the pan caspase inhibitor) by increasing the number of cells that 
accumulated in the G0 phase (low DNA content per cell) and induced a 
decrease in mitochondrial membrane potential (which was also prevented 
by Z-VAD, data not shown). Caspase-induced activation of apoptosis is 
usually regulated by changes in function of Bcl-2 family member proteins, 
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and so the effects of imatinib on the expression levels of several of these 
proteins was investigated. 
For LAMA-84 cells, imatinib treatment did not result in any 
significant decreases in expression levels of Bcl-2 or Bcl-XL, two anti-
apoptotic members of this family.  While it is possible that imatinib affected 
the localisation or activity of these proteins, no changes in overall levels of 
these proteins would indicate that they are unlikely to be affected by this 
drug. However, major changes in the levels of the anti-apoptotic protein, 
Mcl-1 were observed in LAMA-84 cells after treatment with imatinib, and 
these decreases were largely prevented by Z-VAD, indicating the 
importance of caspase activation in this process. A previous report has 
shown that imatinib decreased the expression of Mcl-1 in K562 cell lines 
(Aichberger et al., 2005) which, like LAMA-84 cells are imatinib-sensitive 
CML cell lines (Greene et al., 2007, Deininger et al., 1997). However, this, 
to my knowledge, is the first report of imatinib-induced decreases in Mcl-1 
levels in LAMA-84 cells as an explanation for induction of cell death by 
this drug. 
In contrast, imatinib had no significant effect on the viability of 
KCL-22 cells. However, surprisingly, it induced a partial cell cycle arrest in 
G1. This was insensitive to Z-VAD and hence independent of caspase 
activation, and has not previously been reported. It has been reported that 
KCL-22 cell line possesses natural resistance to imatinib (Deininger et al., 
1997, Mahon et al., 2000). Therefore, this supports the idea that KCL-22 
could act as a model for imatinib-insensitive CML for further studies. 
However, the mechanism of the resistance of KCL-22 to imatinib is still 
unclear. It has been reported that KCL-22 can resist imatinib without 
increasing of BCR-ABL expression (Mahon et al., 2000, Ohmine et al., 
2003), but other mechanisms might involve BCR-ABL-independent 
resistance to imatinib (Mahon et al., 2000).   
However, a more recent study has shown that KCL-22 have doubled 
expression of both BCR-ABL mRNA and protein compared to other 
imatinib-resistant cell lines (Quentmeier et al., 2011). This report also 
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demonstrated that there was high expression of mutated kinase activity in 
KCL-22 cells. This point mutation results in an amino acid change in PI3K 
of E545G. This suggests that this mutation might constitutively activate the 
PI3K pathway in KCL-22 cells (Quentmeier et al., 2011). Thus, this could 
partly explain the mechanism of resistance of KCL-22 cell line.  
Interestingly, like mature neutrophils (Moulding et al., 2001), KCL-
22 cells did not express the anti-apoptotic protein Bcl-2. They did express 
Bcl-XL (unlike mature neutrophils) and Mcl-1 (like mature neutrophils), but 
imatinib did not induce any changes in expression levels of these latter two 
proteins, in line with its inability to induce apoptosis.  
Another important finding from this study was the usefulness of 
measuring mitochondrial membrane polarisation using the fluorescence 
indicator JC-1. This dye is cell permeable and “stacks” in the inner 
membrane of polarised mitochondria (Reers et al., 1995). These JC-1 
aggregates in polarised membranes emit red fluorescence (590 nm) when 
excited at 499 nm. However, upon membrane depolarisation, these 
aggregates dissociate to the monomeric form of JC-1, which emits green 
fluorescence (530 nm). This red:green shift can be detected by flow 
cytometry. An advantage of using this technique to measure apoptosis, is 
that changes in mitochondrial inner membrane potential are amongst the 
first cellular changes to be detected during activation of apoptosis. 
Interestingly, changes in JC-1 fluorescence in LAMA-84 cells were 
detected within 2-4 h of incubation with imatinib, making it suitable for 
rapid screening new molecules with the potential to induce apoptosis.  
Taken together, the results obtained in this Chapter confirm that 
these two cell lines can be used as experimental tools to study imatinib-
sensitive and imatinib-insensitive CML cells.  
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CHAPTER 4:  EFFECTS OF PURVALANOL A ON 
IMATINIB-SENSITIVE AND -INSENSITIVE CML CELL 
LINES  
4.1 Introduction 
The results in Chapter 3 show that imatinib induces apoptosis in 
LAMA-84 cells, but has little effect on apoptosis of KCL-22 cells (although 
it does induce a G1 arrest). Therefore, these two cells lines would appear to 
be suitable to test the effects of new inhibitors in imatinib-sensitive and –
insensitive CML cells.  
There is much interest in the development of kinase inhibitors to 
treat cancers or inflammatory diseases and many new molecules are 
undergoing clinical trials (Zhang et al., 2009a, Cohen and Alessi, 2013). 
While new-generation, rationally-designed tyrosine kinase inhibitors are 
being developed to overcome specific mutations in BCR-ABL, resistance to 
these new drugs is now emerging (see Introduction). Therefore, there is a 
need to develop new ways to treat CML cells, perhaps in conjunction with 
TKIs.  Many cancers are resistant to apoptosis or have dysregulated cell 
cycle control, and so many drugs under development are targeting these two 
important cellular processes (Elmore, 2007, Hassan et al., 2014).  
Cyclin-dependent kinases (CDKs) play important roles in the 
regulation the cell cycle and deregulation of their activity results in 
uncontrolled cell proliferation, leading to cancer (McDonald and El-Deiry, 
2000). Therefore, several small molecule CDK inhibitors have been 
developed to block CDK activities. These include the purines (such as 
olomucine, roscovutine, and purvalanol A) and piperidine-substituted 
purines (such as flavopiridol, indirubin, and paullones) (reviewed in 
(Knockaert et al., 2002a)).  
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Although these inhibitors have diverse chemical structures, they all 
bind to the ATP-binding site of CDKs. These inhibitors generate their anti-
proliferative effects by arresting the cell cycle in G1 and/or G2/M phase 
(Knockaert et al., 2002a). Various studies have evalauted the effects of 
these inhibitors on cancer cells (Damiens and Meijer, 2000, Senderowicz 
and Sausville, 2000) and some of these inhibiters have shown promising 
results in many types of cancer, including CML (Fischer and Lane, 2000, 
Bright et al., 2010, Fisher and Morgan, 1994). 
One of the most potent CDK inhibitors developed to date is 
purvalanol A, which binds between the 2, 6, 9-tri substituted purines and 
the ATP-binding site of human CDK2 (Gray et al., 1998, Gray et al., 1999), 
resulting in competitive inhibition of ATP-binding. This inhibition induces 
cell cycle arrest and cell apoptosis in both mouse fibroblasts and in several 
cancer cell lines (Villerbu et al., 2002). In addition, recent studies in human 
cancer cell lines showed that purvalanol A treatment inhibits both CDK 
activity and the expression of several anti-apoptotic proteins of the Bcl-2 
family, such as Bcl-2 and Bcl-XL (Iizuka et al., 2007, Iizuka et al., 2008).  
Purvalanol A was found to interact with purified CDK2 and this 
may explain its anti-mitotic properties (Knockaert et al., 2002a). However, 
its actual intracellular targets are still undefined.  One group reported that 
purvalanol also interacts with p42/p44 MAPK protein in various cell lines, 
as detected by affinity chromatography (Knockaert et al., 2002b). In 
addition, purvalanol inhibited p42/p44 MAPK activities in a dose-
dependent manner in the Chinese hamster lung fibroblast cell line, CCL39 
(Knockaert et al., 2002b). This suggests that the anti-proliferative effects of 
purvalanol may be mediated by both CDK inhibition and interactions with 
p42/p44 MAPK. 
Purvalanol A was identified in a previous project in our laboratory 
that screened a Tocris Kinase Inhibitor array for effects on the viability of 
LAMA-84 and KCL-22 cells, in the presence and absence of imatinib. 
Purvalanol A showed promising results by significantly decreasing cell 
viability of KCL-22 cells (Guest, 2012). Thus, the effects of purvalanol A 
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on the molecular signalling pathways regulating apoptosis in the imatinib-
sensitive and imatinib-insensitive CML cell lines are the major focus of this 
Chapter.  
The aims of the work described in this Chapter were: 
i) To determine the effects of purvalanol A on the growth and 
apoptosis of these two cell lines.  
ii) To measure the expression of Bcl-2 family members in these 
two cell lines and to determine how their protein levels are 
affected by purvalanol A. 
iii) To investigate the effects of these two inhibitors on the 
activation status of intracellular signalling systems that are 
directly or indirectly regulated by BCR-ABL activity. 
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4.2 Methods 
All methods used were as described in Chapter 2. Purvalanol A was 
dissolved in DMSO, and so control suspensions contained the same volume 
of DMSO as was used for purvalanol A, and these had no effect on any of 
the parameters measured (result not shown).  
4.3 Results 
Initial experiments measured the effects of purvalanol A on 
apoptosis of these cell lines using the Viacount assay, cell number, cell 
morphology and cell cycle kinetics. Also, changes in the mitochondrial 
membrane potential were measured as the red:green shift in fluorescence of 
JC-1. The levels of expression of pro- and anti-apoptotic proteins, such as 
Mcl-1, Bcl-2, Bcl-XL, and Bak, plus the effects of the pan-caspase inhibitor 
Z-VAD were also measured. The effects of purvalanol A on the activation 
status of several intracellular signalling systems, including Erk, STAT3, 
p38 and Akt were also investigated. Lastly, the effects of purvalanol A with 
BIRB796, p38 MAPK inhibitor, were also measured. 
4.3.1 Effects of purvalanol A on the viability of LAMA-84 and KCL-22 
cell lines  
LAMA-84 and KCL-22 cell lines were initially tested for their 
sensitivity to purvalanol A, in terms of the cell viability. LAMA-84 and 
KCL-22 cells were incubated for 24 h in the presence and absence of 
purvalanol A at different concentrations, and viability was assessed using 
the Viacount assay.  
Purvalanol A induced a dose-dependent decrease in cell viability of 
both cell lines (Figure 4.1). However, purvanalol A had a greater effect on 
the viability of KCL-22 cells than on LAMA-84 cells at each dose tested 
and these differences were highly significant (P≤0.001, two-way ANOVA 
with replication). The maximal effect of purvalanol A on both cell lines was 
achieved at a concentration of 30 μM. Thus, this concentration was used in 
further experiments unless stated otherwise. 
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When used at a concentration of 30 μM, purvalanol A significantly 
induced apoptosis in LAMA-84 cell line, (p≤0.01, n=3). After 24 h of 
incubation with purvalanol A, LAMA-84 cell viability was decreased 
significantly (from 92.7 ± 0.5 % cell viability of control samples to 63.8 ± 
0.6 % cell viability of purvalanol A treated samples). Similarly, purvalanol 
A significantly decreased cell viability in KCL-22 cells line which are 
insensitive to imatinib (p≤0.01, n=3). KCL-22 cell viability was decreased 
from 92.4 ± 0.6 % of control samples to 30 ± 3.2 % in samples treated for 
24 h with 30 µM purvalanol A (Fig. 4.1).  
The effects of purvalanol A in combination with imatinib on 
viability of these cell lines were then measured. Both cell lines were 
incubated for 24 h with the combination of both 10 μM imatinib and 30 μM 
purvalanol A. However, there was no additive inhibitory effect observed 
when imatinib and purvalanol were used in combination, (p>0.05, n=3) 
(Figure 4.2). 
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Figure 4.1 Differential sensitivity of LAMA-84 and KCL-22 cell lines to 
purvalanol A. LAMA-84 and KCL-22 cell lines were incubated in the 
absence and presence of gradient concentrations of purvalanol A (10, 20, 
30, 40, and 50 µM). Viability was determined using the Viacount assay, in 
control cells, or cells incubated with gradient concentrations of purvanol A 
(P), as follows: LAMA-84 cell line ●; KCL-22 cell line ○. Data are shown 
as mean (±SEM, n=3) **=p≤0.01, ***=p≤0.001 (paired two-tailed 
student’s t-test).  
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Figure 4.2 Differential sensitivity of LAMA-84 and KCL-22 cell lines to 
imatinib and purvalanol A. LAMA-84 and KCL-22 cells were incubated 
with gradient concentrations of purvalanol A together with a constant 
concentration of imatinib (10 µM). Values show are % of cell viability, as 
follows: purvalanol A treated ●; imatinib plus purvalanol A treated ○. Data 
are shown as mean (±SEM, n=3). 
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4.3.2 Effects of purvalanol A on cell number and morphology of 
LAMA-84 and KCL-22 cell lines 
The number of cells and cell morphology were assessed by flow 
cytometry and light microscopy, respectively. Both LAMA-84 and KCL-22 
cells were incubated for 24 h in the absence (untreated control) and 
presence of 10 μM imatinib and 30 μM purvalanol A and then were counted 
and viewed microscopically to confirm the levels of apoptosis. 
Cell counts by flow cytometry (Figure 4.3) showed that imatinib 
significantly decreased the total cell count of LAMA-84 cells, but not KCL-
22 cells, confirming previous experiments (Chapter 3). In contrast to the 
effects of imatinib, purvalanol A decreased the total number of cells 
counted in both cell lines. In LAMA-84 cells, the total number of cells 
counted was decreased from 2.2 x 106 ± 1.7 x 105 untreated cells/mL to 1.3 
x 106 ± 1.4 x 104 cells/mL after 24 h incubation, (p≤0.05, n=3). Similarly, 
purvalanol A decreased the total number of KCL-22 cells counted from 2.2 
x 106 ± 1.3 x 105 untreated cells/mL to 1.4 x 106 ± 4.8 x 104 cells/mL after 
24 h incubation, (p≤0.05, n=3). 
In addition, the combination treatment of imatinib and purvalanol 
decreased the total cell counts significantly, (p≤0.05, n=3, respectively) in 
both cell lines (1.3 x 106 ± 6.5 x 104 cells/mL and 1.3 x 106 ± 1.1 x 105 
cells/mL in LAMA-84 and KCL-22 cells, respectively). However, the 
combined effects of these two drugs on cell numbers were not significantly 
different to those obtained by the use of purvalanol A alone, (p>0.05, n=3). 
These results correlate with the viability changes observed when the cells 
were treated with imatinib and purvalanol A using the Viacount assay. 
Analysis of cell morphology showed that purvalanol A induced 
apoptosis in both LAMA-84 and KCL-22 cells, as detected by appearance 
of apoptotic cells with condensed chromatin (Figure 4.4). 
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Figure 4.3 Effects of imatinib and purvalanol A on the number of 
LAMA-84 and KCL-22 cells. Both LAMA-84 and KCL-22 cells were 
incubated for 24 h in the absence (U) and presence (I) of imatinib (10 μM), 
(P) purvalanol A (30 μM), and (IP) imatinib (10 μM) with Purvalanol A (30 
μM). Total cell counts were assessed by flow cytometry using the Viacount 
reagent and protocol (see Materials and Methods). Data are shown as mean 
(±SEM, n=3) *= p≤0.05 (paired two-tailed student’s t-test).  
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Figure 4.4 Effect of imatinib and purvalanol A on LAMA-84 and KCL-
22 cell morphology. Both LAMA-84 and KCL-22 cells were incubated for 
24 h in the absence (U) and presence (I) of imatinib (10 μM), (P) purvalanol 
A (30 μM), and (IP) with the combination of imatinib (10 μM) and 
purvalanol A (30 μM). Cell morphology was analysed by light microscope 
(see Materials and Methods). Inset shows cells viewed at higher 
magnification.  
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4.3.3 Effects of purvalanol A on cell cycle kinetics of LAMA-84 and 
KCL-22 cell lines 
Results in Chapter 3 showed that imatinib resulted in a significant 
increase of G0 cells in the population of LAMA-84 cells, but not in KCL-
22 cells. In this Chapter, the effects of purvalanol A on cell cycle kinetics 
were measured in order to compare the effects with those of imatinib. 
LAMA-84 cells and KCL-22 cells were incubated for 24 h in the 
presence and absence of gradient concentrations of purvalanol A (10, 20, 
30, 40, and 50 µM) prior to measuring cell cycle kinetics. As shown in 
Figure 4.5, 10-30 µM purvalanol A treatment caused a significant increase 
in the number of cells in the G0 phase in both cell lines and 30 µM showed 
maximal effect, (p≤0.05, n=3)  (Figure 4.5A).  
30 µM purvalanol A significantly induced cell cycle accumulation 
in G0 in LAMA-84 cells from 14.4 ± 1.5 % of the total population of 
untreated samples to 40.6 ± 3.4 % of total in population purvalanol A 
treated samples after 24 h incubation. In KCL-22 cells, purvalanol A 
induced a significant increase in G0 (45.6 ± 1.5 % of the total cell 
population in purvalanol A treated samples compared to 13.1 ± 0.8 % of the 
total cell population in untreated samples), with fewer cells accumulating in 
G2 (data not shown). In contrast to imatinib, purvalanol A did not cause cell 
accumulation in G1 in either of the cell lines (Figure 4.5 B) 
However, the combination treatment did not show any increased 
accumulation in the G0 population compared to purvalanol A alone, 
(p>0.05, n=3) (Figure 4.6).  
To conclude, the results of this cell cycle analysis appeared to 
confirm those of the Viacount assay, in that purvalanol A, used alone, 
induces apoptosis in both imatinib-sensitive and –insensitive CML cell 
lines.  
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Figure 4.5 Effect of purvalanol A on LAMA-84 and KCL-22 cell cycle 
kinetics. Cell cycle parameters (expressed as a percentage of the total cell 
population) of cell arrested in G0 (A) and G1 (B) were determined by 
measuring DNA content and flow cytometry. Data are shown as mean 
(±SEM, n=3) *=p≤0.05 (paired two-tailed student’s t-test). 
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Figure 4.6 Effects of purvalanol A alone and with imatinib on LAMA-
84 and KCL-22 cell cycle kinetics. LAMA-84 and KCL-22 cells were 
incubated with gradient concentrations of purvalanol A together with a 
constant concentration of imatinib (10 µM). Values show are % of cells 
arrested in G0, as follows: purvalanol A treated ●; imatinib plus purvalanol 
A treated ○. Data are shown as mean (±SEM, n=3). 
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4.3.4 Effects of purvalanol A on mitochondrial membrane potential of 
LAMA-84 and KCL-22 cell lines. 
Changes in mitochondrial inner membrane potential can be detected 
by the JC-1 assay (see Chapter 3). This assay was performed in order to 
measure the initial events controlling apoptosis induced by purvalanol A. 
Both cell lines were treated with imatinib, purvalanol A, and imatinib and 
purvalanol A together for 0 h, 30min, 1, 2, 4, 6, 18, 24 h.  After incubation, 
all samples were then incubated with JC-1 before measuring red and green 
fluorescence by flow cytometry. 
Figure 4.7 shows that purvalanol A induced mitochondrial 
membrane depolarisation in both LAMA-84 and KCL-22 cells. In LAMA-
84 cells, purvalanol A caused a significant mitochondrial depolarisation 
change that was detected within 2 h of incubation (4.9 ± 0.5 % at 0 h to 
15.6 ± 0.4 % after 2 h purvalanol A incubation), (p≤0.05, n=3).  
In KCL-22 cells, purvalanol A also significantly induced 
mitochondrial polarisation within 2 h of incubation (p≤0.05, n=3), whereas 
imatinib had no effect on this cell line. Purvalanol A induced mitochondrial 
depolarisation from 8.7 ± 0.3 % at 0 h to 17.6 ± 0.8 % after 2 h purvalanol 
A incubation (Figure 4.7). This indicates that purvalanol A caused a rapid 
change in mitochondrial function associated with apoptosis in both cell 
lines. There was, however, no additive effect of purvalanol A and imatinib 
when used together, in either cell line. 
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Figure 4.7 Effects of Imatinib and Purvalanol A on mitochondrial 
membrane potential in LAMA-84 and KCL-22 cells. Both LAMA-84 
and KCL-22 cell lines were incubated with imatinib (I, 10 μM) or 
purvalanol A (P, 30 μM) or the combination of imatinib and purvalanol A 
(IP) (∆). Values shown are % of cells showing mitochondrial membrane 
depolarization (no depolarization was detected in control cells incubated 
under identical conditions). Data are shown as mean (±SEM, n=3) * = 
p≤0.05, **=p≤0.01 compared to 0 h timepoint (One-way ANOVA followed 
by Bonferroni post hoc comparisons tests). 
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4.3.5 Effects of purvalanol A on expression of the Bcl-2 family proteins 
in LAMA-84 and KCL-22 cell lines 
Results in Chapter 3 showed that imatinib had no significant effect 
on the expression of members of the Bcl-2 family, except for decreased 
Mcl-1 expression in LAMA-84 cells. Thus, the effects of purvalanol A on 
the expression levels of Bcl-2 family proteins in both LAMA-84 and KCL-
22 cell lines were measured by western blotting. Both cell lines were treated 
with purvalanol A for 24 h and protein extracts prepared. Western blots 
were then performed using a range of anti-human Bcl-2 family antibodies to 
detect expression of Bcl-2, Bcl-XL, Bak, and Mcl-1.  
4.3.5.1 Anti-apoptotic protein, Bcl-2 
In LAMA-84 cells, purvalanol A resulted in a slight decrease in Bcl-
2 expression, but this decrease did not reach statistical significance, 
(p>0.05, n=3) when compared to untreated samples. In contrast, KCL-22 
cells did not express Bcl-2 protein (Figure 4.8) and purvalanol A did not 
induce its expression.  
4.3.5.2 Anti-apoptotic protein, Bcl-XL 
Purvalanol A resulted in a slight decrease in Bcl-XL expression in 
both LAMA-84 and KCL-22 cells, but while this decrease was greater in 
KCL-22 compared to LAMA-84 cell line, these change in expression did 
not reach statistical significance when compared to control, untreated cells, 
(p>0.05, n=3) (Figure 4.8).  
4.3.5.3 Pro-apoptotic protein, Bak 
Similar to imatinib, purvalanol A resulted a slight increase in 
expression of the pro-apoptotic Bak protein in both cell lines, but these 
changes did not reach statistical significance (p>0.05, n=3) (Figure 4.8). 
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Figure 4.8 Effects of Purvalanol A and imatinib on expression of Bcl-2, 
Bcl-XL, and Bak in LAMA-84 cells and KCL-22 cells. (A) Cells were 
incubated for 24 h in the absence (U) and presence of (I) imatinib, (P) 
purvalanol A, and (IP) imatinib with purvalanol A and samples were 
prepared for Western blotting for Bcl-2 (22 kDa), Bcl-XL (25 kDa), Bak (30 
kDa) and actin (42 kDa). (B) Densitometric analysis of the effects of 
purvalanol A on Bcl-2, Bcl-XL, and Bak expression. Data are expressed as a 
% of untreated samples (±SEM, n=3). Western blot shown is representative 
from n=3 experiments. 
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4.3.5.4 Anti-apoptotic protein, Mcl-1 
Results in Chapter 3 showed that imatinib significantly decreased 
the levels of Mcl-1 expression in LAMA-84 cells, but had no effect in 
KCL-22 cells.  
In contrast to the effects of imatinib, purvalanol had very little effect 
on Mcl-1 expression in LAMA-84 cells. 24 h incubation with purvalanol A 
resulted in a decrease in Mcl-1 expression, but this decrease did not reach 
statistical significance (relative expression of 69.2 ± 6.9 % compared to 100 
% of control), (p>0.05, n=3). However, purvalanol A resulted in a 
significant decrease in Mcl-1 expression in KCL-22 cells. Mcl-1 expression 
was barely detectable after 24 h incubation with purvalanol A (relative 
expression 2.6 ± 1.8 % compared to 100 % of control), (p≤0.01, n=3) 
(Figure 4.9).  
To conclude, purvalanol A, like imatinib, caused no significant 
changes in expression of Bcl-2, Bcl-XL, and Bak proteins. However, the 
effects of purvalanol A on Mcl-1 expression were totally different in both 
cell lines. In contrast to imatinib, purvalanol A caused a significant decrease 
in expression of anti-apoptotic protein, Mcl-1 in KCL-22 cells, but did not 
significantly alter expression of this protein in LAMA-84 cells.  
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Figure 4.9 Effects of imatinib and purvalanol A on expression of Mcl-1 
in LAMA-84 cells and KCL-22 cells. (A) Cells were incubated for 24 h in 
the absence (U) and presence (I) of imatinib (10 μM) or (P) purvalanol A 
(30 μM) and samples were prepared for Western blotting for Mcl-1 (40 
kDa) and actin (42 kDa). Representative blots are shown in (A).  (B) 
Densitometric analysis of the effects of purvalanol A on Mcl-1 expression. 
Data are shown as mean (±SEM, n=3) *=p≤0.05, **=p≤0.01, ***=p≤0.001 
(paired two-tailed student’s t-test). Western blot shown is representative 
from n=3 experiments. 
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4.3.6 Effects of purvalanol A and the pan-caspase inhibitor on LAMA-
84 and KCL-22 cell apoptosis  
The effects of the pan-caspase inhibitor, Z-VAD, were measured to 
evaluate the role of caspases (and hence apoptosis) on the effects of 
purvalanol A on CML cells. 
4.3.6.1 Effects of Purvalanol A and the pan-caspase inhibitor, Z-VAD, on 
cell viability. 
In LAMA-84 cell lines, after 24 h incubation with purvalanol A cell 
viability was significantly decreased in the absence of Z-VAD. However, in 
the presence of the Z-VAD cell viability of purvalanol A treated LAMA-84 
cells was unaffected (63.8 ± 0.6 % cell viability in absence of Z-VAD and 
66.3 ± 7.8 % cell viability in presence of Z-VAD) (p>0.05, n=3) (Figure 
4.10). This is different from the effect of imatinib on cell viability that 
induced caspase-dependent apoptosis in LAMA-84 cells.  
In KCL-22 cells, 24 h incubation with purvalanol A decreased cell 
viability significantly in the absence of Z-VAD but viability was also 
largely unaffected by the presence of Z-VAD (Figure 4.10). This result also 
indicates a low level of caspase-dependent decrease in cell viability 
triggered by purvalanol A. 
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Figure 4.10 Effects of purvalanol A and the pan caspase inhibitor, Z-
VAD, on CML cell viability. Both LAMA-84 and KCL-22 cell lines were 
incubated for 24 h in the absence (U) and presence (P) of purvalanol A (30 
μM), with and without the broad spectrum caspase inhibitor Z-VAD-fmk 
(Z) (20 μM). Viability was assessed by flow cytometry using the Viacount 
reagent and protocol (see Materials and Methods). Data are shown as a 
percentage of viable cells (±SEM, n=3) *=p≤0.05, **=p≤0.01 (paired two-
tailed student’s t-test). 
. 
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4.3.6.2 Effects of purvalanol A and the pan-caspase inhibitor, Z-VAD, on 
cell cycle kinetics. 
In LAMA-84 cells, after 24 h incubation of purvalanol A, there was 
a large increase in the percentage of cell population in the G0 phase of the 
cell cycle in absence of Z-VAD. The presence of Z-VAD did not prevent 
this cell cycle accumulation in G0 (Figure 4.11).  This is similar to results 
obtained by Viacount assay (Section 4.3.6.1).  
In KCL-22 cells, the caspase-independent apoptosis caused by 
purvalanol A was confirmed by cell cycle analysis. Purvalanol A caused a 
large increase in cell cycle accumulation in G0 in both the absence and 
presence of Z-VAD, but these differences were not statistically significant, 
(p>0.05, n=3),  (45.6 ± 1.5 % of cell cycle accumulation in G0 in the 
absence of Z-VAD and 55 ± 1.8 % of cell cycle accumulation in G0 in the 
presence of Z-VAD) (Figure 4.11). This confirms that this phenomenon 
was caspase-independent.  
 
 
 
 
 
 
 
 
 
132 
 
 
 
Figure 4.11 Effects of purvalanol A and the pan caspase inhibitor (Z-
VAD-fmk) on CML cell cycle kinetics. Both LAMA-84 and KCL-22 cell 
lines were incubated for 24 h in the absence (U) and presence (P) of 
purvalanol A (30 μM), with and without Z-VAD (Z) (20 μM). Cell cycle 
parameters (expressed as a percentage of the total cell population) were 
determined by measuring DNA content and flow cytometry (see Materials 
and Methods). Data are shown as mean (±SEM, n=3) *=p≤0.05 (paired 
two-tailed student’s t-test) compared to untreated control (U). 
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4.3.6.3 Effects of purvalanol A and the pan-caspase inhibitor, Z-VAD-
fmk on expression of the anti-apoptotic protein, Mcl-1 expression.  
Western blotting was performed to determine the effects of 
purvalanol A together with the pan-caspase inhibitor on the expression of 
Mcl-1 in both cell lines. After 24 h incubation of LAMA-84 cells with 
purvalanol A, Mcl-1 levels decreased in absence of Z-VAD. However, in 
the presence of Z-VAD, the Mcl-1 levels were approximately the same 
compared to levels observed in the absence of Z-VAD.  (88.7 ± 3.5 % in 
absence of Z-VAD to 86.5 ± 8.7 % in presence of Z-VAD) (Figure 4.12A, 
p>0.05). This indicates that purvalanol A induced a caspase-independent 
change in Mcl-1 levels in LAMA-84 cell lines. 
In KCL-22, purvalanol A induced a very large decrease in Mcl-1 
expression by 24 h of incubation in the absence of Z-VAD. In the presence 
of Z-VAD, this decrease in Mcl-1 was not protected (Figure 4.12B). This 
confirms the caspase-independency of this decrease in protein level. 
To conclude, the Mcl-1 decrease induced by purvalanol A is caspase 
independent in both cell lines. These results confirm the role of apoptosis 
induction by purvalanol A from the Viacount and cell cycle kinetic assay 
(Section 4.3.6.1 and 4.3.6.2). 
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Figure 4.12 Effects of imatinib and purvalanol A on expression of Mcl-
1 in LAMA-84 cells (A) and KCL-22 cells (B). Cells were incubated for 
24 h in the absence (U) and presence (I) of imatinib (10 μM) or (P) 
purvalanol A (30 μM), ± Z-VAD (20 μM), and samples were prepared for 
Western blotting for Mcl-1 (40 kDa) and actin (42 kDa), quantified by 
densitometry. Data expressed as a % of untreated samples (±SEM, n=3), * 
= p≤0.05, **=p≤0.01, ***=p≤0.001 (paired two-tailed student’s t-test). 
Western blot shown is representative from n=3 experiments. 
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4.3.7 Effects of purvalanol A and imatinib on intracellular signalling 
pathways in LAMA-84 and KCL-22 cell lines  
The effects of these two inhibitors on the activation status of several 
intracellular signalling systems were subsequently investigated. Both 
LAMA-84 and KCL-22 cell lines were incubated with 30 µM purvalanol A 
or 10 µM imatinib for 15, 30 min and 1 h before the cell lysates were 
prepared and western analysis was performed to determine the effects of 
these drugs on CML signalling pathways. Erk, STAT3, Akt, and p38 
signalling pathways were investigated in this study. 
4.3.7.1 Erk signalling pathway 
Imatinib completely abrogated Erk activation in LAMA-84 cells and 
completely decreased levels of pErk in KCL-22 cells. In contrast, 
purvalanol A treatment resulted in a partial decrease in pErk levels in 
LAMA-84 cells, but complete ablation of activation of this protein in KCL-
22 cells (Figure 4.13). Purvalanol A treatment resulted in a decrease of 
pErk level in KCL-22 cell line by 97 ± 1.7% in 15 min (p≤0.01, n=3). 
4.3.7.2 STAT3 signalling pathway 
Activated STAT3 could not be detected in LAMA-84 cells in spite 
of the fact that this protein was expressed, as detected by pan-STAT3 
antibodies. In KCL-22 cells, purvalanol A treatment decreased pSTAT3 
level significantly (p≤0.05, n=3) to 22 ± 5.4 % by 15 min and completely 
decreased levels of pSTAT3 by 1 h of incubation (Figure 4.14).   
4.3.7.3 Akt signalling pathway 
Purvalanol A and imatinib treatment both decreased pAkt levels 
significantly in the KCL-22 cell line.  The level of phosphorylated Akt was 
decreased by almost 100 % after every treatment for 15 min. However, 
pAkt was consistently undetected in LAMA-84 cell line (Figure 4.15). 
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Figure 4.13 Effects of imatinib and purvalanol A on Erk activation in 
LAMA-84 and KCL-22 cells. Both cell lines were incubated in the 
absence (U ●) or presence of 10 µM imatinib (I ○) and 30 µM purvalanol A 
(P    ) for 15, 30 min and 1 h before preparation for Western blotting for 
pErk and Pan Erk (42-44 kDa), quantified by densitometry. (A) shows 
typical western blots, while (B) shows densitometry analysis, expressed as a 
% of untreated control, untreated samples at time zero (±SEM, n=3), * = 
p≤0.05, **=p≤0.01, ***=p≤0.001 (One-way ANOVA followed by 
Bonferroni post hoc comparisons tests). Western blot shown is 
representative from n=3 experiments. 
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Figure 4.14 Effects of imatinib and purvalanol A on STAT3 activation 
in LAMA-84 and KCL-22 cells. Both cell lines were incubated in the 
absence (U ●) or presence of 10 µM imatinib (I ○) and 30 µM purvalanol A 
(P    ) for 15, 30 min and 1 h before preparation for Western blotting for 
pSTAT3 and Pan STAT3 (79 kDa), quantified by densitometry. (A) shows 
typical western blots, while (B) shows densitometry analysis, expressed as a 
% of untreated control samples at time zero (±SEM, n=3), *=p≤0.05, 
***=p≤0.001 (One-way ANOVA followed by Bonferroni post hoc 
comparisons tests). Western blot shown is representative from n=3 
experiments. 
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Figure 4.15 Effects of imatinib and purvalanol A on Akt activation in 
LAMA-84 and KCL-22 cells. Both cell lines were incubated in the 
absence (U ●) or presence of 10 µM imatinib (I ○) and 30 µM purvalanol A 
(P     ) for 15, 30 min and 1 h before preparation for Western blotting for 
pAkt and Pan Akt (60 kDa), quantified by densitometry. (A) shows typical 
western blots, while (B) shows densitometry analysis, expressed as a % of 
untreated control samples at time zero (±SEM, n=3), *=p≤0.05, 
***=p≤0.001 (One-way ANOVA followed by Bonferroni post hoc 
comparisons tests). Western blot shown is representative from n=3 
experiments. 
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4.3.7.4 p38 signalling pathway 
Unlike Erk and STAT3 signalling pathways, purvalanol A treatment 
resulted in an increase of phosphorylated p38 in both LAMA-84 and KCL-
22 cell lines. Purvalanol A significantly increased phosphorylated p38 by 
28 ± 6 % after 15 min incubation in KCL-22 cells. LAMA-84 cells also 
increased phosphorylated p38 significantly by 22 ± 17 % after 30 min 
(Figure 4.16). 
In conclusion, imatinib completely abrogated Erk activation, but had 
no effect on the activation levels of p38-MAPK in LAMA-84 cells. 
Activated STAT3 or Akt could not be detected in LAMA-84 cells in spite 
of the fact that these two proteins appeared to be expressed, as detected 
using pan-antibodies.  
In KCL-22 cells, imatinib completely decreased levels of pErk and 
pAkt, but had no significant effect on pSTAT3 or phospho-p38-MAPK 
levels. Purvalanol A treatment resulted in a partial decrease in pErk levels 
in LAMA-84 cells, but complete ablation of activation of this protein in 
KCL-22 cells, and also a complete loss of activation of pSTAT3. In 
complete contrast, purvalanol A treatment resulted in enhanced activation 
of p38-MAPK in both cell lines.  
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Figure 4.16 Effects of imatinib and purvalanol A on p38 activation in 
LAMA-84 and KCL-22 cells. Both cell lines were incubated in the 
absence (U ●) or presence of 10 µM imatinib (I ○) and 30 µM purvalanol A 
(P     ) for 15, 30 min and 1 h before preparation for Western blotting for 
Phospho-p38 and Pan p38 (43 kDa), quantified by densitometry. (A) shows 
typical western blots, while (B) shows densitometry analysis, expressed as a 
% of untreated control, untreated samples at time zero (±SEM, n=3), * = 
p≤0.05, **=p≤0.01, ***=p≤0.001 (One-way ANOVA followed by 
Bonferroni post hoc comparisons tests). Western blot shown is 
representative from n=3 experiments. 
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4.3.8 Effects of purvalanol A and BIRB796 on the viability of LAMA-
84 and KCL-22 cell lines  
The above experiments show that purvalanol A activated p38-
MAPK and so it is possible that activated p38 may play a role in regulating 
Mcl-1 expression. Therefore, the effects of BIRB796 (Kuma et al., 2005) on 
purvalanol induced apoptosis and Mcl-1 decrease were tested.  
LAMA-84 cells and KCL-22 cells were incubated for 6 h in the 
absence (untreated control) and presence of 30 µM purvalanol A, 10 µM of 
the p38 MAPK inhibitor, BIRB796, and both inhibitors together.  Cell 
viability was then assessed using the ViaCount assay.  
Purvalanol A significantly induced apoptosis in both cell lines, 
(p≤0.01, n=3). After 6 h of incubation with purvalanol A, LAMA-84 cell 
viability was decreased significantly (from 94.4 ± 0.4 % cell viability of 
control samples to 80.6 ± 0.4 % cell viability of purvalanol A treated 
samples). Similarly, purvalanol A significantly decreased cell viability in 
KCL-22 cells line (p≤0.01, n=3). KCL-22 cell viability was decreased from 
92.5 ± 0.2 % of control samples to 77.7 ± 1.3 % in samples treated with 
purvalanol A (Figure 4.17).  
In contrast, BIRB796 alone did not decrease cell viability in both 
cell lines. However, the level of apoptosis caused by the combination of 
purvalanol A and BIRB796 was significantly lower than that observed by 
purvalanol A alone in both cell lines (to 87.2 ± 1.4 %, (p≤0.05, n=3) and to 
88.6 ± 0.5 %, (p≤0.01, n=3) in LAMA-84 and KCL-22 cell line, 
respectively).  
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Figure 4.17 Effects of purvalanol A and BIRB796 on cell viability of 
CML cell lines.  LAMA-84 and KCL-22 cell lines were incubated in the 
absence (U) and presence of 30 µM purvalanol A (P), 10 µM BIRB796 (B), 
and both (PB) Viability was determined using the Viacount assay. Data are 
shown as mean (±SEM, n=3) *= p≤0.05, **=p≤0.01 (paired two-tailed 
student’s t-test).  
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4.3.9 Effects of purvalanol A and BIRB796 on expression of Mcl-1 in 
LAMA-84 and KCL-22 cell lines  
Both cell lines were treated for 0-4 h in the absence (untreated 
control) and presence of 30 µM purvalanol A, 10 µM BIRB796, and both. 
Then, protein lysates were collected for western blotting.  
In both cell lines, the co-incubation of purvalanol A with BIRB796 
resulted in a significant increase of Mcl-1 protein expression compared to 
expression after incubation with purvalanol A alone. Densitometric analysis 
indicated that Mcl-1 expression was increased significantly from 66 ± 9.8 
% in  purvalanol A treated samples to 92.5 ± 8.3 % in purvalanol A plus 
BIRB796 treated samples (p≤0.05, n=3) in LAMA-84 cell line. Similarly, 
Mcl-1 expression in KCL-22 cell line was also increased significantly from 
14.3 ± 2.6 % in  purvalanol A treated samples to 32.5 ± 2.4 % in purvalanol 
A plus BIRB796 treated samples (p≤0.05, n=3), (Figure 4.18). 
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Figure 4.18 Effects of purvalanol A and BIRB796 on expression of Mcl-
1 in LAMA-84 cells and KCL-22 cells. (A) Cells were incubated for 0-4 h 
in the absence (U) and presence 30 μM purvalanol A and (P) and 10 μM 
BIRB796 (B), and both inhibitors together (PB). Samples were prepared for 
Western blotting for Mcl-1 (40 kDa) and actin (42 kDa). Representative 
blots are shown in (A).  (B) Densitometric analysis of the effects of 
purvalanol A and BIRB796 on Mcl-1 expression. Data are shown as mean 
(±SEM, n=3) *=p≤0.05, **=p≤0.01, ***=p≤0.001 (paired two-tailed 
student’s t-test). Western blot shown is representative from n=3 
experiments. 
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4.4 Discussion and Conclusions 
In this Chapter, the effects of purvalanol A on CML viability were 
investigated in order to determine if this inhibitor could induce apoptosis of 
TKI-sensitive and –insensitive cell lines.  Purvalanol A, originally 
developed as a CDK2 inhibitor, has been shown to inhibit CDK2 kinase 
activity in various cancer cell lines (Villerbu et al., 2002). However, there 
are no reports to date of the clinical or laboratory effects of purvalanol A on 
CML cells. Therefore, this study provides the first preliminary results into 
the effects of this inhibitor on imatinib-sensitive and –insensitive CML cell 
lines. 
The effects of purvalanol A on LAMA-84 and KCL-22 cell lines 
were first investigated using cell viability measurements. This part of the 
study showed that purvalanol A decreased cell viability in both cell lines. 
Apart from the effects of purvalanol A used as a single agent in both cell 
lines, its effects in combination with imatinib were also investigated.  
However, no synergistic effects were found in these preliminary 
experiments, unlike in a number of other studies using inhibitors that block 
BCR-ABL downstream signalling pathways in combination with imatinib, 
some of which have found synergistic effects (Tipping et al., 2002, 
Radujkovic et al., 2005, Tseng et al., 2005, Kancha et al., 2008). For 
example, the combination of imatinib and a PDK-1 inhibitor has been 
shown to induce synergistic effects in imatinib-resistant cell lines (Tseng et 
al., 2005). 
In addition to its effects on cell viability, Purvalanol A induced 
mitochondrial depolarisation rapidly in both LAMA-84 and KCL-22 cell 
lines (within 2 h). This result supports previous findings that have been 
reported that purvalanol A induced mitochondrial dysfunction before 
induction of apoptosis (Iizuka et al., 2008). The effects of purvalanol A on 
the expression of various pro- and anti-apoptotic proteins of the Bcl-2 
family were also investigated in order to determine if changes in the 
expression levels of these proteins may explain the increased apoptosis 
observed after purvalanol A treatment. While purvalanol A induced 
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apoptosis in both cell lines, it induced a very large decrease in Mcl-1 levels, 
but only in the KCL-22 cell line. This effect was specific for Mcl-1 and was 
not observed for other anti-apoptotic proteins measured. This result 
supports the concept that Mcl-1 plays a crucial role in apoptosis of CML 
cells, as other reports have shown that many leukaemia cells are more 
sensitive to anti-Mcl-1 drugs than Bcl-2 targeted drugs (Brunelle et al., 
2009). However, this result is quite different from a number of other studies 
using purvalanol A treatment on other cell lines to inhibit CDK2 activity. 
For example, studies on the human gastric adenocarcinoma cell lines and 
breast cancer cell lines showed that purvalanol A treatments significantly 
decreased the levels of Bcl-2 and Bcl-XL in these cells (Obakan et al., 2014, 
Iizuka et al., 2007, Iizuka et al., 2008).  
The effects of purvalanol A on the expression of the anti-apoptotic 
protein Mcl-1 were investigated in the presence of pan-caspase inhibitor, Z-
VAD. It was found that the inhibition of caspase activity did not protect the 
decreases in Mcl-1 levels in both cell lines. This implies that in both cell 
lines, the decrease in Mcl-1 levels observed is not driven by caspase 
activity, an important observation because Mcl-1 degradation is reported to 
be caspase-sensitive under some circumstances (Weng et al., 2005, Herrant 
et al., 2004, Akgul, 2009). Therefore, the decreases in Mcl-1 are more liken 
to drive apoptosis, rather than vice versa. However, a previous study has 
shown that purvalanol A induces caspase-dependent apoptotic cell death by 
involving Bcl-2 family members in an aggressive Estrogen Receptor 
positive (ER+) breast cancer cell line, more so than in a breast cancer cell 
line that is Estrogen Receptor negative (ER-) (OBakan et al., 2014). This 
might suggest that purvalanol A has a specific effect on CML cell lines but 
the mechanisms of action are still unclear and the reasons for differences in 
responses of different cancer cells to this drug also need further 
investigations. It is also curious to note that while purvalanol A induced 
apoptosis in both cell lines, it was much more potent in inducing apoptosis 
in the imatinib-insensitive cell line (KCL-22) and did not result in a marked 
decrease in Mcl-1 in LAMA-84 cells.  
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Mcl-1 is subject to numerous post-translational modifications that 
can alter its function, localization and turnover rate (Thomas et al., 2010). 
Many of these post-translational modifications result from reversible 
phosphorylation on a number of Serine or Threonine residues, particularly 
in the large and unique N-terminal domain of the protein (Thomas et al., 
2012). While some of the kinases responsible for these phosphorylation 
events have been identified (Inoshita et al., 2002, Domina et al., 2004), the 
precise mechanisms regulating Mcl-1 turnover are not fully defined. It is 
possible, therefore, that these differential effects of purvalanol A on Mcl-1 
turnover in LAMA-84 and KCL-22 cells are explained, at least in part, by 
differences in their intracellular signalling processes that, apart from 
regulating cell activation could also target Mcl-1 to alter its function. 
Therefore, the effects of purvalanol A on several important 
signalling pathways were investigated. Purvalanol A resulted in a down-
regulation of phosphorylated Erk, STAT3, and Akt in KCL-22 cell line. 
This supports another study that used purvalanol A on different cell lines 
(Iizuka et al., 2008, Knockaert et al., 2002b). Moreover, this result is also 
related to other inhibitors on CML cell lines. For example, the proteasome 
inhibitor, carfilzomib, also caused a down-regulation of pERK in various 
types of CML models (Crawford et al., 2014). These results also support 
the findings that BCR-ABL activates many downstream signalling 
pathways, including ERK, STATs, and Akt pathways that contribute to the 
proliferation and survival of CML cells (Voss et al., 2000, Danial and 
Rothman, 2000, Kirchner et al., 2003).  
However, the data presented in this Chapter revealed a number of 
interesting and unexpected findings. First, in spite of the fact that LAMA-
84 cells appear to express STAT3 and Akt (as evidenced by the detection of 
an appropriate signal in western blots using pan-specific antibodies), no 
activated forms of these proteins could be detected under any experimental 
conditions tested in this study. Second, while imatinib had little effect on 
the growth kinetics of KCL-22 cells (apart from a partial G1 arrest), it 
ablated activation of both pErk and pAkt. Third, purvalanol A, but not 
imatinib, down-regulated STAT3 activation in KCl-22 cells. Fourth, 
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purvalanol A, but not imatinib resulted in increased activation of p38. 
Previous work has implicated p38 in neutrophil apoptosis (Aoshiba et al., 
1999), and the work presented here supports the notion that activated p38 
generates a death signal, perhaps directly or indirectly via increased 
turnover of Mcl-1. To address this question, p38 MAPK inhibitor, 
BIRB796, which inhibits all p38 isoforms (Kuma et al., 2005), was used 
with purvalanol A to determine its effect on CML cell lines. BIRB796 was 
found to decrease apoptosis and Mcl-1 loss caused by purvalanol A in both 
cell lines. This suggests that p38 MAPK plays a role in apoptosis induction 
by purvalanol A. 
The experiments described here show that purvalanol A induced 
apoptosis in imatinib-insensitive cells, but the mechanism of action of 
purvalanol A still needs to be defined. Therefore, effects of purvalanol A on 
Mcl-1 will be investigated further in the next Chapter. 
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CHAPTER 5:  EFFECTS OF PURVALANOL A ON THE 
EXPRESSION OF THE ANTI-APOPTOTIC PROTEIN, 
MCL-1, IN IMATINIB-SENSITIVE AND –INSENSITIVE 
CML CELL LINES 
5.1 Introduction 
Mcl-1 was first identified as an early induction gene expressed 
during myeloid leukemia cell differentiation (Kozopas et al., 1993). It was 
found to share amino acid sequence similarities with previously identified 
Bcl-2 (Reynolds et al., 1994), and to possess similar functions. It possesses 
three putative BH domains, which mediate anti-apoptotic functions within 
members of this protein family. These functions are able to delay apoptosis 
induced by various stimuli such as, UV-irradiation, etoposide treatment 
(Zhou et al., 1997) and hypoxia (Liu et al., 2006). Mcl-1 also possesses a 
transmembrane domain which is able to insert into many cellular 
membranes under resting conditions, including the mitochondria (Yang et 
al., 1995) and nuclear envelop (Leuenroth et al., 2000). Mcl-1 can bind to 
the pro-apoptotic proteins, Bak and Bax, to inhibit them from forming pores 
in the mitochondrial membrane. This binding inhibits cytochrome c release 
from mitochondria and thus can prevent apoptosis (Thomas et al., 2010).  
Mcl-1 protein and mRNA have a very short half-lives (Yang et al., 
1995, Schubert and Duronio, 2001) and regulation of Mcl-1 protein 
expression is mediated by multiple levels as described below. Mcl-1 is 
approximately twice as large as other Bcl-2 family members due to its 
extensive N-terminal domain containing PEST sequences and Arg:Arg 
motifs (Kozopas et al., 1993), which are responsible for the high rate of 
protein turnover (Rechsteiner and Rogers, 1996). Degradation of Mcl-1 can 
be via caspase- and proteasome-mediated mechanisms (Thomas et al., 
2010).  
The proteasome plays a crucial role in cellular protein degradation.   
More than 80% of intracellular proteins are degraded by the 26S 
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proteasome as it plays a role as a dynamic proteolytic complex of the 
ubiquitin-proteasome system. Many vital cellular processes are regulated by 
the proteasome, such as cell cycle kinetics, DNA repair, and apoptosis 
(Piccinini et al., 2003). The rapid turnover of Mcl-1 is mediated by 
ubiquitination at lysine residues by a Mcl-1 specific ligase, leading to 
proteasome degradation (Derouet et al., 2004, Chou et al., 2006). Apart 
from proteasome degradation, Mcl-1 can also be degraded by caspases 
(Herrant et al., 2004) and granzyme B (Han et al., 2005) at specific sites in 
the PEST regions. Thus, the short half-life characteristic of Mcl-1 can partly 
be explained by these protein turnover mechanisms. 
Although Mcl-1 can be transcriptionally regulated, protein  
expression can be also regulated by post-translational regulation, as Mcl-1 
residues can be phosphorylated/dephosphorylated at different sites and 
these modifications can alter the turnover rate or function of Mcl-1 thereby 
affecting its role in apoptosis (Thomas et al., 2010). Various 
phosphorylation sites within the PEST regions have been identified, such as 
Ser64 (Kobayashi et al., 2007), Ser159 (Maurer et al., 2006), Ser121 
(Inoshita et al., 2002), and Ser163 (Domina et al., 2004). Phosphorylation 
of these site affects Mcl-1 stabilisation and subsequent Mcl-1 degradation 
(Thomas et al., 2010). Thus, Mcl-1 protein levels are dynamically regulated 
in cells and this is important for cell survival regulation. 
Mcl-1 appears to have a distinct role and unique characteristics 
among other Bcl-2 family members, mainly due to its relatively high rate of 
turnover and hence transient expression. Mcl-1 expression can be rapidly 
regulated during development and differentiation in several cell types such 
as B and T lymphocytes (Opferman et al., 2003), cerebellar granular 
neurons (Zhang and D'Ercole, 2004), and neuroendocrinal cells (Krajewski 
et al., 1995). Mcl-1 knock-out in mice is embryonically lethal and this 
suggests it has a specific role in embryo development (Rinkenberger et al., 
2000). 
It has been reported that Mcl-1 over-expression in mice resulted in 
the development of B-cell lymphoma (Zhou et al., 2001). There are several 
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additional reports showing that Mcl-1 over-expression is frequently found 
in many types of cancer. These include multiple myeloma (Le Gouill et al., 
2004), prostate cancer (Cavarretta et al., 2007), hepatocellular, carcinoma 
(Fleischer et al., 2006), breast cancer (Henson et al., 2006), and also CML 
(Aichberger et al., 2005). Aichburger and colleagues (Aichberger et al., 
2005) showed that BCR/ABL promoted the expression of Mcl-1 via 
RAS/RAF/MAPK activation. This result suggests that Mcl-1 is an 
important regulator of cell survival in CML. Mcl-1 has been shown to be 
implicated in chemoresistant cancer (Campbell et al., 2010) and so is an 
interesting target in cancer therapy. Obatoclax, a BH-3 mimetic, has been 
developed to treat cancer (van Delft et al., 2006).  
Therefore, the regulation of turnover of Mcl-1 in CML is 
investigated further in this chapter. 
The aims of this chapter were 
i)  To compare the effect of the combined use of purvalanol A 
with imatinib or purvalanol A alone as a single agent on 
Mcl-1 expression in CML cell lines. 
ii)  To determine if the half-life of Mcl-1 is affected by 
purvalanol A. 
iii)  To measure the effects of purvalanol A on Mcl-1 mRNA. 
iv)  To confirm that constitutive degradation of Mcl-1 is 
mediated by the ubiquitin-proteasome pathway. 
v)  To identify the phosphorylation site of Mcl-1 that affects the   
stabilization of Mcl-1. 
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5.2 Material and Methods 
All methods described in this Chapter are more fully detailed in 
Chapter 2. For most experiments, imatinib and purvalanol A were used at 10 
µM and 30 µM, respectively, unless stated otherwise.  These concentrations 
were the lowest concentration that induced the maximal effects on the CML 
cells, as used in previous Chapters. As these drugs were dissolved in DMSO, 
all untreated control contained an equivalent volume of DMSO as used after 
the addition of inhibitors.  
5.3 Results 
Initial experiments measured the effects of purvalanol A on Mcl-1 
expression in these cell lines using western blotting. The levels of Mcl-1 
mRNA expression were measured by quantitative PCR. 
5.3.1 Concentration dependent effects of purvalanol A on Mcl-1 
expression  
Western blotting was used to determine the effects of purvalanol A 
on the expression levels of Mcl-1 in KCL-22 cells, which were treated with 
and without purvalanol A over a range of different concentrations (2.5, 5, 
10, 20, and 30 µM) in the presence and absence of imatinib (10 µM) for 24 
h and then protein lysates were prepared for western blotting. After 24 h 
incubation with purvalanol A in the absence of imatinib, Mcl-1 levels 
decreased significantly at concentrations of 20 µM (56.8 ± 9.7 %) and 30 
µM (17.5 ± 12.9 %) compared to untreated control (p≤0.05, n=3).  
However, in the presence of imatinib, the Mcl-1 levels were 
significantly decreased at the concentration of purvalanol A at 10 µM (58 ± 
8 %), 20 µM (19.8 ± 6.3 %), and 30 µM (1 ± 0.4 %) (p≤0.05, n=3).  
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Figure 5.1 Effect of different concentrations of purvalanol A on 
expression of Mcl-1 in KCL-22 cells. Cells were incubated in the absence 
and presence of purvalanol A (P) at concentrations of 0, 2.5, 5, 10, 20, and 
30 μM with and without imatinib (10 μM) for 24 h and samples were 
prepared for Western blotting for Mcl-1 (40 kDa) and actin (42 kDa), 
quantified by densitometry. (A) Shows a typical western blot analysis, 
while densitometric analysis is shown in (B). Data are expressed as % of 
untreated samples (±SEM, n=3) * = p≤0.05, ** = p≤0.01, *** = p≤0.001 
(paired two-tailed student’s t-test). 
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The combination of purvalanol A and imatinib decreased Mcl-1 
expression in KCL-22 cells more than purvalanol A alone at the equivalent 
concentration. These results showed that there was a significant difference 
between the incubation of purvalanol A with the presence and absence of 
imatinib at the 20 µM concentration of purvalanol A (p≤0.05, n=3) (Figure 
5.1).  
In addition, the combination of purvalanol A and other TKIs 
(nilotinib and dasatinib) showed similar effect to imatinib. The combination 
treatment showed greater effect in Mcl-1 level reduction when compared to 
single treatment (Figure 5.2 and 5.3). 
5.3.2 Time course of effects of purvalanol A on Mcl-1 expression  
Subsequent experiments were then performed to measure the time 
course of the effects of imatinib and purvalanol A on Mcl-1 expression. 
LAMA-84 and KCL-22 cell lines were treated with purvalanol A for 0, 1, 2, 
4, 6, 18, and 24 h before protein extracts were prepared for western blot 
analysis. The results showed that purvalanol A decreased Mcl-1 levels 
rapidly in KCL-22 cells, but not LAMA-84 cells. In KCL-22 cells, 
significantly decreased Mcl-1 was observed by 1 h (83 ± 7.5 %) of 
purvalanol A incubation (p≤0.05, n=3) (Figure 5.4). In addition, purvalanol 
A decreased Mcl-1 expression by 50 % of the time zero values within 
approximately 4 h of incubation (Figure 5.4).  
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Figure 5.2 Effect of different concentrations of purvalanol A and 
nilotinib on expression of Mcl-1 in KCL-22 cells. Cells were incubated in 
the absence and presence of purvalanol A (P) at concentrations of 0, 2.5, 5, 
10, 20, and 30 μM with and without nilotinib (2 µM) (N) for 24h and 
samples were prepared for Western blotting for Mcl-1 (40 kDa) and actin 
(42 kDa), quantified by densitometry. (A) Shows a typical western blot 
analysis, while densitometric analysis is shown in (B). Data are expressed 
as % of untreated samples (±SEM, n=3), * = p≤0.05, ** = p≤0.01, *** = 
p≤0.001 (paired two-tailed student’s t-test). 
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Figure 5.3 Effect of different concentrations of purvalanol A and 
dasatinib on expression of Mcl-1 in KCL-22 cells. Cells were incubated 
in the absence and presence of purvalanol A (P) at concentrations of 0, 2.5, 
5, 10, 20, and 30 μM with and without Dasatinib (150 nM) (D) for 24h and 
samples were prepared for Western blotting for Mcl-1 (40 kDa) and actin 
(42 kDa), quantified by densitometry. (A) Shows a typical western blot 
analysis, while densitometric analysis is shown in (B). Data are expressed 
as % of untreated samples (±SEM, n=3), * = p≤0.05, ** = p≤0.01, *** = 
p≤0.001 (paired two-tailed student’s t-test). 
  
*
* 
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Figure 5.4 Time course of effects of purvalanol A on expression of Mcl-
1 in LAMA-84 cells and KCL-22 cells. Cells were incubated in the 
absence and presence of purvalanol A (30 μM), and samples were collected 
at various incubation times and prepared for Western blotting for Mcl-1 (40 
kDa) and actin (42 kDa), quantified by densitometry. (A) Shows a typical 
western blot analysis, while densitometric analysis of LAMA-84 and KCL-
22 cell lines is shown in (B). Data expressed as a % of untreated samples 
(±SEM, n=3) * = p≤0.05, ** = p≤0.01, *** = p≤0.001 (paired two-tailed 
student’s t-test). 
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5.3.3 Effect of purvalanol A on the half-life of Mcl-1 
Mcl-1 has a short half-life that can be decreased even further in the 
presence of certain apoptosis-inducing agonists, or enhanced by agents that 
delay apoptosis, such as GM-CSF (Derouet et al., 2004). The following 
experiments were performed to determine if purvalanol A induced 
apoptosis via changes in the turnover rate of Mcl-1. Cells were incubated 
with the de novo protein synthesis inhibitor, cycloheximide (CHX), prior to 
purvalanol A treatment. After this pre-incubation period, the 
cycloheximide-treated cells were incubated for 1, 2, 4, and 6 h in the 
absence and presence of 30 µM of purvalanol A, and protein extracts were 
prepared. Levels of Mcl-1 protein in these cells that were blocked in protein 
synthesis were determined by western blotting. 
These results show that when de novo protein synthesis was 
blocked, Mcl-1 was constitutively degraded and this turnover was 
accelerated in the presence of purvalanol A in KCL-22, but not LAMA-84 
cells.  
  In control cells (cycloheximide but no purvalanol A), the half-life 
of Mcl-1 (the time taken for the level of Mcl-1 to decrease by 50 % of time 
zero values in cycloheximide-blocked cells) was ~3 h in both LAMA-84 
cells and KCL-22 cells. Purvalanol A resulted in only a slight change in the 
half-life of Mcl-1 in LAMA-84 cells (Figure 5.5), but a large decrease in 
the half-life of Mcl-1 in KCL-22 cells to approximately 1.5 h (Figure 5.6). 
Mcl-1 levels in KCL-22 were significantly lower after 4 h after 
CHX treatment in the presence of purvalanol A incubation (20.1 ± 5.3 %) 
compared to treatment with CHX alone (42.1 ± 2.7) (p≤0.05, n=3). These 
experiments indicate that the very rapid decrease in Mcl-1 levels in KCL-22 
cells induced by purvalanol A treatment is explained, at least in part, by an 
increase in the turnover rate of Mcl-1.  
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Figure 5.5 Effect of purvalanol A on the half-life of Mcl-1 in LAMA-84 
cells. Cell lines were pre-incubated for 10 min with cycloheximide (CHX) 
prior to 0, 1, 2, 4, and 6 h incubation in the absence (U), or presence of 30 
μM purvalanol A (P). Cell samples were collected at various times and 
prepared for Western blotting for the levels of Mcl-1 (40 kDa) and actin (42 
kDa), which were quantified by densitometry. (A) Shows a typical western 
blot analysis, while densitometric analysis is shown in (B). The half-life of 
untreated samples and purvalanol A treated samples were indicated with 
IC50 (shown in dashes). Data are expressed as % of untreated samples 
(±SEM, n=3). Western blot shown is representative from n=3 experiments. 
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Figure 5.6 Effect of purvalanol A on the half-life of Mcl-1 in KCL-22 
cells. Cell lines were pre-incubated for 10 min with cycloheximide (CHX) 
prior to 0, 1, 2, 4, and 6 h incubation in absence (U), or presence of 30 μM 
purvalanol A (P). Cell samples were collected at various times and prepared 
for Western blotting for the levels of Mcl-1 (40 kDa) and actin (42 kDa), 
were quantified by densitometry. (A) Shows a typical western blot analysis, 
while densitometric analysis is shown in (B). The half-life of untreated 
samples and purvalanol A treated samples were indicated with IC50 (shown 
in dashes). Data are expressed as % of untreated samples (±SEM, n=3), * = 
p≤0.05 (paired two-tailed student’s t-test). Western blot shown is 
representative from n=3 experiments. 
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5.3.4 Effect of purvalanol A on Mcl-1 mRNA expression 
The effects of purvalanol A on Mcl-1 mRNA expression and mRNA 
turnover were then determined in view of the finding in previous 
experiments which showed that purvalanol A caused an enhanced rate of 
Mcl-1 turnover in imatinib-resistant cells. LAMA-84 and KCL-22 cells 
were treated with and without 30 µM purvalanol in the presence and 
absence of 10 µM imatinib for 30 min and 2 h and then total RNA was 
isolated for cDNA synthesis and used to perform qPCR. 
In LAMA-84 cells, imatinib and purvalanol A had no significant 
effect on the relative expression of Mcl-1 mRNA (Figure 5.7).  
KCL-22 cells showed a different response in Mcl-1 mRNA 
expression after purvalanol A exposure. The relative expression of Mcl-1 
mRNA was not affected by imatinib over a period of 2 h incubation. In 
contrast, Mcl-1 mRNA was significantly down-regulated after 30 min 
exposure to purvalanol A (63.9 ± 7.3 %). The combination of imatinib and 
purvalanol A also significantly decreased the relative expression of Mcl-1 
mRNA after a period of 2 h incubation (55.5 ± 6.3 %), (p≤0.05, n=3) 
(Figure 5.7). The maximal decrease in Mcl-1 mRNA expression was 
detected by 2 h incubation (39.2 ± 19.6 %) after purvalanol A treatment of 
KCL-22 cells (p≤0.05, n=3). 
 
 
 
 
 
162 
 
 
 
Figure 5.7 Effect of imatinib and purvalanol A on mRNA expression of 
Mcl-1 in LAMA-84 (A) and KCL-22 cells (B). Cell lines were incubated 
in absence (U), or presence of 10 μM imatinib (I), 30 μM purvalanol A (P), 
and a combination of the two drugs (IP) for 0, 30 min and 2 h incubation. 
Cell samples were collected and prepared for RNA isolation, followed by 
quantitative PCR for the levels of Mcl-1L and β-actin. Data are expressed 
as % of untreated samples (±SEM, n=3), * = p≤0.05 (paired two-tailed 
student’s t-test).  
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5.3.5 Effect of purvalanol A and proteasome inhibition on Mcl-1 
protein expression 
The above results suggest that purvalanol A induced apoptosis in 
KCL-22 cell line by increasing Mcl-1 protein turnover. Thus, it was 
necessary to determine whether purvalanol A decreased Mcl-1 expression 
in KCL-22 cells by proteasome degradation and promoting ubiquitination. 
To address this question, both LAMA-84 and KCL-22 cells were 
incubated for 2 h in the absence (U) and presence of 30 μM purvalanol A 
(P) with and without 10 μM cycloheximide (C) and 50 μM of the 
proteasome inhibitor, MG-132 (M). After this incubation, samples were 
collected and prepared for western blotting for Mcl-1 (40 kDa) and actin 
(42 kDa).  
In LAMA-84 cells, the level of Mcl-1 protein were always higher in 
the presence of MG-132, than in the absence of this proteasome inhibitor. 
There was a significant difference in Mcl-1 expression between purvalanol 
A treated samples (P as 81.5 ± 7.2 %) and purvalanol A together with MG-
132 (MP as 107.7 ± 5.3 %), (p≤0.05, n=3) (Figure 5.8). This suggests that 
turnover of Mcl-1 in the presence of purvalanol A occurs via the 
proteasome. In addition, over-exposed western blots in Figure 5.10A 
indicate the presence of high molecular mass bands of Mcl-1 in MG-132 
cells incubated together with purvalanol A (b) than when incubated with 
purvalanol A alone (a). These higher molecular mass forms of Mcl-1 may 
be ubiquitinated forms of the protein in the presence of the proteasome 
inhibitor, MG-132.  
Similar to LAMA-84 cells, MG-132 prevented the loss of Mcl-1 in 
KCL-22 cells when exposed to purvalanol A. The Mcl-1 expression in cells 
treated with MG-132 together with purvalanol A (MP as 115.4 ± 3.7 %) 
was significantly higher that purvalanol A alone (P as 47.8 ± 3.6 %), 
(p<0.05, n=3) (Figure 5.9). Also, over-exposed western blots (Figure 
5.10B) shows more higher molecular mass forms of Mcl-1 band in the 
presence of MG-132 in purvalanol A treated samples (d) compared to 
purvalanol A alone (c).  
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To conclude, these results suggest that purvalanol A promoted 
ubiquitination and proteasome degradation in both LAMA-84 and KCL-22 
cell lines. 
 
Figure 5.8 Effect of purvalanol A and proteasome inhibitor on Mcl-1 
protein expression in LAMA-84. Cells were incubated in the absence (U) 
and presence of purvalanol A (P) (30 μM) with and without cycloheximide 
(C) and MG-132 (M) for 2 h, and samples were collected and prepared for 
Western blotting for Mcl-1 (40 kDa) and actin (42 kDa), quantified by 
densitometry. (A) Shows a typical western blot analysis, while 
densitometric analysis is shown in (B). Data expressed as a % of untreated 
samples (±SEM, n=3), * = p≤0.05 (paired two-tailed student’s t-test). 
Western blot shown is representative from n=3 experiments. 
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Figure 5.9 Effect of purvalanol A and proteasome inhibitor on Mcl-1 
expression in KCL-22. Cells were incubated in the absence (U) and 
presence of purvalanol A (P) (30 μM) with and without cycloheximide (C) 
and MG-132 (M) for 2 h, and samples were collected and prepared for 
Western blotting for Mcl-1 (40 kDa) and actin (42 kDa), quantified by 
densitometry. (A) Shows a typical western blot analysis, while 
densitometric analysis is shown in (B). Data expressed as a % of untreated 
samples (±SEM, n=3), * = p≤0.05 (paired two-tailed student’s t-test). 
Western blot shown is representative from n=3 experiments. 
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Figure 5.10 Effects of purvalanol A and proteasome inhibitor on Mcl-1 
expression in LAMA-84 and KCL-22. Cells were incubated in the 
absence (U) and presence of purvalanol A (P) (30 μM) with and without 
cycloheximide (C) and MG-132 (M) for 2 h, and samples were collected 
and prepared for Western blotting for Mcl-1 (40 kDa) and actin (42 kDa), 
quantified by densitometry (films were over-exposed to membranes for at 
least 10 min). (A) Shows a typical western blot analysis of LAMA-84 cells, 
while a typical western blot analysis of KCL-22 cells is shown in (B). (a-d) 
indicates higher molecular mass forms of Mcl-1. Western blot shown is 
representative from n=3 experiments. 
  
167 
 
5.3.6 Effect of purvalanol A on phospho-Mcl-1 expression 
The above experiments showed that purvalanol A induced apoptosis 
by an increase of Mcl-1 turnover, possibly involving enhanced 
ubiquitination, and subsequent proteasome degradation. Recent work 
suggests that phosphorylation of Mcl-1 may promote ubiquitination 
(Inuzuka et al., 2011, Magiera et al., 2013). Thus, levels of phospho-Mcl-1 
expression were investigated to address this question. Both LAMA-84 and 
KCL-22 cells were incubated for 2 h in the absence (U) and presence of 30 
μM purvalanol A (P) with and without 10 μM imatinib (I). Cell lysates were 
collected and prepared for western blotting for phospho-Mcl-1 (Ser 159 / 
Thr 163) (40 kDa), Mcl-1 (40 kDa), and actin (42 kDa).  
There was no significant difference observed in p-Mcl-1 expression 
after any treatment in LAMA-84 cell line. Figure 5.11A shows a typical 
western blot analysis of p-Mcl-1. p-Mcl-1 appeared as a double band at 
around 40 kDa and Figure 5.11C illustrates the ratio of the relative 
expression of the upper band and the lower band (to indicate hyper 
phosphorylation). In LAMA-84 cells, the relative expression of the upper 
band (p-Mcl-1) was significantly higher than the lower band (p≤0.05, n=3). 
This suggests that purvalanol A may induce p-Mcl-1 (Ser 159 / Thr 163) 
hyper phosphorylation in these cells. 
In contrast, purvalanol A decreased p-Mcl-1 expression significantly 
in KCL-22 cell line (P = 29.4 ± 9.3 %, IP = 40.9 ± 8.7 %, compared to 
untreated controls (U), p≤0.05, n=3), while imatinib alone did not have the 
same effect. However, there was no significant difference in the ratio 
between the relative expression p-Mcl-1 as determined by the ratio of the 
upper and lower band of p-Mcl-1. 
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Figure 5.11 Effects of purvalanol A on phospho-Mcl-1 expression. Cells 
were incubated in the absence (U) and presence of purvalanol A (P) (30 
μM) with and without imatinib (10 μM) (I) for 2 h, and samples were 
collected and prepared for Western blotting for p-Mcl-1 (40 kDa), Mcl-1 
(40 kDa), and actin (42 kDa). (A) Shows a typical western blot analysis, 
while densitometric analysis of p-Mcl-1 quantified by Pan Mcl-1 is shown 
in (B). (C) shows the ratio of relative expression between upper and lower 
band. Data expressed as a % of untreated samples (±SEM, n=3), * = p≤0.05 
(paired two-tailed student’s t-test). Western blot shown is representative 
from n=3 experiments. 
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5.4 Discussion and Conclusions 
Mcl-1 expression is implicated in drug resistance in various types of 
cancers, such as leukaemias (van Delft et al., 2006). A recent report has 
shown that Mcl-1 transgenic mice over-expressing Mcl-1 developed 
lymphopoeisis that was refractory to chemotherapy (Campbell et al., 2010). 
Thus, there is a need to find new ways to decrease the level of Mcl-1 
expression, as this may have potential to function as an alternative therapy 
for cancer treatment.  
Mcl-1 protein and mRNA have a very short half-lives (Yang et al., 
1995, Schubert and Duronio, 2001) which can be decreased even further in 
the presence of certain apoptosis-inducing agonists (Derouet et al., 2006). 
This characteristic suggests that the level of Mcl-1 expression is highly 
regulated by transcription and/or translation inhibition. This study confirms 
the hypothesis that purvalanol A induced apoptosis in imatinib-insensitive 
cell line by enhancing Mcl-1 turnover. This result supports the concept that 
Mcl-1 plays a crucial role in apoptosis of CML cells (Aichberger et al., 
2005). There are several reports supporting this concept that Mcl-1 can be 
targeted by many agents that affect its turnover. For example, Seliciclib, a 
CDK inhibitor, can induce RNA polymerase II-dependent transcription, 
which results in Mcl-1 degradation and induction of apoptosis (MacCallum 
et al., 2005). Moreover, it has been reported that quercetin, a plant 
flavonoid, induced apoptosis in U-937 cell lines via Mcl-1 down-regulation 
(Cheng et al., 2010).  
Mcl-1 can be regulated indirectly by alterations in its turnover rate 
by some agents. For example, obatoclax, the BH3-like compound, can 
interfere with the interaction between Mcl-1 and the pro-apoptotic protein, 
Bak and this leads to cell apoptosis (Nguyen et al., 2007, Trudel et al., 
2007). The work presented in this Chapter suggests that purvalanol A can 
be included in this group of compounds as it increases Mcl-1 turnover in 
imatinib-insensitive CML cell lines. However, its mechanism of action 
should be investigated further.  Apart from its effects on increasing protein 
turnover, the decrease of Mcl-1 expression in imatinib-insensitive cells 
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could also be partly explained by effects on transcriptional and/or post 
transcriptional inhibition. Thus, the effects of purvalanol A on Mcl-1 
mRNA expression were determined by qPCR.  The experiments described 
in this Chapter shows that purvalanol A decreased Mcl-1 mRNA levels in 
imatinib-resistant cells in a time-dependent manner. Thus, the effects of 
purvalanol A on Mcl-1 are of potential therapeutic interest, as Mcl-1 can be 
inhibited at transcriptional level, leading to a decrease in Mcl-1 expression 
in imatinib-insensitive CML cells. 
This study also suggests that purvalanol A promoted ubiquitination 
prior to proteasome degradation in both imatinib-sensitive and –insensitive 
CML cell lines. This supports the concept that Mcl-1 degradation depends 
on proteasome-dependent mechanisms (Thomas et al., 2010). This is 
because the N-terminal region of Mcl-1 contains PEST domains that 
contain motifs that can regulate protein degradation. This PEST region 
contains ubiquitination sites (lysine residues) that can promote proteasome 
degradation (Thomas et al., 2010, Akgul, 2009). This suggests that 
purvalanol A has different modes of actions on Mcl-1 expression in 
addition to Mcl-1 mRNA down-regulation. To support this concept, it has 
been reported that quercetin down-regulated Mcl-1 by disturbing mRNA 
stability and enhancing proteasome degradation in CLL cells (Spagnuolo et 
al., 2011). Also, another report showed that the Mcl-1 down-regulation was 
mediated by a proteasomal-dependent pathway in the presence of certain 
apoptosis-inducing agent in human neutrophils (Lucas et al., 2013). 
In this Chapter, some preliminary experiments on Mcl-1 
phosphorylation are provided. The experiments described here showed that 
purvalanol A decreased p-Mcl-1 expression (Ser159 / Thr163) in imatinib-
insensitive cells. This supports the concept that Mcl-1 can be post-
translationally regulated by phosphorylation at specific residues on Mcl-l.  
In this study, the potential phosphorylation sites that were studied using the 
antibody were at Ser159 and Thr163. These phosphorylated sites have been 
experimentally confirmed (Maurer et al., 2006, Inoshita et al., 2002, 
Domina et al., 2004). It has been reported that phosphorylation at Thr163 
increases Mcl-1 stability by delaying its turnover (Domina et al., 2004). 
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However, another report shows that phosphorylation at this site induced 
Mcl-1 inactivation after H2O2 treatment (Inoshita et al., 2002). Thus, the 
role of Thr163 phosphorylation is still unclear and need to be investigated 
further. 
Taken together, these results provide new insights into how Mcl-1 
turnover is regulated by purvalanol A. These include Mcl-1 mRNA down-
regulation, ubiquitination and proteasome degradation, and protein 
phosphorylation. However, more research, including more in vitro 
experiments, need to be performed to determine the effects of purvalanol A 
on the Mcl-1 in CML cells and primary immune cells, such as PBMCs and 
neutrophils. 
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CHAPTER 6:  EFFECTS OF PURVALANOL A ON 
PRIMARY LEUKOCYTES 
6.1 Introduction 
White blood cells (leukocytes) protect the human body from 
pathogens and other foreign invaders. They are derived from hematopoietic 
stem cells in the bone marrow and circulate throughout the body via the 
blood circulation system. White blood cells can be divided into five 
different types by their physical and functional characteristics. These 
include neutrophils, eosinophils, basophils, lymphocytes, and monocytes 
(Janeway, 2001). 
Neutrophils are the most abundant white blood cells in human blood 
and account for about 40-65 % of all leukocytes. They form the first line of 
defence against bacterial and fungal infections by migrating through blood 
vessels into inflammatory sites and then eliminate the pathogens 
(Kolaczkowska and Kubes, 2013).  Neutrophils possess a multi-lobe 
nucleus and their cytoplasm contains different types of granules containing 
essential proteins and enzymes that have different functions. These 
functions include killing ingested pathogens and digesting basement 
membranes in order to allow neutrophil migration from the circulation into 
sites of infection or inflammation (Segal, 2005). 
The lifespan of neutrophils is normally shorter than other types of 
white blood cells, with an estimated life span around 8-20 h, but their life 
span can be prolonged during inflammation when they migrate from the 
blood circulation to infected tissue (Pillay et al., 2010). In an absence of 
cytokines and other pro-inflammatory agents, neutrophil undergo apoptosis 
before being removed by macrophages. This is to prevent them from 
releasing their cytotoxic contents to damage surrounded tissues (Savill et 
al., 1989). Neutrophil apoptosis can be regulated via several mechanisms 
such as Ca2+ influx shutdown, release of cytochrome c from mitochondria, 
and exposure of phosphatidylserine on the outer leaflet of the plasma 
membrane (Akgul et al., 2001, Ayub and Hallett, 2004).  
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Other leukocytes include mononuclear phagocytes (that can 
differentiate into macrophages) and lymphocytes. The latter cells can be 
distinguished by their round nucleus with relatively small volumes of 
cytoplasm (Janeway, 2001). Lymphocytes can be divided into T cells, B 
cells, and natural killer (NK) cells. These cells have different roles in 
immune function: T cells bind to antigenic peptides presented on major 
histocompatibility molecules (MHC) class II of antigen presenting cells and 
then produce cytokines that coordinate with immune response to kill 
infected cells (Josefowicz et al., 2012). The second group is B cells. They 
play a major role in antibody production. These antibodies bind to 
pathogens and then enhance pathogen destruction (Mauri and Bosma, 
2012). Lastly, NK cells kill infected cells that do not display MHC 
molecule especially in the situation of viral infection and cancer (Vivier et 
al., 2008).  
Monocytes can be distinguish from their relatively large size with 
unilobar nucleus (Janeway, 2001). They can migrate from vasculature into 
tissue and become macrophages to remove cell debris and attack pathogens. 
Apart from their phagocytic function, they also present pathogens to T cells 
to achieve additional immune response (Saha and Geissmann, 2011). 
Apoptosis plays a key role in lymphocyte homeostasis. Enhance 
lymphocyte apoptosis leads to immunodeficiency diseases. Also, decrease 
in lymphocyte apoptosis resulted in autoimmune diseases and lymphoma 
(Rathmell and Thompson, 2002). Apoptosis of these cells is regulated by 
various signal transductions. These includes death receptor Fas 
(CD95/APO-1) and Bcl-2 family proteins (Xu and Shi, 2007). 
In conclusion, white blood cells are major parts of cells in blood 
circulation together with red blood cells and platelets. They are functionally 
important in immune system and their apoptosis is highly regulated via 
several pathways. Therefore, effects of purvalanol A on white blood cells 
apoptosis are investigated in this Chapter.  
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From all above, neutrophils and PBMCs represent most of 
population of white blood cells. For this reason, these cells were used as 
validate models of actual circulating white blood cells. 
The aims of the work described in this Chapter were: 
i) To determine the effects of purvalanol A on apoptosis of 
neutrophils and PBMCs. 
ii) To measure the expression of Bcl-2 family members in these 
white blood cells and to determine how their protein levels 
were affected by purvalanol A. 
iii) To investigate the effects of purvalanol A on the activation 
status of intracellular signalling systems. 
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6.2 Methods 
Imatinib and purvalanol A were used at 10 µM and 30 µM, 
respectively, which was shown in previous Chapters to induce maximal 
effects on the growth of CML cell lines. GM-CSF was used at 5 ng/ml as 
this concentration was previously shown to increase neutrophil survival in 
(Derouet et al., 2004, Derouet et al., 2006) 
Purvalanol A and imatinib were dissolved in DMSO, and so control 
experiments contained equivalent amounts of this solvent (0.1-0.3 %, v/v). 
These concentrations did not have any measured effect of any of the cell 
parameters analysed on neutrophils and PBMCs. 
6.3 Results 
The purpose of the experiments in this Chapter was to measure the 
effects of purvalanol A on apoptosis of white blood cells using the Annexin 
V and PI assay and cell morphology, while the levels of expression of anti-
apoptotic proteins, including Mcl-1, Bcl-2, and Bcl-XL were measured by 
western blotting. The effects of purvalanol A on the activation status of 
several intracellular signalling systems, including Erk, STAT3, Akt, and 
p38 were also investigated. Also, the effects of BIRB796 was determined. 
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6.3.1 Effects of imatinib and purvalanol A on primary leukocyte 
apoptosis  
Firstly, the effects of purvalanol A on apoptosis of white blood cells 
were determined by measuring Annexin V binding and PI staining by flow 
cytometry (see Materials and Methods). Neutrophils and PBMCs were 
isolated from three healthy donors (n=3) and incubated with AB serum with 
or without imatinib and purvalanol A to investigate whether cell apoptosis 
was affected by these agents.  Neutrophils and PBMCs were incubated in 
vitro with 10 μM imatinib, 30 μM purvalanol A, and both together in order 
to compare the effects of these concentrations of drugs used with CML cells 
in the previous Chapter. Cells were incubated for a total of 18 h and the 
percentage of cell apoptosis was compared between untreated and treated 
cells using flow cytometry. 
There was no significant difference in the percentage of neutrophil 
apoptosis (both early (annexin V positive) and late (PI staining) apoptosis) 
between untreated control, imatinib, purvalanol A treated, and imatinib plus 
purvalanol A treated cells, after 18 h of incubation (Figure 6.1). There was 
a trend for increased apoptosis in neutrophils exposed to imatinib and 
purvalanol A, but this did not reach statistical significance (p>0.05, n=3) 
when compared to the untreated control. 
Imatinib, purvalanol A, and combination treatment did not induce 
significant levels of PBMC apoptosis compared to untreated controls 
(Figure 6.1). Similarly to neutrophils, there was a trend for increased 
apoptosis when cells were treated with these agents, but this also did not 
reach statistical significance (p>0.05, n=3). The percentage of PBMC 
apoptosis was relatively lower when compared to neutrophil incubation 
under the same conditions. However, the percentage of early apoptosis of 
untreated neutrophils was relatively higher than untreated PBMCs (64.2 ± 
5.3 % and 10.2 ± 0.2 %, respectively).  
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Figure 6.1 Effects of imatinib and purvalanol A on primary leukocyte 
apoptosis. Neutrophils and PBMCs were isolated from three healthy donors 
and incubated for 18 h in the absence (U) and presence (I), (P)  and (IP) of 
imatinib (10 μM), Purvalanol A (30 μM), and the combination of imatinib 
(10 μM) plus Purvalanol A (30 μM). Apoptosis was assessed by flow 
cytometry using annexin V and PI. Data represent mean ± SEM.  
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Therefore, these results show that there was a trend for purvalanol A 
to induce apoptosis in white blood cells, but this did not reach statistical 
significance. However, high levels of neutrophil apoptosis were detected in 
the untreated control after 18 h incubation (>50 % of cells underwent early 
apoptosis). This suggests that 18 h incubation may be too long to measure 
effects of purvalanol A on apoptosis of neutrophils, which have a short half-
life. Therefore, the effects of this drug on neutrophil apoptosis over shorter 
incubation times (0-6 h) were determined.   
6.3.2 Effects of purvalanol A on primary leukocyte apoptosis over 
short incubation times 
Both neutrophils and PBMCs were incubated with 30 μM 
purvalanol A for 0, 2, 4, and 6 h before measuring apoptosis by Annexin V 
and PI staining. In neutrophils, there was a trend for increased apoptosis 
over time after purvalanol A treatment. Purvalanol A significantly induced 
both early and late apoptosis (p≤0.05, n=3) after 6 h of incubation 
(untreated cells at 6 h; early 9.5 ± 0.5 % and late 0.3 ± 0.1 %:  purvalanol A 
treated cells at 6 h; early 33.8 ± 4.2 % and late 0.9 ± 0.1 %, Figure 6.2A). 
In contrast, purvalanol A induced only low levels of PBMC 
apoptosis (<15% of cells that underwent early apoptosis after 6 h 
incubation, Figure 6.2B).  
Another parameter which can be used to detect apoptosis is cell 
morphology. Cell samples were stained and visualised by light microscopy. 
Neutrophils and PBMCs were incubated in the absence (untreated control) 
and presence of purvalanol A for total 6 h. These results showed that 
purvalanol A caused no significant increase in neutrophil and PBMC cell 
morphology by this incubation time. After purvalanol A treatment, some 
neutrophils were misshaped and showed condensed chromatin after 6 h 
incubation (cells in Figure 6.3, particularly inset at high magnification). 
However, cells with this morphology were also found in untreated 
neutrophils after the same (6 h) incubation time.   
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Figure 6.2 Effects of short term purvalanol A incubation on primary 
leukocyte apoptosis. Neutrophils, and PBMCs were isolated from three 
healthy donors and incubated for 0-6 h in the absence (U) and presence (P) 
of 30 μM purvalanol A. Apoptosis was assessed by flow cytometry using 
annexin V and PI. Data are shown as mean (±SEM, n=3) *=p≤0.05 (paired 
two-tailed student’s t-test compared to untreated control at the same time 
point) 
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Figure 6.3 Effect of purvalanol A on primary leukocyte morphology. 
Both neutrophils and PBMCs were incubated for 6 h in the absence (U) and 
presence (P) of purvalanol A (30 μM). Cell morphology was observed by 
light microscopy after staining of cytospins (see Materials and Methods).  
 
 
  
181 
 
 In the same way as with neutrophils, some purvalanol A treated 
PBMCs were misshaped and showed condensed chromatin after 6 h of 
incubation. However, these apoptotic appearances were also found in 
untreated PBMCs at the same (6 h) incubation time (Figure 6.3).  
6.3.3 Effects of purvalanol A on Mcl-1 expression in primary 
leukocytes 
The anti-apoptotic protein, Mcl-1, plays a key role in survival of 
primary immune cells and apoptosis, especially in neutrophils (Moulding et 
al., 2001). Neutrophils and PBMCs were therefore incubated in the absence 
(untreated control) and presence of 30 µM purvalanol A up to 6 h and 
protein lysates were collected at 0, 2, 4, and 6 h. The expression of Mcl-1 in 
these cells were determined by western blotting (normalised to actin).   
Mcl-1 expression in neutrophils incubated with purvalanol A was 
significantly decreased after 4 h of incubation (65.3 ± 4.2 %) compared to 
untreated control at the same time (4 h) (90.9 ± 1 %), (n=3, p≤0.05), (Figure 
6.4). Similar to neutrophils, Mcl-1 expression in PBMCs incubated with 
purvalanol A was also decreased after 6 h of incubation (68.2 ± 4.3 %) 
compared to untreated control at 6 h (93.6 ± 3.2 %), (n=3, p≤0.05), (Figure 
6.5).  
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Figure 6.4 Effects of purvalanol A on Mcl-1 expression in neutrophils. 
Cells were incubated in the absence (U ○) or presence of 30 µM purvalanol 
A (P ●) for 2, 4 and 6 h before preparation for Western blotting for Mcl-1 
(40 kDa) and β-actin (42 kDa), quantified by densitometry. (A) shows 
typical western blots, while (B) shows densitometry analysis, expressed as a 
% of untreated control, untreated samples at time zero (±SEM, n=3), * = 
p≤0.05,  (paired two-tailed student’s t-test). Western blot shown is 
representative from n=3 experiments. 
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Figure 6.5 Effects of purvalanol A on Mcl-1 expression in PBMCs. 
Cells were incubated in the absence (U ○) or presence of 30 µM purvalanol 
A (P ●) for 2, 4 and 6 h before preparation for Western blotting for Mcl-1 
(40 kDa) and β-actin (42 kDa), quantified by densitometry. (A) shows 
typical western blots, while (B) shows densitometry analysis, expressed as a 
% of untreated control, untreated samples at time zero (±SEM, n=3), * = 
p≤0.05,  (paired two-tailed student’s t-test). Western blot shown is 
representative from n=3 experiments. 
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6.3.4 Effects of purvalanol A on other anti-apoptotic protein 
expression in PBMCs 
 Although, purvalanol A had a little effect on PBMCs apoptosis, it 
did significantly decrease Mcl-1 expression in PBMCs after 6 h incubation 
(p≤0.05, n=3). Thus, the effects of purvalanol A on other anti-apoptotic 
proteins were determined to investigate effects on other anti-apoptotic 
proteins that would protect against cell death. PBMCs were incubated with 
and without 30 µM purvalanol A for up to 6 h and protein lysates were 
collected at 0, 2, 4, and 6 h. The expression of Bcl-2 and Bcl-XL in these 
cells were determined by western blotting (normalised to actin).  
6.3.4.1 The effects of purvalanol A on Bcl-2 expression in PBMCs 
In contrast to Mcl-1, Bcl-2 expression in purvalanol A treated 
PBMCs continued to be increase over time. Bcl-2 expression in purvalanol 
A treated PBMCs was significantly increased after 6 h incubation (at 126.2 
± 3.7 %) compared to untreated control at the same time (at 94.6 ± 2.1 %), 
(p≤0.05, n=3). (Figure 6.6).  
6.3.4.2 The effects of purvalanol A on Bcl-XL expression in PBMCs 
Bcl-XL expression in purvalanol A treated PBMCs remained at 
approxmately the same level over time compared to untreated control 
(Figure 6.7). 
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Figure 6.6 Effects of purvalanol A on Bcl-2 expression in PBMCs. Cells 
were incubated in the absence (U ○) or presence of 30 µM purvalanol A (P 
●) for 2, 4 and 6 h before preparation for Western blotting for Bcl-2 (22 
kDa) and β-actin (42 kDa), quantified by densitometry. (A) shows typical 
western blots, while (B) shows densitometry analysis, expressed as a % of 
untreated control, untreated samples at time zero (±SEM, n=3), * = p≤0.05,  
(paired two-tailed student’s t-test). Western blot shown is representative 
from n=3 experiments. 
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Figure 6.7 Effects of purvalanol A on Bcl-XL expression in PBMCs. 
Cells were incubated in the absence (U ○) or presence of 30 µM purvalanol 
A (P ●) for 2, 4 and 6 h before preparation for Western blotting for Bcl-XL 
(25 kDa) and β-actin (42 kDa), quantified by densitometry. (A) shows 
typical western blots, while (B) shows densitometry analysis, expressed as a 
% of untreated control, untreated samples at time zero (±SEM, n=3). 
Western blot shown is representative from n=3 experiments. 
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6.3.5 Effects of purvalanol A and GM-CSF on neutrophils. 
As shown in previous results, purvalanol A significantly decreased 
Mcl-1 expression in neutrophils after 4 h incubation (p≤0.05, n=3). GM-
CSF has been shown to delay neutrophil apoptosis and stabilize Mcl-1 
protein levels and thus, the effects of purvalanol A were investigated in the 
absence and presence of GM-CSF. 
6.3.5.1 Effects of purvalanol A and GM-CSF on neutrophil apoptosis. 
Neutrophils were incubated with 30 μM purvalanol A in the absence 
and presence of 50ng/ml GM-CSF for 0, 2, 4, and 6 h before measuring 
apoptosis by Annexin V and PI binding. Figure 6.8 shows that GM-CSF 
decreased neutrophil apoptosis (% early and % late) induced by purvalanol 
A. When used as a single agent, purvalanol early and late apoptosis at 6 h 
was 33.8 ± 4.2 % and 0.9 ± 0.1 %, respectively, whereas in combination 
with GM-CSF, early and late apoptosis were 15.2 ± 4.9 % and 0.7 ± 0.2 %, 
respectively. (p>0.05, n=3). 
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Figure 6.8 Effects of purvalanol A and GM-CSF on neutrophil 
apoptosis. Neutrophils were isolated from three healthy donors and 
incubated for 0-6 h in the absence (U) and presence of 30 μM purvalanol A 
(P), 50 ng/ml GM-CSF (G), and both together (PG). Apoptosis was 
assessed by flow cytometry using annexin V and PI. Data are shown as 
mean (±SEM, n=3), *=p≤0.05, (paired two-tailed student’s t-test) compared 
to untreated controls at the same time point. 
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6.3.5.2 Effects of purvalanol A and GM-CSF on Mcl-1 expression in 
neutrophils. 
 Neutrophils were incubated as described in 6.3.6.1 and cell lysates 
were prepared for western blotting. Figure 6.9 confirms that purvalanol 
significantly decreased Mcl-1 expression in neutrophils after 4 h incubation 
(60.8 ± 10.2 %) compared to untreated control (at 101.1 ± 2.8 %), (p≤0.05, 
n=3). In addition, co-incubation of purvalanol A with GM-CSF increased 
Mcl-1 levels (at 67.8 ± 5.6 %) compared to purvalanol A treated cells (at 
60.8 ± 10.2 % (4 h)). This suggests that the effect of GM-CSF slightly 
interfered with the effect of purvalanol A in decreasing Mcl-1 expression in 
neutrophils.  
   GM-CSF alone significantly increased Mcl-1 expression in 
neutrophils (at 123.8 ± 3.8 % at 2 h) compared to untreated controls (at 105 
± 23.2 % at 2 h), (n=3, p≤0.01). In addition, there was a significant 
difference between GM-CSF treated expression and after co-incubation 
with GM-CSF and purvalanol A at 4 and 6 h of incubation, (p≤0.05, n=3). 
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Figure 6.9 Effects of purvalanol A and GM-CSF on Mcl-1 expression in 
neutrophils. Cells were incubated in the absence (U ○) or presence of 30 
µM purvalanol A (P ●), 50ng/ml GM-CSF (G ), and both (PG x) for 2, 4, 
and 6 h before preparation for Western blotting for Mcl-1 (40 kDa) and β-
actin (42 kDa), quantified by densitometry. (A) shows typical western blots, 
while (B) shows densitometry analysis, expressed as a % of untreated 
control samples at time zero (±SEM, n=3), * = p≤0.05, **=p≤0.01, (One-
way ANOVA followed by Bonferroni post hoc comparisons tests). Western 
blot shown is representative from n=3 experiments. 
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6.3.6 Effects of purvalanol A on half-life of Mcl-1 in neutrophils. 
The following experiments were performed to determine if 
purvalanol A caused apoptosis via changes in the turnover rate of Mcl-1 in 
neutrophils, as has previously been reported in this thesis for CML cell 
lines. Neutrophils were incubated with cycloheximide (CHX) for 10 min 
before incubating with purvalanol A for 1, 2, 3, and 4 h in the absence and 
presence of 30 µM of purvalanol A, and protein extracts were prepared. 
Levels of Mcl-1 protein in these cells were determined by western blotting. 
This result shows that when de novo protein synthesis was blocked 
by cycloheximide, Mcl-1 was constitutively degraded and this turnover was 
accelerated in the presence of purvalanol A (Figure 6.10). The half-life of 
Mcl-1 in untreated, control neutrophils was approximately 3 h and 30 min, 
whilst in the presence of purvalanol A, this had decreased to 2 h and 30 min 
(p≥0.05, n=3). 
Mcl-1 levels were significantly lower after 6 h after CHX treatment 
in the presence of purvalanol A incubation (20.1 ± 5.3 %) compared to 
treatment with CHX alone at the same time (42.1 ± 2.7 %), (p≤0.05, n=3).  
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Figure 6.10 Effect of purvalanol A on the half-life of Mcl-1 in 
neutrophils. Neutrophils were pre-incubated for 10 min with 10 g/mL 
cycloheximide (CHX) prior to 0, 1, 2, 3, and 4 h incubation in the absence 
(U), or presence of 30 μM purvalanol A (P). Cell samples were collected at 
the times indicated and prepared for Western blotting for the levels of Mcl-
1 (40 kDa). (A) shows typical western blots, while (B) shows densitometry 
analysis, expressed as a % of untreated control samples at time zero 
(±SEM, n=3), * = p≤0.05, (paired two-tailed student’s t-test). Western blot 
shown is representative from n=3 experiments. 
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6.3.7 Effects of purvalanol A and GM-CSF on intracellular signalling 
pathways in neutrophils 
The effects of purvalanol A and GM-CSF on the activation status of 
several intracellular signalling systems were subsequently investigated. 
Neutrophils were incubated with 30 µM purvalanol A and/or 50 ng/ml GM-
CSF for 15, 30 min and 1 h before the cell lysates were prepared and 
western analysis was performed to determine the effects of purvalanol A 
and GM-CSF on neutrophil signalling pathways. Erk, STAT3, Akt, and p38 
signalling pathways were investigated in this study. 
6.3.7.1 Erk signalling pathway 
GM-CSF increased levels of pErk in neutrophils significantly after 
15 min of incubation (1428.1 ± 233.4 %) compared to untreated control at 
the same time (99.9 ± 0.3 %), (p≤0.05, n=3). In contrast, purvalanol A 
treatment resulted in a slight increase in pErk levels after 15 min of 
incubation and then this effect continued to decrease after 30 min and 1 h of 
incubation. The co-incubation of purvalanol A and GM-CSF resulted in a 
partial increase in pErk levels after 15 min incubation (n=3, p>0.05).  
There was a significant difference between the combination 
treatment (504.2 ± 102.2 %) and GM-CSF treated cells (934.3± 71 %) after 
1 h of incubation, (p≤0.05, n=3), (Figure 6.11). 
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Figure 6.11 Effects of purvalanol A and GM-CSF on Erk activation in 
neutrophils. Cells were incubated in the absence (U ○) or presence of 30 
µM purvalanol A (P ●), 5 ng/ml GM-CSF (G ), and both (PG x) for 15, 
30 min and 1 h before preparation for Western blotting for pErk and Pan 
Erk (42-44 kDa), quantified by densitometry. (A) shows typical western 
blots, while (B) shows densitometry analysis, expressed as a % of untreated 
control, untreated samples at time zero (±SEM, n=3), * = p≤0.05, 
**=p≤0.01 (One-way ANOVA followed by Bonferroni post hoc 
comparisons tests). Western blot shown is representative from n=3 
experiments. 
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6.3.7.2 STAT3 signalling pathway 
Similar to Erk signalling pathway, GM-CSF increased levels of 
pSTAT3 significantly after 15 min of incubation (1492.3 ± 124.4 %) 
compared to untreated controls at the same time points (103.2 ± 0.6 %), 
(p≤0.01, n=3). In contrast, both purvalanol A and co-incubation with GM-
SCF and purvalanol A resulted in no significant change in pSTAT3 levels 
at any time point measured, (p>0.05, n=3), (Figure 6.12), indicating that 
purvalanol A abrogated the stimulatory effect of GM-CSF on STAT3 
activation. 
6.3.7.3 Akt signalling pathway 
Purvalanol A and GM-CSF treatment both increased pAkt levels 
significantly in neutrophils, (p≤0.01 and p≤0.001, respectively, n=3).  The 
level of phosphorylated Akt was increased by almost 7-10 times compared 
to untreated control after incubation for 15 min (Figure 6.13). 
Similar to purvalanol and GM-CSF as a single treatment, the 
combination treatment of purvalanol A and GM-CSF also increased the 
levels of pAkt significantly after 15 min of incubation (1301.5 ± 272.5 %) 
compared to untreated control at the same time (at 113.4 ± 2.8 %), ( p≤0.05, 
n=3). 
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Figure 6.12 Effects of purvalanol A and GM-CSF on STAT3 activation 
in neutrophils. Cells were incubated in the absence (U ○) or presence of 30 
µM purvalanol A (P ●),  5ng /ml GM-CSF (G ), and both (PG x) for 15, 
30 min and 1 h before preparation for Western blotting for pSTAT3 and 
Pan STAT3 (80 kDa), quantified by densitometry. (A) shows typical 
western blots, while (B) shows densitometry analysis, expressed as a % of 
untreated control, untreated samples at time zero (±SEM, n=3), * = p≤0.05 
(One-way ANOVA followed by Bonferroni post hoc comparisons tests). 
Western blot shown is representative from n=3 experiments. 
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Figure 6.13 Effects of purvalanol A and GM-CSF on Akt activation in 
neutrophils. Cells were incubated in the absence (U ○) or presence of 30 
µM purvalanol A (P ●), 5 ng/ml GM-CSF (G ), and both (PG x) for 15, 
30 min and 1 h before preparation for Western blotting for pAkt (60 kDa) 
and Actin (42 kDa), quantified by densitometry. (A) shows typical western 
blots, while (B) shows densitometry analysis, expressed as a % of untreated 
control, untreated samples at time zero (±SEM, n=3), * = p≤0.05 (One-way 
ANOVA followed by Bonferroni post hoc comparisons tests). Western blot 
shown is representative from n=3 experiments. 
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6.3.7.4 p38 signalling pathway 
 In contrast to Erk, STAT3, and Akt signalling pathways, purvalanol 
A treatment resulted in a dramatic increased phosphorylated p38 in 
neutrophils. Purvalanol A significantly increased phosphorylated p38 after 
15 min incubation (791.2 ± 87.7 %) compared to untreated controls at the 
same time (108.5 ± 34.2 %), (p≤0.01, n=3). Furthermore, co-incubation of 
purvalanol A and GM-CSF also increased the levels of Phospho-p38 
significantly after 15 min incubation (828.6 ± 69.8 %) compared to 
untreated controls at the same time (108.5 ± 34.2 %), (p≤0.01, n=3). 
However, there was no significant change compared to the effect of 
purvalanol A as a single agent (Figure 6.14) that is the effects on p38 
observed in the presence of GM-SCF and purvalanol A together were due 
to that observed by purvalanol A alone. 
GM-CSF treatment resulted in an increase in the level of Phospho-
p38 in neutrophils. However, this effect was lower than that observed in 
response to purvalanol A treatment. In contrast to Erk, STAT3, and Akt 
signalling pathways, GM-CSF treatment did not increase the level of 
Phospho-p38 significantly in neutrophils (p>0.05, n=3). 
6.3.8 Effects of purvalanol A and BIRB796 on expression of the Mcl-1 
in neutrophils  
               Neutrophils were incubated in the absence (untreated control) and 
presence of 30 µM purvalanol A, 10 µM BIRB796, and both inhibitors 
together. Then, cell lysates were prepared for western blotting.  
               Figure 6.15 confirms that purvalanol decreased Mcl-1 expression in 
neutrophils In addition, co-incubation of purvalanol A with BIRB796 
increased Mcl-1 levels significantly (at 62.2 ± 4.7 % (6 h)) compared to 
purvalanol A treated cells (at 28.4 ± 9.6 % (6 h)), (p≤0.05, n=3). This 
suggests that BIRB796 blocked the effect of purvalanol A in decreasing 
Mcl-1 expression in neutrophils.  
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Figure 6.14 Effects of purvalanol A and GM-CSF on p38 activation in 
neutrophils. Cells were incubated in the absence (U ○) or presence of 30 
µM purvalanol A (P ●), 5 ng/ml GM-CSF (G ), and both (PG x) for 15, 
30 min and 1 h before preparation for Western blotting for Phospho-p38 
and Pan p38 (43 kDa), quantified by densitometry. (A) shows typical 
western blots, while (B) shows densitometry analysis, expressed as a % of 
untreated control samples at time zero (±SEM, n=3), * = p≤0.05 (One-way 
ANOVA followed by Bonferroni post hoc comparisons tests). Western blot 
shown is representative from n=3 experiments.                 
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Figure 6.15 Effects of purvalanol A and BIRB796 on Mcl-1 expression 
in neutrophils. Cells were incubated in the absence (U ○) or presence of 30 
µM purvalanol A (P ●), 10 µM BIRB796 (B ), and both (PB x) for 2, 4, 
and 6 h before preparation for Western blotting for Mcl-1 (40 kDa) and β-
actin (42 kDa), quantified by densitometry. (A) shows typical western blots, 
while (B) shows densitometry analysis, expressed as a % of untreated 
control samples at time zero (±SEM, n=3), * = p≤0.05 (One-way ANOVA 
followed by Bonferroni post hoc comparisons tests). Western blot shown is 
representative from n=3 experiments.                 
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6.4    Discussion and Conclusions  
The effects of purvalanol A on neutrophils and PBMCs were 
investigated in this Chapter. This was to determine if this inhibitor could 
induce apoptosis in normal white blood cells as well as CML cell lines. 
This is an important factor to consider if purvalanol A, or compounds like 
it, could ever be used therapeutically to treat CML or other diseases.  
The effects of purvalanol A on neutrophil and PBMC cell apoptosis 
were first investigated using Annexin V and PI binding. Both cell types 
were initially incubated with 10 µM imatinib and/or 30 µM purvalanol A 
for 18 h. However, more than 50% of the untreated neutrophil population 
underwent apoptosis after 18 h incubation. This confirms that neutrophils 
have a short half-life (around 8-20 h) (Pillay et al., 2010) but made it 
difficult to determine if purvalanol A rapidly induced neutrophil apoptosis. 
Therefore, subsequent experiments were performed using 0-6 h incubation 
time. 
At 6 h incubation, purvalanol A significantly induced apoptosis in 
neutrophils, but not in PBMCs. As a consequence, the effects of purvalanol 
A on Mcl-1 expression were investigated by western blotting. This part of 
the study showed that purvalanol A also decreased Mcl-1 expression 
significantly in both neutrophils and PBMCs after 4 and 6 h incubation, 
respectively. These findings support previous studies which showed that 
other CDK inhibitors, such as roscovitine, induced apoptosis in neutrophils 
by decreasing Mcl-1 protein expression (Rossi et al., 2006). Also, it has 
been reported that purvalanol A inhibited leukocyte adhesion and migration 
from the blood circulation to tissue during infections (Liu et al., 2008).  
The effects of purvalanol A on the expression of other anti-apoptotic 
proteins of the Bcl-2 family (Bcl-2 and Bcl-XL) in PBMCs were also 
investigated in order to determine if changes in the expression levels of 
these proteins may explain the survival of these cells, even though the drug 
induced a decrease in Mcl-1 expression. Purvalanol A was found to 
increase the level of Bcl-2 expression in PBMCs significantly after 6 h 
incubation, while the levels of Bcl-XL remained steady over this time 
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period. This result supports the concept that Bcl-2 plays a crucial role in an 
apoptosis of PBMCs, as other reports have shown that Bcl-2 is involved in 
PBMCs apoptosis from several chronic viral infections such as human 
immunodeficiency and hepatitis C virus (Boudet et al., 1996, Nakamoto et 
al., 2002). Also, PBMC numbers in mice with a knockout of Mcl-1 are 
normal, while they are severely neutropenic (Dzhagalov et al., 2007), 
indicating that levels of this protein do not play a major role in their cell 
survival. Therefore, this result suggests that there are compensating 
mechanisms involving Bcl-2 or Bcl-XL expression in purvalanol A treated 
PBMCs.  
Neutrophil apoptosis induced by purvalanol A was investigated 
further using powerful neutrophil survival factor, GM-CSF, in order to 
determine if the effect of purvalanol A could override anti-apoptotic signal 
from GM-CSF. It was found that effects of purvalanol A on neutrophil 
apoptosis and Mcl-1 expression was partially blocked with GM-CSF as 
there was no significant difference when comparing the effects of 
purvalanol A alone and the effects of purvalanol A with GM-CSF. This 
relates to another study using roscovitine treatment in neutrophils, where it 
was reported that roscovotine induced apoptosis in neutrophils by 
overriding the effects of GM-CSF (Rossi et al., 2006).  
These observations might suggest that purvalanol A has a specific 
effect on Mcl-1 expression in neutrophils. Mcl-1 protein is normally 
expressed in neutrophils and its level decrease before the onset of apoptosis 
(Edwards et al., 2004). It has been found that GM-CSF can increase Mcl-1 
stability in neutrophils in order to delay apoptosis (Derouet et al., 2004). 
The experiments reported in this Chapter show that purvalanol A increased 
Mcl-1 turnover in neutrophils, as it does in KCL-22 cells. This supports the 
concept that Mcl-1 half-life can be decreased in the presence of certain 
apoptosis-inducing agonists, or enhanced by agents that delay apoptosis, 
such as GM-CSF (Derouet et al., 2006).  
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                It was then necessary to investigate the effects of purvalanol A on 
several important signalling pathways in neutrophils. It was found that 
purvalanol A resulted in a significant up-regulation of phosphorylated Akt 
and p-38 while GM-CSF resulted in a significant up-regulation of 
phosphorylated Erk, STAT3, and Akt. This supports another study that used 
GM-CSF in neutrophils (Suzuki et al., 1999, Nolan et al., 1999, Al-Shami 
et al., 1998). However, the results obtained in this Chapter showed that 
purvalanol A increased the level of Phospho-p38 in neutrophils. It has been 
demonstrated that cellular stresses can stimulate p38 MAPK activity to 
induce apoptosis (Aoshiba et al., 1999). The findings presented here support 
the notion that activated p38 generates a death signal in neutrophils (Frasch 
et al., 1998), perhaps directly or indirectly leading to increased turnover of 
Mcl-1. In addition, p38 MAPK inhibitor (BIRB796) can block the effect of 
purvalanol A in decreasing Mcl-1 expression in neutrophils.  
The experiments described here provide preliminary results to show 
that purvalanol A induced apoptosis in neutrophils, as well as CML cell 
lines. Therefore, further experiments concerning drug toxicity are required 
in the next step of this study. 
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CHAPTER 7:  EFFECTS OF JAK3 INHIBITOR, ZM39923, 
ON IMATINIB-SENSITIVE AND -INSENSITIVE CML 
CELL LINES 
7.1 Introduction 
The BCR-ABL tyrosine kinase contains several domains which 
promote protein-protein interactions. BCR-ABL can also serve as a domain 
for various adaptor proteins, such as GRB2, leading to protein 
phosphorylation. As a consequence, many signalling pathways are activated 
including, RAS, PI3K, and JAK-STAT (Deininger et al., 2000, Danial and 
Rothman, 2000). These activated signalling pathways can regulate various 
cellular effects such as cell proliferation and suppression of apoptosis, 
which are implicated in CML pathology (Ren, 2005).  
The Janus family of kinases (JAKs) are crucial signal transducers 
for the receptors of several cytokines, growth factors, and interferons which 
intrinsically lack of kinase activities, such as the receptors for 
erythropoietin (Epo), granulocyte-macrophage stimulating factor (GM-
CSF), and interleukins (IL) (Schindler, 2002). The Janus family of kinases 
has four members including JAK1, JAK2, JAK3, and non-receptor tyrosine 
kinase 2 (TYK2). JAK1 is important in pro-inflammatory cytokine 
signalling such as IL-1, IL-6, and Tumour necrosis factor alpha (TNFα) 
(Ihle and Kerr, 1995). JAK2 plays a crucial role in hematopoietic growth 
factors signalling including GM-CSF, Epo and IL-3, while JAK3 is 
primarily expressed in haematopoietic cells (Ihle and Kerr, 1995). It has 
been reported that mice deficient in JAK3 developed severe combined 
immunodeficiency (SCID) (Nosaka et al., 1995) and TYK2 can transduce 
intracellular signals of cytokine receptors, such as IL-12 (Pesu et al., 2008). 
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JAKs can recruit the signal transducer and activator of transcription 
family (STATs) by SH2 domain recognition (Chen et al., 2003). JAKs 
activates STAT transcriptional activity, leading to the expression of genes 
involved in cell proliferation, apoptosis, differentiation, as well as the 
expression of inflammatory proteins (Figure 7.1) (Yu et al., 2009). 
JAK/STAT signalling pathways are critical in promoting the growth and 
survival of haematopoietic cells (Park et al., 1995). 
 
 
 
Figure 7.1 Effects of BCR-ABL on JAK/STAT signalling pathways. 
This figure shows how transcription factors, STATs are activated by BCR-
ABL through direct phosphorylation or indirectly through phosphorylation 
by JAK (Redrawn from (Danial and Rothman, 2000)). 
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Therefore, several pharmacologic inhibitors that target JAK-STAT 
pathways have been developed and tested in clinical trials in recent years 
(Luo and Laaja, 2004). As JAK/STAT can act as a regulator of B-
lymphocyte differentiation, it is a pharmaceutical target for several immune 
and autoimmune diseases such as type I diabetes, inflammatory bowel 
disease and rheumatoid arthritis (O'Shea et al., 2004).  In addition, 
JAK/STAT inhibition was found to prolong allograft survival by targeting 
of JAK3 to inhibit immune rejection (Stepkowski et al., 2002).   
Apart from inhibition of JAK/STAT in immune and autoimmune 
diseases, the inhibition of JAK/STAT represents a strategy for 
chemotherapeutic development (Quintas-Cardama et al., 2011). JAKs can 
be potential targets in cancer treatment due to the fact that many tumours 
exhibit constitutive STATs activation, including CML (Fabbro, 2012). 
STATs are constitutively activated in Philadelphia chromosome positive 
cells and previous studies have shown that STAT5 is a major regulator of 
CML cell proliferation while STAT1 is activated in some cases (Danial and 
Rothman, 2000). STATs also induce gene transcription of several Bcl-2 
family proteins, such as the anti-apoptotic proteins, Bcl-XL and Mcl-1. Bcl-
XL may be regulated by JAK/STAT signalling and the anti-apoptotic 
characteristics of CML cells (Danial and Rothman, 2000), while Mcl-1 has 
been reported to be transcriptionally controlled by STAT3 (Dong et al., 
2011).  
However, the point mutation of JAK2, V615F, has been identified 
recently in many types of myeloproliferative neoplasms (MPNs) (Quintas-
Cardama, 2013). Thus, this mutation is considered to be a new therapeutic 
target. Roxutinib, the ATP competitive JAK2 inhibitor, has been developed 
and has now entered phase III clinical trials for the treatment of 
myelofibrosis. This inhibitor successfully decreased spleen size and 
improved symptoms related to haematological disease (Verstovsek et al., 
2010).  
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Several small molecules which inhibit JAKs have been identified by 
high throughput screening methods in the last decade (Sonbol et al., 2013). 
Among these, ZM39923 displays distinct JAK inhibition. ZM39923 is a 
naphthyl ketone with an N-benzyl-N-isopropyl substitution which leads to 
superior JAK3 inhibition.  It also inhibits JAK1, but is less potent compared 
to its effects on JAK3 (Brown et al., 2000). However, this inhibitor has not 
been studied in cancer cell lines, but the potent and selective inhibition of 
JAK3 might induce apoptosis in CML cells especially when used in 
combination with imatinib. 
The aims of the work described in this Chapter were: 
i) To determine the effects of the JAK3 inhibitor, ZM39923, 
on the growth and apoptosis of LAMA-84 and KCL-22 cell 
lines. 
ii)  To measure the expression of anti-apoptotic protein, Mcl-1, 
in these two cell lines and to determine how their protein 
levels are affected by ZM39923.  
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7.2 Methods 
ZM39923 was used at a range of concentrations between 10, 30, and 
60 µM, unless stated otherwise, which was shown in previous studies in this 
laboratory (Davies, 2013, Jackson, 2014) to induce effects on the growth of 
LAMA-84 and KCL-22 cell lines. As ZM39923 was dissolved in DMSO, 
all control experiments contained equivalent amounts of this solvent. In 
experiments using ZM39923 plus other compounds dissolved in DMSO, 
the maximal DMSO used in experiments was 0.7 % (v/v) and this 
concentration did not have any measured effect of any of the cell 
parameters analysed. 
7.3 Results 
Initial experiments measured the effects of ZM39923 and imatinib 
on apoptosis of these cell lines using the Viacount assay and the cell cycle 
assay described in Chapter 2. The levels of expression of anti-apoptotic 
protein, Mcl-1 were also measured by western blot.  
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7.3.1 Effects of ZM39923 on the viability of LAMA-84 and KCL-22 
cell lines  
Previous work in this laboratory (Davies, 2013, Jackson, 2014) 
showed that ZM39923 caused a decrease in cell viability in both cell lines. 
Therefore, it was important to investigate the effects of ZM39923 on cell 
viability further in these cell lines. LAMA-84 and KCL-22 were either 
incubated with a range of concentrations of 10, 30, or 60 µM ZM39923 
alone or in combination with 10 µM imatinib for 24 h. Then, cell viability 
was determined by flow cytometry using the Viacount assay. 
Figure 7.2 confirmed previous results in Chapter 3 that imatinib 
decreased the viability of LAMA-84 cells significantly (n=3, p≤0.01), but 
not KCL-22 cells (n=3, p>0.05) under these experimental conditions. In the 
LAMA-84 cell line, viability was also decreased following ZM39923 
treatment in a dose-dependent manner. At the lowest concentration used of 
ZM39923 (10 µM), the viability was decreased significantly (n=3, p≤0.01) 
from 92.2 ± 2.3 % in untreated controls to 78.2 ± 1.3 % in ZM39923 treated 
samples. In addition, viability was further decreased following ZM39923 
treatment in combination with imatinib (from 57.5 ± 3.3 % and  78.2 ± 1 % 
in 10 µM imatinib and ZM39923 treated sample, respectively compared to 
38.3 ± 4.2 % in 10 µM ZM39923 plus imatinib treated sample). This 
difference between both imatinib and ZM39923, used alone, and ZM39923 
together with imatinib was found to be significance (n=3, p≤0.05). Thus, 
the combined effects of these two drugs was greater than when either drug 
was used alone. 
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Figure 7.2 Differential sensitivity of LAMA-84 and KCL-22 cell lines to 
imatinib and ZM39923. Both cell lines were incubated in an absence (UT) 
and presence of 10 µM imatinib (I) or 10, 30 or 60 µM ZM39923 (Z) alone 
or in combination (IZ) for 24 h. Viability was determined using the 
Viacount assay. Data are shown as mean (±SEM, n=3) *= p≤0.05, 
**=p≤0.01, ***=p≤0.001 compared to untreated controls (paired two-tailed 
student’s t-test).  
  
211 
 
Similar to LAMA-84, ZM39923, used alone, decreased KCL-22 cell 
viability significantly (n=3, p≤0.05) in a dose-dependent manner (from 94.2 
± 0.8 % in untreated control to 82.1 ± 0.2 % in 10 µM ZM39923 treated 
sample). However, decreases in viability were lower than those observed in 
LAMA-84 cells. Also, the combination of ZM39923 with imatinib 
decreased viability greater than when both imatinib and ZM39923 were 
used alone (from 93 ± 0.2 % and 86.8 ± 0.2 % in 10 µM imatinib and 
ZM39923 treated sample, respectively to 78.5 ± 1.6 % in 10 µM ZM39923 
and imatinib treated sample). These differences were found to be significant 
(n=3, p≤0.05). Again, the effects of both drugs used together were greater 
than the effects observed using either drug alone. 
 
7.3.2 Effects of ZM39923 on the cell cycle kinetics of LAMA-84 and 
KCL-22 cell lines  
The results from the Viacount assay, showed that ZM39923 
decreased viability in both LAMA-84 and KCL-22 cell lines significantly. 
Therefore, the effects of ZM39923 were determined on the cell cycle 
kinetics in order to confirm the previous results from Viacount assay.  Both 
cell lines were incubated with imatinib (10µM), ZM39923 (10, 30 and 60 
µM) or a combination of both for 24 h and cell cycle kinetics were analysed 
using flow cytometry.  
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Figure 7.3 Effect of imatinib and ZM39923 on LAMA-84 and KCL-22 
cell cycle kinetics. Cells were incubated as described in the legend to 
Figure 7.2. Cell cycle parameters (expressed as a percentage of the total cell 
population) of cells arrested in G0 were determined by measuring DNA 
content and flow cytometry. Data are shown as mean (±SEM, n=3) 
*=p≤0.05, **=p≤0.01, ***=p≤0.001 compared to untreated controls (paired 
two-tailed student’s t-test). 
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After incubation of LAMA-84 cells with imatinib, the percentage of 
cells arrested in G0 increased significantly (n=3, p≤0.01), as seen 
previously in Chapter 3. ZM39923 slightly increased the percentage of cells 
arrested in G0, with corresponding slight decreases in cells in all other 
phases (results not shown) in dose-dependent manner (Figure 7.3).  
However, cell viability measured by Viacount assay was decreased 
significantly by ZM39923 and so a greater effect on accumulation of cells 
in G0 might have been predicted.  There was a significant difference (n=3, 
p≤0.01) in the number of cell arrested in G0 following incubation with 10 
µM and 30 µM ZM39923 alone and in combination with imatinib (from 
24.5 ± 4.7 % in 10 µM ZM39923 treated samples to 56.2 ± 3.8 % in 10 µM 
ZM39923 plus imatinib treated sample), but the numbers of cells arrested in 
G0 was not different compared to imatinib, used alone, i.e. there was no 
increase in G0 arrest in cells treated with the combination of drugs, 
compared to the effects of imatinib alone.  
In KCL-22 cells, there was an increase of the number of cells 
arrested in G0 in dose-dependent manner following ZM39923 incubation, 
but this increase did not reach statistical significance (n=3, p>0.05). 
However, at 10 µM and 30 µM ZM39923 the number of cells arrested in 
G0 was significantly increased (n=3, p≤0.01 and p≤0.001, respectively) 
when used in combination with imatinib (from 12.35 ± 1.67 % in untreated 
control to 26.3 ± 1.4 % in 10 µM ZM39923 and imatinib treated sample). 
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7.3.3 Effects of ZM39923 on Mcl-1 expression in LAMA-84 and 
KCL-22 cell lines  
 As Mcl-1 is a major anti-apoptotic protein that regulates apoptosis 
in LAMA-84 and KCL-22 cells (details in Chapter 3, 4 and 5). Thus, it is 
crucial to determine the effects of ZM39923 on the expression of Mcl-1 in 
these cells. Both cell lines were incubated with 10μM imatinib, 10, 30 or 60 
μM ZM39923 or both for 24 h. After incubation, the levels of expression of 
Mcl-1 were determined using western blotting. 
  In LAMA-84 cells, treatment with imatinib decreased the 
expression of Mcl-1 significantly (n=3, p≤0.01) (Figure 7.4). This confirms 
the resulted obtained in previous Chapters.  ZM39923, used alone at 30 and 
60 μM caused a slight decrease in Mcl-1 expression in a dose-dependent 
manner, but this did not reach statistical significance (n=3, p>0.05). In 
contrast, the combination of ZM39923 with imatinib significantly decreased 
Mcl-1 expression (n=3, p≤0.05). This dramatic decrease in Mcl-1 
expression is different from the effects of ZM39923 used alone (n=3, 
p≤0.05), this was a significant difference when compared with imatinib as a 
single treatment (from 108.2 ± 7.2 % in 10 μM ZM39923 treated sample to 
28.5 ± 8.5 % in 10 µM ZM39923 plus imatinib treated sample, (n=3, 
p≤0.05). 
In KCL-22 cells, imatinib did not decrease Mcl-1 expression 
confirming the results from previous Chapters. In the same way with 
LAMA-84 cells, 30 μM and 60 μM ZM39923, used alone caused only a 
slight decrease in Mcl-1 expression in a dose-dependent manner (n=3, 
p>0.05).  The combination of 30 μM and 60 μM ZM 39923 with imatinib 
decreased Mcl-1 expression significantly (n=3, p≤0.05). ZM39923, used 
together with imatinib caused significant decreases in protein levels (n=3, 
p≤0.05) when compared to ZM39923 and imatinib as single agents (from 
99.6 ± 13.6 % and  93.8 ± 7.7 % in 10 µM imatinib and 30 µM ZM39923 
treated samples, respectively to 35.2 ± 4.7 % in 30 µM ZM39923 plus 
imatinib treated sample) (Figure 7.5). 
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Figure 7.4 Effects of imatinib and ZM39923 on Mcl-1 protein 
expression in LAMA-84 cell line. Cells were incubated as described in the 
legend to Figure 7.2. (A) Levels of Mcl-1 expression were measured by 
western blotting using an anti-Mcl-1 antibody. (B) Densitometric analysis 
of Mcl-1 relative expression. Data expressed as a % of untreated samples 
(±SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired two-tailed student’s t-test). 
Western blot shown is representative from n=3 experiments. 
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Figure 7.5 Effects of imatinib and ZM39923 on Mcl-1 protein 
expression in KCL-22 cell line. Cells were incubated as described in the 
legend to Figure 7.2. (A) Levels of Mcl-1 expression were measured by 
western blotting using an anti-Mcl-1 antibody. (B) Densitometric analysis 
of Mcl-1 relative expression. Data expressed as a % of untreated samples 
(±SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired two-tailed student’s t-test). 
Western blot shown is representative from n=3 experiments.  
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7.3.4 The time course of effects of ZM39923 and imatinib on Mcl-1 
expression  
 As shown above, 30 µM ZM39923 together with 10 µM imatinib 
significantly decreased Mcl-1 expression levels in both LAMA-84 and 
KCL-22 cell lines, following 24 h incubation (n=3, p≤0.01). Therefore, the 
effects on Mcl-1 expression of this drug combination were determined in 
time course analysis. Both cell lines were incubated in the absence 
(untreated control), or with 10µM imatinib, 30µM ZM39923, and both 
drugs together for 0, 3, and 6 h. After incubation, cell lysates were prepared 
and Mcl-1 expression levels were analysed using western blotting. 
In LAMA-84 cell line, Mcl-1 expression remained fairly constant 
throughout the 6 h of incubation with ZM39923, imatinib, and both 
ZM39923 and imatinib together (Figure 7.6A). However, while 30 µM 
ZM39923 together with imatinib decreased Mcl-1 expression dramatically 
to less than 20 % after 24 h incubation (Figure 7.3A), this combination did 
not affect Mcl-1 expression within this 6 h time course incubation. 
Similar to LAMA-84 cells, the combination of ZM39923 and 
imatinib did not decrease Mcl-1 expression in KCL-22 cell over the period 
of the 6 h incubation. In contrast, there was a decrease in Mcl-1 expression 
when cells were incubated with ZM39923 alone (Figure 7.6B).  
To conclude, Mcl-1 expression levels did not decrease upon 
exposure to ZM39923 together with imatinib treatment, in both cell lines 
over the 0-6 h time incubation period. However, over a 24 h incubation 
time, this combination caused significant decreases in Mcl-1 levels in both 
cell lines (n=3, p≤0.01).  
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Figure 7.6 Effects of ZM39923 and imatinib on Mcl-1 expression in 
LAMA-84 (A) and KCL-22 (B) cell lines over an incubation period of 6 
h. Cells were incubated in an absence (U) or presence of 30 µM ZM39923 
(Z), 10 µM imatinib (I), or both  (ZI) and lysates were prepared at 0, 3, and 
6 h. Levels of Mcl-1 expression were measured by western blotting using 
an anti-Mcl-1 antibody (n=1).  
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7.3.5 The effect of ZM39923 and imatinib on the half-life of Mcl-1 
The following experiments were performed to determine if the 
combination of ZM39923 and imatinib caused apoptosis via changes in the 
turnover rate of Mcl-1 in both cell lines. 
 LAMA-84 and KCL-22 cell lines were incubated with CHX, prior 
to ZM39923 and imatinib treatment. After this pre-incubation period, the 
cycloheximide-treated cells were incubated for 1, 2, 4, and 6 h in the 
absence and presence of 10 µM ZM39923, 10 µM imatinib, or both drugs 
together. After incubation, protein extracts were prepared at the indicated 
time points. Levels of Mcl-1 protein in these cells that were blocked in 
protein synthesis were determined by western blotting. 
In LAMA-84 cells, the half-life of Mcl-1 in untreated controls was 
around 2 h (Figure 7.6). However, ZM39923, imatinib, and when both 
drugs were used together, resulted in an increase of the half-life of Mcl-1 to 
more than 6 h (Figure 7.6). This increased stability of Mcl-1 was greatest 
when the two drugs were used in combination. 
Similarly, ZM39923 and imatinib, used alone, increased the half-life 
of Mcl-1 from around 2-3 h in untreated control to around 6 h in KCL-22 
cells. However, the combination of ZM39923 and imatinib did not increase 
the half-life of Mcl-1 and this combination caused no change in half-life of 
Mcl-1 when compared to untreated control (around 2-3 h). 
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Figure 7.6 Effect of ZM39923 and imatinib on the half-life of Mcl-1 in 
LAMA-84 cells. Cells were pre-incubated for 10 min with cycloheximide 
(CHX) prior to 0, 1, 2, 4, and 6 h incubation in absence (U), or presence of 
30 μM purvalanol A (P). (A) Shows a typical western blot analysis, while 
(B) shows densitometric analysis. The half-life were indicated with IC50 
(shown in dashes). Data are expressed as % of untreated samples (±SEM, 
n=3).  Western blot shown is representative from n=3 experiments 
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Figure 7.7 Effect of ZM39923 and imatinib on the half-life of Mcl-1 in 
KCL-22 cells. Cells were pre-incubated for 10 min with cycloheximide 
(CHX) prior to 0, 1, 2, 4, and 6 h incubation in absence (U), or presence of 
30 μM purvalanol A (P). (A) Shows a typical western blot analysis, while 
(B) shows densitometric analysis. The half-life were indicated with IC50 
(shown in dashes). Data are expressed as % of untreated samples (±SEM, 
n=3).  Western blot shown is representative from n=3 experiments. 
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7.4    Discussion and Conclusions  
In this Chapter, the effects of ZM39923 were investigated in order 
to determine if this drug could be considered as an alternative therapeutic 
strategies to overcome TKI resistance and also to compare its effects with 
purvalanol A in order to understand the mechanisms of action. 
Until now, there are no reports of the effects of the JAK3-specific 
inhibitor, ZM39923, in any CML cell line. Thus, this study provides the 
first preliminary results into the effects of ZM39923 on imatinib-sensitive 
and –insensitive CML cell lines. It was found that a low concentration of 
ZM39923 (10 µM) decreased cell viability in LAMA-84 and KCL-22 cells. 
However, this was not confirmed by cell cycle analysis. Interestingly, the 
use of a combination of ZM39923 and imatinib resulted in an enhanced 
response seen both in the cell viability and cell cycle results. These result 
supports the concept of combinatorial CML treatment by targeting other 
key signalling proteins alongside targetting TKIs. This finding supports 
several studies using inhibitors that block BCR-ABL downstream signalling 
pathways in combination with imatinib, which have found synergistic 
effects (Tipping et al., 2002, Radujkovic et al., 2005, Tseng et al., 2005, 
Kancha et al., 2008). For example, the combination of imatinib and PDK1 
inhibitor (Tseng et al., 2005) and small molecule Grb2 SH2 domain binding 
antagonists, TB03, (Zhang et al., 2014) have been shown to induce 
synergistic effects in CML cell lines. In addition, an apoptosis induction in 
K562 cell line by TB03 was associated with cell cycle arrest. TB03 
increased the number of cells arrested in G0/G1, with corresponding lower 
numbers of cells arrested in S/G2 phase of the cell cycle (Zhang et al., 
2014). As ZM39923 sensitised KCL-22 cells to the effects of imatinib, this 
opens the possibility of consideration of a dual therapy option. This could 
decrease adverse effects from therapeutic agents that target processes in 
non-malignant cells as low concentrations of drug could be used in dual 
therapy. 
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These findings confirm the idea that JAK3 can be a therapeutic 
target for CML. One research group reported that JAK3 is physically 
associated with ABL by co-immunoprecipitation. They found that selective 
JAK inhibition decreased ABL kinase activity by 61 % at 6 h of treatment. 
This indicates that JAK3 is involved in ABL kinase constitutive activation 
(Lin et al, 2005). As a consequence, further investigation of the effects of 
ZM39923 on CML cell lines should improve molecular understanding and 
lead to more effective treatment of CML.  
The effect of ZM39923 on the apoptotic protein, Mcl-1 was also 
determined in this Chapter as Mcl-1 is crucial in the regulation of apoptosis 
in CML (Aichberger et al., 2005).  The results obtained show that 
ZM39923 in combination with imatinib, decreased level of Mcl-1 
expression significantly over 24 h of incubation in both cell lines. It has 
been reported that Mcl-1 expression was decreased by another JAK3 
inhibitor, PF956580, in chronic lymphocytic leukaemia cells (Steele et al., 
2010). 
However, this decrease in Mcl-1 expression did not occur within 6 h 
incubation time (from time course analysis experiment).  Also, ZM39923 
used alone and ZM39923 used with imatinib did not decrease the half-life 
of Mcl-1 protein in both cell lines.  Therefore, the decrease in Mcl-1 caused 
by the combination of ZM39923 and imatinib is not due to any changes in 
the rate of protein turnover (as for purvalanol A induced Mcl-1 turnover in 
KCL-22 cells), but therefore more likely to be due to changes in 
transcription/translation of the protein. 
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In conclusion, ZM39923 was demonstrated in this Chapter to 
decrease cell viability in LAMA-84 and KCL-22 cell lines and decrease in 
Mcl-1 expression levels, when used in combination with imatinib. These 
observations indicate that it induces apoptosis and sensitises imatinib-
resistant cells to treatment with imatinib. This work should promote more 
studies regarding the use JAK3 inhibitors in the treatment of CML. 
However, the mechanism of action of this inhibitor on Mcl-1 expression is 
still unclear and requires further investigations beyond these preliminary 
results.  
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CHAPTER 8:  GENERAL DISCUSSION AND 
CONCLUSIONS 
Chronic Myeloid Leukemia is associated with a single genetic 
abnormality known as the Philadelphia (Ph) chromosome.  This 
chromosome results from a t(9;22) reciprocal translocation which results in 
the formation of the BCR/ABL fusion gene (Deininger et al., 2000).  This 
gene encodes a constitutively-active protein tyrosine kinase, leading to a de-
regulation of tyrosine kinase activity in the cells (Quintas-Cardama and 
Cortes, 2009). A major breakthrough in the treatment of CML was the 
development of the specific BCR-ABL inhibitor, imatinib, which is now 
used as the first line therapy. Following its initial success, resistance to this 
drug developed via several mechanisms, including mutations in the BCR-
ABL gene (Corbin et al., 2003). Hence, new generations of tyrosine kinase 
inhibitors (TKIs), for example, nilotinib, dasatinib, and ponatinib have been 
developed.  
While these new generation tyrosine kinase inhibitors have overcome 
many of the problems associated with failure of patients to respond to 
imatinib because of mutations, resistance to these inhibitors is still a 
problem. This is because during the advanced stages of CML, rates of 
mutations are high (Zhang et al., 2009).  In addition, the BCR-ABL gene 
may become amplified and other mechanisms of resistance (e.g. changes in 
activity of drug influx and efflux mechanisms) may develop (Mahon et al., 
2000). Therefore, there is a continued need to find new ways to induce 
CML cell death, perhaps when used in combination with TKIs. Inhibitors of 
other target kinases may therefore have clinical potential. Among these 
kinases, CDK inhibitors have shown promising results.  
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CDKs are a family of serine/threonine kinases that are involved in 
cell cycle progression (Diallo and Prigent, 2011), expressed in both 
unicellular and multicellular organisms (Malumbres and Barbacid, 2005). 
In several pathological conditions, there are abnormalities in CDK 
expression and regulation such as viral infections, neurodegenerative 
disorders and cancer (Cicenas et al., 2014). Therefore, several small 
molecule CDK inhibitors have been developed in order to treat these 
diseases. 
Most recently (in February 2015), the CDK4 and 6 inhibitor, 
pablociclib, was approved by the FDA to treat breast cancer (Turner et al., 
2015). In addition, several CDK inhibitors have been developed in both 
preclinical and clinical studies and most of these inhibitors have shown 
promising results and now in the process of drug development (reviewed in 
(Cicenas et al., 2014)). It has been reported that CML is associated with 
altered CDK activity. For example, a deregulated oncogene, ras, targets 
CDKs leading to their inappropriate activation. Therefore, CDK inhibitors 
might be a promising alternative CML treatment (Cortez et al., 1997).  
Recently, the combination use of flavopiridal and imatinib has 
begun in phase I clinical trials in CML patients and is encouraging 
responses have been observed, particularly in imatnib-resistant CML 
patients (Bose et al., 2012). This follows from experiments that 
demonstrated its ability to induce apoptosis in human leukaemic cells in 
both in vitro and in vivo experiments (Decker et al., 2001). In addition, it 
was found to enhance the activity of imatinib in imatinib-insensitive CML 
cell lines (Yu et al., 2002).  
As a result, CDK inhibitors, used alone and in combination with 
TKIs, are now a promising avenue for treatment of imatinib-resistant CML. 
Therefore, the main objective of this study was to investigate the effects of 
CDK inhibitor, purvalanol A, on imatinib-sensitive and –insensitive chronic 
myeloid leukeamia cell lines. In addition, the effects of purvalanol A were 
also investigated in normal white blood cells, including neutrophils and 
PBMCs to provide the first experiments to evaluate its toxicity. Lastly, the 
227 
 
effects of other inhibitor, ZM39923 (JAK3 inhibitor), on imatinib-sensitive 
and –insensitive chronic myeloid leukeamia cell lines were also 
investigated to understand the potential of JAK inhibition as a therapeutic 
approach for CML. 
 
The main findings of my studies were as follows: 
i) Imatinib induced apoptosis in imatnib-sensitive CML cell 
line (LAMA-84), but not imatinib-insensitive CML cell line 
(KCL-22). 
ii) Purvalanol A induced apoptosis in both LAMA-84 and 
KCL-22 cells. 
iii) Purvalanol A induced mitochondrial depolarization in both 
cell lines within 2 h of incubation. 
iv) Purvalanol A increased Mcl-1 (both protein and mRNA) 
turnover in KCL-22 cells, but not in LAMA-84 cells. 
v) Purvalanol A induced apoptosis in neutrophils, but not 
PBMCs. 
vi) Purvalanol A resulted an increase of phosphorylated p38 
MAPK in KCL-22 cells and neutrophils. 
vii) JAK inhibition induced apoptosis in both CML cell lines 
when used in combination with imatinib. 
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Results from this study indicate, for the first time, that the Cdk2 
inhibitor, purvalanol A can induce rapid cell death in an imatinib-
insensitive cell line, KCL-22. In spite of its known effects on Cdk2 and cell 
cycle arrest, the effects observed on KCL-22 viability are likely to be 
independent of its effects on the cell cycle. Instead, a clear effect of this 
inhibitor was demonstrated on expression of the anti-apoptotic protein, 
Mcl-1 in the absence of any detectable changes in expression of other anti-
apoptotic proteins, such as Bcl-2 and Bcl-XL. While purvalanol A decreases 
mRNA levels within 30 min incubation, profound and rapid decreases in 
protein levels were observed that are attributable to a decrease in the half-
life of this protein, from around 3 h to around 1.5 h. This decrease in Mcl-1 
stability, together with the decrease in mRNA levels, resulted in a marked 
decreased expression of this protein that was significant by 1 h treatment 
with this drug. Thus, this rapid decline in Mcl-1 levels is probably 
responsible for the rapid activation of apoptosis in these cells. In contrast to 
purvalanol A, the JAK3 inhibitor, ZM39923, did not increase Mcl-1 
turnover, while it induced apoptosis in both cell lines. 
Mcl-1 is an unusual member of the Bcl-2 family and has properties 
that distinguish it from other family members (Reynolds et al., 1994). It is a 
much larger protein (37 kDa) than either Bcl-2 or Bcl-XL (22 and 25 kDa, 
respectively) and while it shares some homology in its BH domains, it 
possesses a unique N-terminal domain that is responsible for its special 
properties (Kozopas et al., 1993). This N-terminal domain contains PEST 
domains and other motifs that are subject to reversible post-translational 
modifications, particularly phosphorylation at Serine and Threonine 
residues (Thomas et al., 2010) that alter and regulate its function. The 
protein has a very short half-life (2-3 h depending on the cell type) and this 
half-life can be shortened or extended by phosphorylation on key residues 
to either accelerate or delay, respectively, cell apoptosis (Thomas et al., 
2012). In human neutrophils and in some cancers, apoptosis delaying agents 
have been shown to extend Mcl-1 half-life, whilst other agonists (e.g. 
sodium salicylate, phosphatase inhibitors) result in accelerated turnover of 
this protein (Derouet et al., 2006) with a concomitant enhancement of 
229 
 
apoptosis. In view of the rapid effects on Mcl-1 stability and turnover, 
purvalanol A could either directly or indirectly lead to a change in the 
phosphorylation status of Mcl-1 that regulates its stability. Many of the 
Serine/Threonine residues targeted and the kinase/phosphatase systems 
responsible for many of these functional changes have been identified 
(Kobayashi et al., 2007, Domina et al., 2004, Maurer et al., 2006, Inoshita 
et al., 2002) and it will now be necessary to identify the post-translational 
modifications of Mcl-1 that are directly or indirectly affected by purvalanol 
A. 
While imatinib induced cell death in LAMA-84 cells via a caspase-
dependent process, this drug had little effect on apoptosis in KCL-22 cells, 
although it did induce a partial accumulation of these cells in G1. Imatinib 
treatment of LAMA-84 cells resulted in a decrease in Mcl-1 protein levels 
(but not Bcl-2 or Bcl-XL levels), both apoptosis and this decrease in Mcl-1 
were prevented by caspase inhibition. This observation would appear to 
confirm the key role for Mcl-1 in imatinib-induced apoptosis of CML cells 
(Aichberger et al., 2005). However, this decrease in Mcl-1 levels in LAMA-
84 cells was not associated by any detectable changes in Mcl-1 protein 
stability. It is therefore likely that imatinib negatively affects MCL1 
transcription/translation, rather than inducing a post-translational 
modification that affect protein stability in these cells.  
In LAMA-84 cells, while purvalanol A treatment had little effect on 
Mcl-1 protein levels, it resulted in a slight decrease in expression of Bcl-2, 
which (as in human neutrophils (Moulding et al., 2001)) is not expressed in 
KCL-22 cells. If purvalanol A does indeed affect the activity of a 
kinase/phosphatase responsible for induction of a post-translational 
modification of Mcl-1 to decrease its stability, it may be hypothesised that 
this kinase/phosphatase system is not activated or is absent in LAMA-84 
cells. Therefore, the levels of activation of a number of key intracellular 
signalling systems that have been implicated in regulation of myeloid cell 
function and apoptosis in these two cell lines were investigated (Quintas-
Cardama and Cortes, 2009). There were clear differences in the levels of 
activation of a number of these systems in these cells types and differences 
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in their responses to imatinib and purvalanol A. For example, pSTAT3 and 
pAkt could not be detected in LAMA-84 cells in spite of the fact that non-
phosphorylated proteins appeared to be detected by the pan-antibodies used. 
These experiments also indicated that while imatinib had little effect on 
apoptosis in KCL-22, this drug completely abrogated activation of both 
pErk and pAkt in these cells, confirming a recent study (Ohmine et al., 
2003). These signalling systems have previously been implicated in 
generating anti-apoptotic signals in myeloid cells (Quentmeier et al., 2011, 
Cortez et al., 1997) and yet knock-down by imatinib had little effect on 
apoptosis in KCL-22 cells. While imatinib had little effect on STAT3 
activation in these cells, purvalanol A completely ablated activation of this 
signalling pathway. Whether STAT3 directly or indirectly regulates Mcl-1 
stability is yet to be determined. Curiously, in KCL-22 cells (and to a lesser 
extent in LAMA-84 cells) purvalanol A induced a rapid and significant 
increase in activation of p38-MAPK. It has previously been proposed that 
this signalling molecule may generate death signals (Zarubin and Han, 
2005, Koul et al., 2013, Jiang et al., 2014) and the present results lend some 
support to this notion. In this study, the effects of purvalanol A on CML 
cell lines were investigated further using the p-38 MAPK inhibitor, 
BIRB796, that can inhibit all isoforms of p38 MAPK (Kuma et al., 2005). 
The combination of BIRB796 and purvalanol A was found to decrease 
CML cell apoptosis and increase Mcl-1 expression in both CML cells and 
neutrophils compared to purvalanol A, used alone. This suggests p38 
MAPK plays a role in the mechanism of action purvalanol A. It is possible 
that activated p38-MAPK can directly or indirectly result in a post-
translational modification of Mcl-1 to increase its rate of turnover. 
 BCR/ABL has been reported to connect with several signalling 
pathways such as Erk, Akt, and JAK-STATs. Recently, p38 MAPK has 
also been reported to be modulated by BCR-ABL (Sanchez-Arevalo Lobo 
et al., 2005). p38 comprises of 4 isoforms, α, β, γ, and δ. These isoforms 
shares more than 60 % sequence homology (Wilson et al., 1996). p38 
isoforms can be phosphorylated by MKK3, 4, and 6 to activate various 
substrates, including transcription factors and protein kinases. This leads to 
231 
 
inflammatory response and cell differentiation (Cuenda and Rousseau, 
2007). Various agents including TKIs (Dumka et al., 2009), chlorogenic 
acid (Bandyopadhyay et al., 2004), and Ara-C (Sanchez-Arevalo Lobo et 
al., 2005) were found to be associated with the activation of p38 MAPK in 
order to induce apoptosis in CML cells. Therefore, this supports the finding 
that p38 MAPK is associated with the apoptosis induced by purvalanol A. 
Recent studies in human cancer cell lines have shown that 
purvalanol A treatment inhibited both CDK activity and the expression of 
several anti-apoptotic proteins of the Bcl-2 family, such as Bcl-2 and Bcl-
XL (Iizuka et al., 2007, Iizuka et al., 2008). Purvalanol A was also found to 
interact with purified Cdk2 and this may explain its anti-mitotic properties 
(Knockaert et al., 2002a). It inhibits the phosphorylation of Cdk substrates, 
such as Retinoblastoma protein (Rb) and cyclin E. Moreover, it increases 
the level of the Cdk inhibitory protein, p21 WAF1/CIP1. These effects lead to 
inhibition of cell proliferation in a range of human cancer cell lines and 
mouse fibroblasts (Villerbu et al., 2002). However, its actual intracellular 
targets are still undefined.  One group has reported that purvalanol also 
interacts with p42/p44 MAPK protein in various cell lines, as detected by 
affinity chromatography (Knockaert et al., 2002b). In addition, purvalanol 
inhibited p42/p44 MAPK activities in dose-dependent manner in the 
Chinese hamster lung fibroblast cell line, CCL39 (Knockaert et al., 2002b). 
This suggests that the anti-proliferative effects of purvalanol may be 
mediated by both Cdk inhibition and interactions with p42/p44 MAPK. It 
has also been shown that purvalanol A suppresses c-Src transformation by 
inhibiting both cell cycle progression and c-Src signalling. Therefore, 
purvalanol A could be a potential inhibitor of cancers that are characterised 
by c-Src up-regulation (Hikita et al., 2010). 
Purvalanol A has now been used in preclinical trials for treating 
several cancers (Cicenas and Valius, 2011, Cicenas et al., 2014) and so its 
toxicity, mechanism of action and effects on drug transporter processes 
purvalanol A are becoming characterised. Therefore, the effects of 
purvalanol A on neutrophils and PBMCs were investigated in this study to 
provide preliminary results regarding drug toxicity in primary leukocytes. 
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Purvalanol A was found to induce apoptosis in neutrophils, but not 
PBMCs. However, it resulted in a decrease in Mcl-1 expression in both 
neutrophils and PBMCs. In spite of the decrease in Mcl-1 expression, there 
was an elevated expression of Bcl-2 in purvalanol A treated PBMCs. These 
results indicate that purvalanol A might cause toxicity during long-term 
treatment as it induced apoptosis in normal white blood cells, particularly in 
neutrophils. Therefore, for this compound to be taken forward as a 
therapeutic option, further toxicity studies will be required to determine the 
therapeutic concentration that is safe to use and causes minimal side effects.  
 
Future directions 
Before entering advanced preclinical and clinical study, purvalanol 
A should undergo more extensive tests to determine if it is ready to 
administer in humans. In this study, preliminary results regarding effects of 
purvalanol A in vitro have been provided, but, ex vivo, and in vivo studies 
are also required to determine its mechanism of action and potential effects 
on humans.  
Further studies should recruit CML patients in order to investigate 
whether purvalanol A could also induce cell death in primary CML cells ex 
vivo, as well as in CML cell lines. Primary cells can be isolated from CML 
patients following leukapheresis. Leukapheresis is performed in CML 
patients with high levels of white blood cells and this procedure leads to 
decreases in the number of white blood cells. (Ranganathan et al., 2008). 
These white blood cells recovered by this process can be tested ex vivo and 
thus provide more data for preclinical studies.  
Furthermore, in vivo studies are also important to provide more 
clinically-relevant data perhaps using using animal models. For example, 
rodent and non-rodent mammalian models can be used to determine 
pharmacokinetic profiles and toxicity patterns (Steinmetz and Spack, 2009). 
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Apart from concerns over the toxicity associated with long term use 
of drugs such as this, other areas of further investigation would be studies 
of signalling pathway activation in both CML cell lines and neutrophils. 
These could explain the mechanisms of purvalanol A induced apoptosis in 
these cells. In this study, p-38 MAPK was activated by purvalanol A in 
both KCL-22 cells and neutrophils. In addition, purvalanol A also increased 
Mcl-1 turnover in these cells, but not in LAMA-84 cells. This might 
suggest that the molecular phenotype of KCL-22 cells is close to that of 
mature neutrophils in terms of signalling pathways. BIRB796 could be 
further used to investigate the role of p38 MAPK in the mechanism of 
action purvalanol A and its role in Mcl-1 turnover on both CML cells and 
neutrophils. As described in this thesis, the preliminary experiments show 
encouraging results. 
In this study, ZM39923 was demonstrated to decrease cell viability 
and Mcl-1 expression levels in both LAMA-84 and KCL-22 cell lines. The 
results obtained indicate that ZM39923 sensitises imatinib-insensitive cells 
to treatment with imatinib. This paves the way for a dual therapy option in 
CML. ZM39923 can be used at lower concentrations with imatinib, thereby 
decreasing the possibility of off-target or adverse toxicity effects. In 
contrast to purvalanol A, there is less preclinical data provided for 
ZM39923 and thus it is necessary to further investigate its effects and 
mechanism of action before considering clinical use. 
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